











Title of Dissertation: INTERPRETING GENETIC VARIANTS FOR 
DISCOVERING DISEASE ETIOLOGY AND 
MECHANISMS   
  
 Kunal Kundu, Doctor of Philosophy, 2020 
  
Dissertation directed by: Professor John Moult                        




High-throughput sequencing methods now provide extensive data on disease-related 
human genetic variants. New methods are required to maximally utilize these data for 
enhanced understanding and treatment of human diseases. This dissertation describes 
my work in addressing three aspects of this challenge: Determining disease-causative 
variants; representing mechanisms by which genetic variant(s) cause disease 
phenotypes; and quantitatively analyzing genetic disease mechanisms.  
 
First, I developed a variant prioritization algorithm, VarP, and objectively tested it in 
CAGI (Critical Assessment of Genome Interpretation). It was ranked best in the 
CAGI challenge on interpreting panel sequencing data for 106 patients, determining 
which disease class each patient has and the corresponding causative variant(s). VarP 
correctly identified the disease class for 36 cases, including 10 where the original 
  
clinical pipeline failed, and found seven cases with strong evidence of an alternative 
disease to that tested. Over-reliance on pathogenicity annotations in the HGMD 
mutation database led to several incorrect cases. Post analysis showed that protein 
structure data could have helped to interpret the impact of many prioritized missense 
variants. 
 
Next, I co-developed and implemented MecCog, a web-based graphical framework to 
represent mechanisms by which genetic variants cause disease phenotypes. A 
MecCog mechanism schema displays the propagation of system perturbations across 
stages of biological organization, using graphical notations to symbolize perturbed 
entities and activities, knowledge gaps, ambiguities and uncertainties, and 
hyperlinked evidence. The web platform enables a user to construct, store, publish, 
browse, query, and comment on schemas. MecCog facilitates better comprehension 
of disease mechanisms, identification of critical unanswered questions on causal 
relationships, and possible new sites of therapeutic intervention. 
 
Finally, I developed a framework to quantitatively represent and analyze mechanisms 
relating genetic variants to complex trait disease. It involves generating a computable 
circuit from MecCog schemas by assigning node functions and parameters to 
represent the behavior of the schema components. I demonstrate that such a circuit 
can be used to analyze the effect size of a variant contributing to disease risk as a 
function of the genetic background in an individual and the extent to which epistatic 
effects may be masked in population averages. I also show that the circuit functions 
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Chapter 1: Introduction 
1.1 Rare variants and human disease 
1.1.1 Genetic variants in the human genome  
Human genetic variants are differences found in DNA sequences between individuals 
within and among populations. Accumulation of DNA mutations due to uncorrected 
DNA replication errors, and exogenous and endogenous factors (such as chemicals, 
ionizing radiation, and oxygen free radicals) are major sources of genetic variants. 
Knowledge of the human genome sequence together with advances has made way for 
executing multiple large-scale initiatives on characterizing genetic variants in the 
human genome. These include the 1000 Genomes Project (1KG) (2504 individuals) 
(Auton et al., 2015), the Exome Sequencing Project (ESP) (7034 individuals) (Auer et 
al., 2016), and the Genome Aggregation Database (gnomAD) (141,456 individuals) 
(Karczewski et al., 2020). It has been found that a typical genome has 4.1 million to 
5.0 million sites that differ from the reference human genome (Auton et al., 2015). 
The primary types of genetic variant are single nucleotide variants (SNVs), short 
indels, structural variants such as large deletions, copy-number variations (CNVs), 
and mobile insertion elements (MEIs). Based on 1000 genome data (Devuyst, 2015), 
typically a genome has ~4.31 million (median) SNVs, ~625K (median) indels, and an 
estimated 2100 to 2500 structural variants. Although SNVs and short indels forms 






In the coding region of the human genome, SNVs may cause synonymous (no amino 
acid change) and non-synonymous (amino acid change resulting in missense, 
nonsense due to creation of termination codon, and stoploss due to loss of a 
termination codon) variations, and indel and structural variants may cause loss of 
function (LoF) variation such as frameshift (change in the reading frame of ORFs), 
and non-frameshift (no change in the reading frame of ORFs) variations. These 
coding variants may also cause aberrant splicing by changing regulatory splice sites 
such as exon splicing enhancer or silencer. In the non-coding region of the human 
genome, variants may alter splice sites or gene expression regulatory sites. In a 
typical genome, about 0.3% of genetic variants are missense (~12000), 0.3% are 
synonymous (~ 13000), 0.004% are LoF (~180), and 12% are in regulatory sites 
(such as promoter, insulator, enhancer, transcription factor binding sites) (~500000) 
(Auton et al., 2015). Genetic variants are also shown to affect long-range intra-
chromosomal functional connections (Smemo et al., 2014). Minor allele frequency 
(MAF) analysis of the variants in populations shows that the majority of variants 
observed in a single genome are common (i.e. MAF > 0.5%) and only 1 to 4% are 
rare variants having MAF < 0.5%. Exome Sequencing Project (ESP) data shows that 
in an individual most coding variants (e.g. missense, synonymous or nonsense) are 
rare variants (MAF<1%) and the majority of these are missense (Auer et al., 2016). 
 
As of August 2020, the two widely used human genetic variant databases, dbSNP 
(Sherry et al., 2001)and gnomAD (Karczewski et al., 2020), contain 700 million and 





amount of sequencing data being produced, currently doubling approximately every 
seven months, establishing human genomics as a big data domain (Stephens et al., 
2015). Knowledge of these variants has provoked intense scientific interest in their 
use to obtain insights into human genetics and diseases.  
 
1.1.2 Role of rare variants in monogenic diseases  
Monogenic diseases are caused by mutations in one gene, so exhibiting a Mendelian 
inheritance pattern (therefore also referred to as Mendelian diseases). For example, 
Lynch syndrome, a hereditary nonpolyposis colorectal cancer, is caused by 
heterozygous mutations in any of the DNA mismatch repair (MMR) genes MLH1, 
MSH2, MSH6, or PMS2 (Sehgal et al., 2014). These diseases are individually rare 
(incidence of 1 in 10000 live births on the upper end; based on data from Orphanet - 
https://www.orpha.net/) but impact millions of individuals and families (Baird et al., 
1988; Carter, 1977), with over ~6200 distinct disease traits known to date (Amberger 
et al., 2019). The World Health Organization (WHO) reports that the global 
prevalence of all single-gene diseases at birth is very high (approximately 1/100) thus 
making this disease type of major scientific interest. Monogenic diseases are 
classified into three categories: (A) Dominant disease where one of the two copies of 
a gene is damaged, (B) Recessive disease where both the copies of a gene are 
damaged, and (C) X-linked disease where the defective gene is on the X 
chromosome. Data in the Online Mendelian Inheritance in Man (OMIM) (August 
2020) databases show that for ~91% of the rare Mendelian diseases the inheritance 





the majority followed by recessive (101). Studies have revealed that these rare 
diseases can also be characterized by more complex modes of inheritance such as 
digenic inheritance (variants at two distinct loci required for trait manifestation), dual 
molecular diagnoses (variants at two distinct loci lead to two independent segregating 
traits), multilocus mutational burden (effect of a highly penetrant variant modified by 
variation at additional loci), and compound inheritance of rare and common variants 
(trait requires one rare and one common variant) (Posey, 2019). The OMIM data also 
shows that only ~20% (3949/~20000) of human protein-coding genes have been 
associated with one or more monogenic diseases. It is reported that genetic testing 
based on these disease genes yields a molecular diagnosis in only 24% of the tested 
patients (Lionel et al., 2018) and new disease genes are only being discovered at a 
rate of 263 a year (Posey et al., 2019). This indicates that there is a tremendous 
amount of research that remains to be done to elucidate the molecular etiology of 
monogenic diseases.  
 
Many rare and novel (not previously seen) SNVs, short insertions/deletions, CNVs, 
and structural variants have been identified to underlie monogenic diseases. 
Commercial (such as the Human Gene Mutation Database (HGMD) (Stenson et al., 
2017)) and public (such as ClinVar (Landrum et al., 2018)) databases have been built 
to collate medically important variants associated with monogenic diseases and 
susceptibility to complex trait diseases. HGMD (August 2020) catalogs ~275K 
variants, of which SNVs (including missense, nonsense, and splicing) are the majority 





rearrangement and repeat variations (1%). ClinVar (August 2020) archives a smaller 
set of ~89K pathogenic and likely pathogenic variants but has a similar trend as 
HGMD with SNVs being the majority (70%), followed by deletions (17%), 
insertion/duplication (8%), copy number (2%) and structural variation (5%). To 
catalog somatic variants in cancer, expert-curated (such as COSMIC (Tate et al., 
2019)) and community-driven (such as CIVIC (Griffith et al., 2017)) databases have 
also been built.   
 
It has been estimated that clinical exome sequencing (CES, covering exomes and 
flanking regions) should capture about 95% of variants that cause genetic disorders 
(Shamseldin et al., 2017). This should make it possible to investigate the impact of 
variants on cis- control of expression, splicing, and protein level mechanisms using 
this type of data. Many such mechanisms have been elucidated. For example, a rare 
(MAF=0.007 in gnomAD) non-frameshift deletion variant rs113993960 
(NM_000492:c.1521_1523del) in the CFTR gene is known to cause cystic fibrosis 
(CF) with a recessive inheritance pattern (Wang & Li, 2014). This variant is present 
in the 11th exon (11/27) of the gene and causes a deletion of three base pairs that leads 
to the loss of amino acid, phenylalanine, at position 508 in the CFTR protein (1480 
amino acids). Studies have reported that the mutation causes a twofold problem  
(https://www.ncbi.nlm.nih.gov/books/NBK540352/) that results in loss of chloride 
channel function: (a) A defect in the protein conformation due to misfolding results in 
the degradation of the mutant protein before it can reach to the cell surface (Cutting, 





has a reduced half-life compared to wildtype protein (Cutting, 2015). Understanding 
such molecular mechanisms aids in devising therapeutic strategies. For example, 
TriKafta (Bear, 2020), a triple combination drug containing tezacaftor, elexacaftor, 
and ivacaftor, is being used as one of the therapies for CF patients. Tezacaftor is a 
CFTR corrector that acts as a pharmacological chaperone that promotes forward 
trafficking of F508del-CFTR to the cell surface (Hanrahan et al., 2017). Elexacaftor 
is also a CFTR corrector that binds to an alternate site than tezacaftor to facilitate the 
trafficking of mutant CFTR to the cell surface (Ridley & Condren, 2020). Ivacaftor is 
a CFTR potentiator as it increases the probability of the CFTR channel open 
conformation, so increasing the chloride ion flow (Condren & Bradshaw, 2013; 
Hanrahan et al., 2017).  
 
1.1.3 Interpretation of rare variants in clinical settings  
Sequencing technologies (whole-genome, whole-exome, or targeted/panel 
sequencing) have recently become more available for clinical diagnostic testing of 
monogenic diseases and cancer. As of August 2020, the Genetic Testing Registry 
(https://www.ncbi.nlm.nih.gov/gtr/) contains entries for about 575 labs worldwide 
and so far a total of 76268 tests on 18695 genes for 16424 conditions. The current 
diagnostic yield ranges widely from 21 to 73%, depending on the phenotypes tested 
(Gilissen et al., 2014; Lionel et al., 2018; Posey, 2019; Soden et al., 2014; Taylor et 
al., 2015). Most clinical labs follow a semi-automated approach for variant 
interpretation, by first making use of available variant annotation and prioritization 





interest in databases and the literature (Sadedin et al., 2015) ( 
https://blog.goldenhelix.com/golden-helix-end-to-end-architecture-for-clinical-
testing-labs). There are dozens of commercial and open-source variant annotation and 
prioritization tools available that identify putative causative variants by considering 
factors such as inheritance pattern, minor allele frequency, genomic region 
(coding/non-coding), mutation type, and in silico impact prediction for 
missense/splicing mutations (Hu et al., 2019). However, it has been demonstrated that 
there are substantial discrepancies between existing tools (McCarthy et al., 2014; 
Pabinger et al., 2014). For instance, on comparing results between two widely used 
annotations tools (Annovar (K. Wang et al., 2010) and VEP (McLaren et al., 2016)) it 
was found that 35% of the LoF variants and 13% of all exonic variants had 
mismatched annotations, with splicing variants having the greatest discrepancies 
(McCarthy et al., 2014). The choice of transcript database (RefSeq or Ensembl) for an 
annotation tool caused 21% and 17% discrepancies for the Lof + missense and all 
exonic variants respectively. These discrepancies illustrate that there is scope for 
improved genome interpretation accuracy through further development of the tools 
and improved annotation. 
     
To standardize assignment of variant pathogenicity in clinical labs, the American 
College of Medical Genetics and Genomics (ACMG) has developed guidelines for 
weighing the evidence of pathogenicity for a variant, with classification into one of 
five categories: pathogenic, likely pathogenic, uncertain significance, likely benign 





the majority of the variants are classified as ‘uncertain significance’ (41%) and with 
only 12% are classified as ‘pathogenic and likely pathogenic’. Additionally, there are 
5% variants with ‘conflicting interpretation of pathogenicity’ for cases with 
conflicting ACMG classification outcomes from different sources. A recent analysis 
of variant reclassification over time showed that predominantly variants are being 
reclassified to ‘conflicting interpretation of pathogenicity’ from all other types (~5000 
per year)  and that there is very low (~150 per year) reclassification traffic towards 
‘pathogenic or likely pathogenic’ types (Shah et al., 2018). These data show a need 
for improving methods for consistently and accurately assigning pathogenicity. One 
of the areas where there is most potential for improvement is the use of computational 
methods. These are currently down-weighted in the ACMG guideline compared to the 
experimental evidence because of low accuracy. 
         
In order to objectively assess methods for interpreting the impact of genetic variants, 
John Moult and Steven Brenner started the Critical Assessment of Genome 
Interpretation (CAGI, https://genomeinterpretation.org/) in 2010 
(https://doi.org/10.1038/news.2010.679). CAGI is an organization that conducts 
community experiments to test methods for relating genotype to phenotype. 
Participants are asked to predict particular phenotypes, given genetic variant 
information. The corresponding results are not released until all participants have 
submitted their predictions; thus, these are bona fide blind predictions. Independent 
experts assess the predictions and the outcomes are discussed at a CAGI conference. 





genomes, whole-exomes, clinical gene panels, and phenotypes that have covered rare 
monogenic diseases, complex trait diseases, and particular types of cancer. One of 
these challenges is of particular interest in this dissertation. The aim was to determine 
which of 14 monogenic disease classes each of 106 patients has together with the 
corresponding causative variants, given each patient’s gene panel sequencing data 
(https://genomeinterpretation.org/content/4-Hopkins_clinical_panel), obtained from a 
genetic testing laboratory. Motivated to build a more accurate variant interpretation 
method that can be used for the clinical diagnosis of rare monogenic diseases, I 
designed and implemented an open-source variant prioritization pipeline and assessed 
its performance on the CAGI gene panel challenge dataset. Chapter 2 describes the 
design and implementation of the prioritization pipeline and its assessment in CAGI.  
 
1.2 Representation of genetic disease mechanisms 
1.2.1 Genetic disease mechanisms  
Variant annotation pipelines, when successful, provide insight into some of the low-
level molecular mechanisms involved in the disease. Development of effective 
treatments, such as in the cystic fibrosis example above, is greatly facilitated by 
knowledge of the full succession of causal links across levels of biological 
organization by which a DNA change leads to a disease phenotype, not just the 
molecular stage steps. Advanced experimental model systems (such as cell lines 
(Pansarasa et al., 2018), organ-on-chips (Santoso & McCain, 2020), organoids 
(Lancaster & Huch, 2019), and model organisms), multi-omics data (such as 





2018; Pegoraro & Misteli, 2017), and bioinformatics approaches (such as 
mathematical modeling and network analysis (Kikuchi et al., 2015; Zhang et al., 
2013)) are facilitating the discovery of these complete causal mechanisms. But so far, 
as discussed below, the field lacks a comprehensive framework for describing and 
evaluating the mechanisms. 
 
1.2.2 Mechanism representation in literature and digital platforms 
 
To illustrate the need for tools for describing disease mechanism, consider the 
example of a mutation that causes Lynch Syndrome, a heritable form of colon cancer 
introduced earlier (Bartosova et al., 2003). The mechanism starts with a novel (not 
reported in the gnomAD or 1000 Genomes databases) heterozygous nonsense variant 
rs63750245:C>T in a DNA mismatch repair gene, MSH2, (Bartosova et al., 2003): 
This variant is in the sixth exon (6/16) of the gene and creates a premature 
termination codon in the mRNA. The codon position corresponds to the first half 
(p.Gln344Ter) of the MSH2 protein (934 amino acids). This causes nonsense-
mediated decay of the MSH2 mRNA and so leads to a decreased abundance of MSH2 
protein in the cell. Normally, MSH2 protein interacts with MSH6 and MSH3 proteins 
to form MutSα and MutSβ complexes respectively. These complexes are involved in 
repairing single nucleotide variants (SNVs), and small (up to 13 nucleotides long) 
insertion/deletions in the genome (Acharya et al., 1996; Drummond et al., 1995; 
Gupta et al., 2012; Lang et al., 2011; Martín-López & Fishel, 2013; Umar et al., 
1996). Perturbation of MSH2 protein abundance affects the abundance of these 





accumulation of more variants, including those that alter the activity of the 
oncogenes/tumor suppressor genes, so increasing the chances of cancer.  
 
This informal description of how a MSH2 variant affects cancer risk is derived from 
considering the information reported in 17 publications. These publications contain 
varying combinations of structured and unstructured data and use many different 
diagrammatic representations. The scattered nature of information about the 
mechanisms by which human variants affect phenotypes is a general trend: querying 
for well-studied disease-related variants such as ‘CFTR rs113993960’ (X. R. ober. 
Wang & Li, 2014), ‘FTO rs1558902’ (Shimaoka et al., 2010) and ‘NOD2 rs2066847’ 
(Hugot et al., 2001a; Ogura et al., 2001) on LitVar (a PubMed and PMC search 
engine for genetic variant data) (Allot et al., 2018) returns ~100 – 200 publications. 
Multiple projects have addressed the resulting knowledge integration problem, 
including the building of disease-specific knowledge managements resources (for 
example alzforum.org (Kinoshita & Clark, 2007)), development of natural language 
processing (NLP) based texting mining methods (DARPA’s Big Mechanism program 
(Cohen, 2015)), development of statistical methods for genotype-phenotype evidence 
integration (Konopka & Smedley, 2020), and the community-driven systems 
medicine disease maps project (Mazein et al., 2018). Each of these contributes 
elements of a solution, but none provides a systems-level representation of the disease 






There have also been major technological advances in the development of tools to 
represent biological mechanism descriptions. These include graphical notations 
(SBGN (Systems Biology Graphical Notation) (Novère et al., 2009a)) and computer-
readable languages (SBML (Systems Biology Markup Language) (Hucka et al., 
2018), KGML (KEGG Markup Language) (https://www.genome.jp/kegg/xml/docs), 
RDF (Resource Description Framework), BEL (Biological Expression Language, 
https://bel.bio/)) to encode representations, software to draw/visualize models (GO-
CAM (Thomas et al., 2019), PathWhiz (Pon et al., 2015), and Cytoscape (P. Shannon 
et al., 2003)), linked data formats such as Nanopublications (http://nanopub.org/) to 
organize provenance and metadata for scientific assertions (Mina et al., 2015), and 
database management systems to store and query graph-based representations (Neo4j 
- https://neo4j.com/). These tools have helped in the creation of pathway databases 
(such as KEGG (Minoru Kanehisa et al., 2016) and Reactome (Fabregat et al., 2017)), 
causal activity models (GO-CAM (Thomas et al., 2019)), causal biological networks 
(Boué et al., 2015), and knowledge graphs that integrate information about bio-
entities (genes, compounds, and diseases) and their relationships (https://het.io/).  
 
Most of these resources overlay disease mechanism information on depictions of 
‘normal’ biological pathways. Two examples are shown in figure 1-1, for KEGG and 
Reactome depictions of Lynch syndrome related mechanisms. Figure 1-1 A is part of 
the KEGG disease pathway map of colorectal cancer (accession: hsa05210), showing 
the relationship between the inactivation of DNA mismatch repair genes (such as 





cancer pathway map is created by adding graphical indicators to represent the 
disease-related perturbations on top of the normal pathway representation. In this 
instance, the colorectal cancer map was created by combining parts of nine normal 
pathways, including those for the cell cycle, apoptosis, and p53 signaling. 
 
 
Figure 1-1. Disease mechanism representations in pathway databases. Both types of 
representation add disease mechanism symbols to ‘normal’ pathways and only show 
perturbations at the molecular level. Figure 1-1 A shows part of the colorectal cancer 
pathway in KEGG (accession: hsa05210) illustrating gene products (green boxes) and 
their interactions (e.g. protein-protein interactions) or relations (e.g. expression, 







arrows with cut marks represent missing or reduced interactions due to mutations. 
Disease-related processes (such as anti-apoptosis and proliferation) are annotated in 
the pathway. Figure 1-1 B shows part of the Defective Mismatch Repair Associated 
With MSH2 pathway in Reactome (accession: R-HSA-5632928.1). Green boxes 
represent proteins, a  red boundary box indicates the presence of a genetic variant, 
light blue boxes represent complexes, ovals represent small molecules, black arrows 
represent normal reaction types, red crosses represent perturbed entities, and red 
arrow represent perturbed reaction types caused by the genetic variants. 
 
 
In the map, the ‘disease genes’ (for instance hMSH2 and hMLH1) are colored red and 
interactions affected by mutations in them are indicated by adding cut marks to the 
corresponding ‘normal’ arrows. Figure 1-1 B shows part of the Reactome disease 
pathway for defective mismatch repair associated with MSH2 (accession: R-HSA-
5632928.1). This disease pathway was created by adding perturbation indicators to 
the normal state of the mismatch repair pathway (accession: R-HAS-5358508.1). 
Perturbed entities are indicated by red crosses, perturbed reaction types by red lines, 
and the presence of genetic variants is indicated by red boundary boxes.  
 
These two pathway representations describe disease mechanisms as perturbations at 
the molecular level only and do not show how perturbations propagate through the 
higher stages of biological organization to cause a disease phenotype. This issue is 
partly addressed by the systems medicine disease map project: these disease maps 





metabolic, and gene regulatory processes at different levels of granularity including 
molecular, subcellular, cellular, tissue, organs, and organism. But they do not 
represent the perturbation propagation across the levels (Mazein et al., 2018). 
Currently, disease maps have been generated for 14 diseases, for example, cystic 
fibrosis, Parkinson’s disease, asthma, and lung cancer. The interactive graphical 
interface includes a feature to zoom in/out from cellular to molecular stages, showing 
the mapping of information across the stages. 
 
 
Figure 1-2. Parkinson’s disease map. Figure 1-2 A shows the top-level view,  







of a neuron), cellular processes (such as autophagy, cell death, calcium signaling) and 
cell types (such as astrocyte). Figure 1-2 B shows the zoomed-in molecular level view 
inside the astrocyte. Green boxes represent proteins, green parallelograms represent 
mRNAs, green ovals represent small molecules, purple colored hexagons represent 
phenotypes, the pink oval shows a drug, and arrows represent reaction types (e.g. 
association, binding, dissociation, transition). Sub-cellular locations (such as the 
nucleus and mitochondria) are also shown.      
 
 
Figure 1-2 shows a view of the Parkinson’s disease map. The top-level view (Figure 
1-2 A) displays a mosaic of disease-related cell types, and related cellular 
components and processes. Zooming into a specific tile displays the normal molecular 
interactions (Figure 1-2 B) but not the perturbed interactions of the diseased system. 
Uncertainties, ambiguities, and ignorance in mechanistic knowledge are not presented 
in the disease maps (only Reactome pathway diagrams label uncertain reaction types). 
This is a serious omission since such knowledge gaps exist in almost all disease 
mechanisms (Greenberg & Amato, 2004; Kametani & Hasegawa, 2018). 
 
The two primary deficiencies of these disease mechanism representations–lack of 
means of displaying the propagation of disease-related perturbation across stages of 
biological organization and absence or inadequate inclusion of knowledge gaps, 
uncertainties and ambiguities–motivated us to develop a new graphical framework for 
disease mechanisms.  Design goals for this framework include depiction of 





possible representation (only included features directly related to disease 
mechanism); an intuitive way to visualize ignorance, uncertainties, and ambiguities in 
the mechanistic information; and tight linkage to evidence in the literature and 
databases. Chapter 3 discusses the design and implementation of this framework.    
 
1.3 Quantitative modeling of complex trait diseases 
1.3.1 Quantitative modeling of biological systems   
Biological systems are formally complex systems that have interconnected and 
interdependent components orchestrating non-linearly to produce system behavior 
(such as regulation of genes, or induction of immune response) in response to inputs 
(Hillmer, 2015). To understand the emergent properties of these systems, either a 
reductionist approach is used where small modular subsystems are discovered and 
studied (for example (Süel, 2011)), or a synthesis approach is used that involves 
approximating a complex system via a tractable number of components (Ellner & 
Guckenheimer, 2006) (for example, (Tsuda et al., 2009)). In both approaches, it may 
be possible to use descriptive sentences to represent relationships within or between 
system components, but exhaustively deriving the implications of these relationships 
is prohibitively laborious, error-prone, and imprecise. Therefore, quantitative models 
are built to numerically describe how system components cross-talk and control 
system output. These models are imperfect but provide a virtual version of a system 
that can be tested to see if it captures salient features (Hillmer, 2015). Successful 
models of this type also allow investigation of system response to varied external 





intensive, costly, and sometimes impossible to achieve experimentally. Model 
building involves first choosing appropriate mathematical and/or computational 
methods that best capture the nature of the biological system and then following an 
iterative procedure (model train-predict-test-repeat all) to fine-tune the model 
properties. Quantitative modeling has a long history and has been used for studying a 
wide range of biological systems including tissue models of the human heart (Kohl & 
Noble, 2009), explaining the chemical basis of morphogenesis (Turing, 1952), and 
predicting disease spread (Keeling, 2005). Another important application of 
quantitative modeling has been to understand the mechanisms of complex trait 
diseases.  
 
Complex trait diseases (for example hypertension, type 2 diabetes, and Crohn’s 
disease) are caused by multiple genetic (DNA variants), epigenetic (such as DNA 
methylation), and environmental factors that perturb the interactions between 
components located within and across stages of biological organization so as to 
manifest the disease phenotype. Many computational modeling approaches have been 
devised to precisely (though not necessarily accurately) model the disease state and so 
obtain insights into the underlying mechanisms. Three primary approaches are 
network modeling, genome-scale metabolic modeling (GEM), and kinetic modeling:  
(1) In network modeling, construction of biomolecular (such as gene-gene and 
protein-protein) association networks is carried out based on large scale data (such as 
RNA-Seq co-expression, and affinity-purification – mass spectrometry (AP-MS)), 





analyzed to discover and characterize the biological significance of the highly 
connected genes/proteins often using packages such as WGCNA (Langfelder & 
Horvath, 2008), and also to identify differences in network structure between healthy 
and disease states using a differential network approach (Ideker & Krogan, 2012). 
Network modeling has resulted in many large-scale networks used to investigate the 
disease states, for example (Greene et al., 2015; Daniel S. Himmelstein & Baranzini, 
2015; Thul & Lindskog, 2018). As these network models are built on data measured 
under a specific stimulus to a biological system, inferring the new network properties 
(such as edge weights) of the model for other instances of the stimulus, for which data 
does not exist or is hard to generate, can be challenging for this modeling approach. 
(2) In genome-scale metabolic modeling (GEM), organism-specific stoichiometric-
based metabolic reaction networks are compiled and analyzed to predict metabolic 
fluxes using linear programming. The latest human GEM (Recon3D (Brunk et al., 
2018)) contains 5835 metabolites, 10600 reactions, and 2248 genes. GEMs can be 
used to identify the impact of the disease-associated genes by knocking out the 
gene/reaction during flux balance analysis (N. E. Lewis et al., 2012). GEM models 
have been used to study types of cancer (such as breast cancer (Gámez-Pozo et al., 
2017), prostate cancer (Asgari et al., 2018; Marín de Mas et al., 2018)), as well as 
chronic diseases (such as type 2 diabetes (J. Sarkar et al., 2019; Väremo et al., 2015)). 
Despite these developments, it has been reported that GEM-based simulations alone 
are insufficient to provide insights into disease mechanisms and there is a need for a 
computational framework that allows simultaneous simulation of material flow 





to capture the highly complex cues and cascading of signals in the diseased system 
(Gu et al., 2019).  
(3) In kinetic modeling, in contrast to genome-scale modeling, a smaller set of 
reactions with known kinetic parameters (such as rate and affinity of reactions) are 
defined by nonlinear differential equations or partial differential equations to indicate 
changes in product concentration during a time period (Resat et al., 2009). These 
models have been developed to understand very specific dynamic aspects of a disease 
such as T cell autoreactivity in autoimmune diseases (Ramos et al., 2019), 
mononuclear phagocyte system function in systemic lupus erythematosus (Meryhew 
et al., 1986), and amyloid formation in prion disease (Come et al., 1993). Large 
kinetic models are also being built to capture the interactions for understanding 
system-wide properties (Bordbar et al., 2015). However, several issues (Miskovic et 
al., 2015) have been noted as the size of the model increases such as difficulties in 
estimating values of the large number of parameters, because of uncertainty in 
available data but also the intrinsic ‘sloppiness’ of these systems, implying a need for 
very high accuracy for some parameters in a kinetic model (Gutenkunst et al., 2007).  
 
Although these modeling approaches are useful to study aspects of biological 
systems, none of them demonstrates the capacity to build large multiscale integrative 
models that can capture emergent properties of a complex disease at each scale 
(Tiwary, 2020). Recently, an integrated model for yeast cells (DCell, http://d-
cell.ucsd.edu/) (J. Ma et al., 2018a) has been built using an old concept of a hybrid 





was first used to model a bioreactor, combining prior knowledge with a neural 
network to estimate the unknown process parameters. It was shown that the hybrid 
model had better properties than standard ‘black-box’ neural network models in terms 
of being easier to analyze and interpret, and requiring significantly fewer training 
data. In the yeast DCell model, prior knowledge is in the form of the Gene Ontology 
(Ashburner et al., 2000) hierarchical structure of 2526 biological subsystems in a 
eukaryotic cell. Those data are integrated with a deep neural network. The model is 
claimed to simulate growth phenotypes in response to gene knockout(s) as accurately 
as laboratory observations (J. Ma et al., 2018b). A key feature of the DCell model is 
interpretability: in spite of the use of a deep neural network, because of the biology-
based architecture, genotype/phenotype relationships can be interpreted in terms of 
perturbed subsystems and their interactions. Thus, DCell provides a proof-of-concept 
on the feasibility and utility of this type of hybrid model for studying biological 
systems.   
 
The fourth chapter focuses on developing a computational framework for building 
integrated quantitative models of complex diseases using a hybrid neural network. 
The approach takes as input results from the mechanism representation framework 
(MecCog (Darden et al., 2018)) described in the third chapter, where the mechanisms 
by which genetic variants cause disease phenotypes are represented as perturbation 






1.3.2 Genetic variants relating to complex trait disease   
As sequencing and genotype technologies have advanced, methods for finding 
genetic variants (primarily single nucleotide polymorphisms (SNPs)) associated with 
the complex trait diseases have evolved. Initially, family-based linkage analysis was 
used to identify chromosomal regions containing the relevant genes. For example, the 
IBD1 risk locus on chromosome 16 for Crohn’s disease (CD) was discovered in this 
way and later was more finely mapped to determine NOD2 as the susceptibility gene 
(Hugot et al., 1996, 2001b). However, the overall results from this approach were 
poor because it could not be applied to finding all relevant genes across the whole 
genome. The advent of genotyping microarray technologies made it possible to screen 
hundreds of thousands of genetic variants in case and control populations allowing 
genome-wide association studies (GWAS). GWAS analyses have also been 
performed to screen for genetic variants associated with continuous traits, such as 
blood pressure (Yan Wang & Wang, 2018), body mass index (Willer et al., 2009), 
age at menarche (He et al., 2009), and height (Allen et al., 2010). A variety of 
statistical approaches have been devised to identify disease-associated variants in 
GWAS (Hayes, 2013). As far as possible, population structure and other confounding 
effects are taken into account in these approaches. The incidence of false positives is 
reduced by validation using an independent dataset. Because of linkage 
disequilibrium (LD), a GWAS variant found to be associated with a phenotype is not 
itself likely to be involved in disease mechanism, but is likely in LD with a variant 
that is. For example, the Illumina Human Omni2.5S-8 chip with only 2.5 million 





al., 2014)). A fine-mapping process is often used to identify the genetic variants in the 
LD region around each GWAS associated variant that are most likely to causally 
influence the examined trait (Schaid et al., 2018). Approaches like GWASeq, a 
targeted re-sequencing follow-up to GWAS loci, (Salomon et al., 2016) are used for 
this purpose. Variant findings from the many GWAS studies are curated and 
maintained in the GWAS Catalog database (https://www.ebi.ac.uk/gwas/). As of 
September 2018, the database contains 71673 variant-phenotype associations based 
on 5687 GWAS studies (Buniello et al., 2019).  
 
Unlike the rare causative variants of monogenic diseases, where each variant usually 
has a large impact on the function of a single protein, the functional effects of 
complex trait variants contributing to a complex trait are usually more subtle and 
often not yet known (Cleynen & Halfvarsson, 2019). Functional interpretation of 
these variants is challenging because: (a) the majority of associated variants are 
located in the non-coding region of the genome with only a small fraction in the 
coding region, making it hard to identify the affected genes and the ways in which 
their function is affected (Edwards et al., 2013; Giral et al., 2018), and (b) the variant 
effect can be influenced by gene-gene and gene-environment interactions. Currently, 
functional genomics datasets (Cano-Gamez & Trynka, 2020), chromatic organization 
datasets (Soskic et al., 2019), and epigenetic datasets (Tak & Farnham, 2015) are 
being used to assist in functionally interpreting the statistical association of these 
variants with the disease phenotype. For example, a previous study on predicting 





seven complex diseases (bipolar disorder, coronary heart, Crohn’s disease, 
hypertension, rheumatoid arthritis, type 1 & 2 diabetes), using an expression 
quantitative trait loci (eQTL) dataset, and in silico tools to predict variant impact, 
found possible mechanisms for 76% of the 356 disease-associated loci (Pal et al., 
2015).  
 
1.3.3 Limitations of GWAS   
Although GWAS has been extremely effective at identifying variants associated with 
complex traits, it has a number of limitations. One is the fact that observations are 
unavoidably made against the varied genetic background found in a human 
population. For example, the effect size of phenotype-associated variants is an 
average over all individuals in the sampled population (Stringer et al., 2011). In 
model organisms, many instances (Galardini et al., 2019; Vu et al., 2015) have been 
reported on the differences in single variant effect size as a function of genetic 
background. For example, in Drosophila melanogaster the severity of the retinitis 
pigmentosa disease phenotype (as measured by the eye size) caused by a missense 
mutation (G69D) in the rhodopsin gene (Rh1) has a strong Drosophila-strain 
dependent effect, with eye size varying from ~14K to ~28K pixels (Chow et al., 
2016). In the fourth chapter, the variation in effect size of human GWAS variants as a 
function of genetic background and its consequences for GWAS are investigated 






A second GWAS limitation is that despite continuous efforts to discover and interpret 
GWAS variants, these variants explain only a small proportion of heritability – the 
portion of phenotypic variance in a population attributable to genetic factors (Kendler 
& Neale, 2009). Heritability of a disease phenotype is zero if it is fully dependent on 
environmental factors and is one if it is only determined by genetic factors. For the 
complex trait diseases, the heritability is between 0 and 1 and is often estimated from 
twin studies. Only a small proportion of the estimated heritability is explained by 
GWAS variants, for example (Manolio et al., 2009), only 20% for Crohn’s disease 
(Barrett et al., 2008), 15% for systemic lupus erythematosus (Harley et al., 2008), and 
6% for type 2 diabetes (Zeggini et al., 2008). Many hypotheses (Maher, 2008) have 
been put forward to explain the reasons for missing heritability. One explanation 
often advanced is the role of epistatic interactions in which one or multiple genes 
influence(s) the effect of another. These effects are not captured by GWAS. The 
fourth chapter investigates the extent of epistatic interactions using the quantitative 
model for complex disease.   
 
1.3.4 Epistatic interactions between genetic variants  
Three different types of epistasis have been proposed (Phillips, 2008): 
(A) Functional epistasis describes the interaction between proteins, either directly in 
the form of protein complexes or indirectly by operating within the same pathway.  
(B) Compositional epistasis describes the altering of the effect of one allele by an 
allele at another locus, in the presence of a specific genetic background. In model 





Sopko et al., 2006) have been conducted to analyze compositional epistatic effects 
between gene pairs. For example, using a Synthetic Genetic Array (SGA) analysis 
that enables large-scale construction and selection of yeast double-mutant strains, the 
majority of all possible yeast gene pairs (~18 million) revealed a network consisting 
of nearly one million genetic interactions (Costanzo et al., 2016). More recently, 
using CRISPR (clustered regularly interspaced short palindromic repeats)-based 
combinatorial loss-of-function screens, epistatic interactions in human cancer cell 
lines have been analyzed to (i) identify potential targets for synthetic lethal-based 
cancer therapy (Najm et al., 2018; Shen et al., 2017), and (ii) identify drug target 
genes for combinatorial therapies in cancer (Han et al., 2017). However, measuring 
compositional epistasis at the human population level is not possible because of the 
very varied genetic backgrounds.  
(C) Statistical epistasis describes the average effect of combinations of alleles at 
different loci estimated over the diverse genetic background found in a population. 
Because of the dependence of the epistatic effect size on genetic background, the 
average will underestimate the phenomena in some individuals and overestimate it in 
others. For example, in Escherichia coli, it has been shown that the size of the 
epistatic effect between two beneficial mutations varies drastically across strains 
(Yinhua Wang et al., 2013).  
 
Quantitative models of the relationship between GWAS risk variants and a phenotype 
such as those outlined earlier effectively incorporate functional epistatic effects – 





potentially can provide a way to determine the compositional epistasis for pairs of 
variants in each individual from GWAS data - the size of the epistatic effect in each 
specific genetic background.  Results in the fourth chapter of this dissertation 
demonstrate this integration of functional, compositional, and statistical epistasis 




The dissertation is organized as follows. In Chapter 2, I start by summarizing the use 
of targeted sequencing approaches in genetic testing for clinical diagnosis of 
monogenic diseases and highlight the inadequacy of the computational methods used 
to interpret the clinical significance of the genetic variants. I then introduce the CAGI 
gene panel challenge that our lab participated in, and for which I developed a variant 
prioritization pipeline for identifying causative variants from gene panel sequencing 
data. I provide a detailed CAGI assessment report of the variant prioritization pipeline 
performance and discuss how its performance may be improved. In Chapter 3, I 
summarize the inadequacy of existing representations for describing disease 
mechanisms at the system level. I then introduce the theory of the MecCog 
framework for graphically representing disease mechanisms. I describe the web-based 
implementation of MecCog and illustrate its use for qualitative representation of 
disease mechanisms. In Chapter 4, I summarize the use of the MecCog framework in 
constructing disease mechanism graphs and as a use-case describe the mechanism 





encoding technique to generate computable circuits from mechanism graphs and 
demonstrate the use of a hybrid neural network approach to learn properties of the 
circuit in a data-driven manner. I show a use-case of how such a disease mechanism-
based circuit can be used to analyze epistatic interactions between genetic variants. In 
Chapter 5, I summarize the conclusions of the three projects and describe the future 
perspectives on improving genetic disease diagnosis, standardizing evidence of 
pathogenicity for disease causative variants, ways of scaling the disease mechanism 
representations in MecCog, and broader use of the quantitatively encoded disease 










Chapter 2: Determination of disease phenotypes and pathogenic 




Kundu, K., Pal, L. R., Yin, Y., & Moult, J. (2017). Determination of disease 
phenotypes and pathogenic variants from exome sequence data in the CAGI 4 gene 
panel challenge. Human Mutation, 38(9), 1201–1216.  
My contribution: computational experiment and data analysis 
 
2.1 Abstract 
The use of gene panel sequence for diagnostic and prognostic testing is now 
widespread, but there are so far few objective tests of methods to interpret these data. 
We describe the design and implementation of a gene panel sequencing data analysis 
pipeline (VarP) and its assessment in a CAGI4 community experiment. The method 
was applied to clinical gene panel sequencing data of 106 patients, with the goal of 
determining which of 14 disease classes each patient has and the corresponding 
causative variant(s). The disease class was correctly identified for 36 cases, including 
10 where the original clinical pipeline did not find causative variants. For a further 
seven cases, we found strong evidence of an alternative disease to that tested. Many 





disease, and these proved the hardest to correctly assign pathogenicity or otherwise. 
Post analysis showed that three-dimensional structure data could have helped for up 
to half of these cases. Over-reliance on HGMD annotation led to a number of 
incorrect disease assignments. We used a largely ad hoc method to assign 
probabilities of pathogenicity for each variant, and there is much work still to be done 
in this area.  
 
2.2 Introduction 
Genetic testing in clinical laboratories is becoming increasingly common: As of 
March 2017, GeneTests.org contains entries for about 706 labs and 1,083 clinics 
worldwide performing a total of 67,187 tests on 5,926 genes for 4,963 genetic 
conditions. So far though, there has been only limited testing of method efficacy 
(Cornish & Guda, 2015; Hwang et al., 2015; McCarthy et al., 2014; Pirooznia et al., 
2014).  Many of the genetic tests use targeted gene sequencing panels for identifying 
variants in a set of genes or gene regions that are known to be associated with a 
disease (Kammermeier et al., 2014; Okazaki et al., 2016). In clinical laboratories 
specializing in specific diseases or classes of disease, panels provide high coverage 
data for genes of interest at relatively low cost, and also reduce the issues in reporting 
incidental findings to patients. A key and challenging step in all these tests is the 
ability to accurately interpret the genetic variants and assign a likelihood of 






Potentially pathogenic sequence variants fall into three classes: (a) those almost 
certain to cause major loss of protein function (LoF), arising from the introduction of 
premature stop codons, frameshifts caused by small insertions or deletions, and direct 
hits on splice sites; (b) those that may or may not significantly affect gene regulation 
(such as regulatory variants at transcription factor binding sites) or protein function, 
particularly missense variants; and (c) those that are more likely benign, particularly 
synonymous, UTR, and deep intronic variants. The main challenge lies in 
understanding the phenotypic consequences of the large fraction of variants falling 
into the last two classes. Most clinical laboratories follow a semi-automated approach 
for variant interpretation, first making use of available variant annotation and 
prioritization tools and then checking the potential causative variants’ association 
with the disease of interest in databases and the literature. For the first step, there are 
dozens of annotation and prioritization tools (open-source or commercial) available 
(for example, Wang et al. 2010; Cingolani et al. 2012; Sifrim et al. 2013; Robinson et 
al. 2014; McLaren et al. 2016), typically providing potentially causative variants 
based on inheritance pattern, allele frequency, genomic region of interest, mutation 
type and in silico analysis of the likely impact of missense mutations. It has been 
demonstrated that there are substantial discrepancies between existing annotation 
tools (McCarthy et al., 2014; Pabinger et al., 2014) so that there is a clear need to 
encourage and monitor advances in this field. In most clinical laboratories,  standard 
guidelines such as those from the American College of Medical Genetics and 
Genomics (ACMG) (Richards et al., 2015a) are followed for variant interpretation 





pathogenicity for variants, these are only considered a ‘supportive’ evidence. Other 
evidence is required to classify a variant as causative. As a consequence, the overall 
contribution of computational methods for variant classification is low and this 
motivates the development and testing of more accurate methods for variant 
interpretation. 
 
CAGI (Critical Assessment of Genome Interpretation) is an organization that 
conducts community experiments to objectively assess computational methods for 
predicting phenotypic impacts of genomic variation 
(https://genomeinterpretation.org/). The most recent round of experiments (CAGI4) 
included a challenge to determine which of 14 disease classes each of 106 patients 
has and the corresponding causal variants, given each patient’s gene panel sequencing 
data (https://genomeinterpretation.org/content/4-Hopkins_clinical_panel). The gene 
panel dataset consists of exons with flanking regions and some complete intron 
sequencing data for 83 genes from each patient. Data were provided by the Johns 
Hopkins DNA Diagnostic Laboratory. The Laboratory is a CLIA and CAP certified, 
Maryland, New York, and Pennsylvania licensed clinical genetic testing laboratory 
specializing in rare, inherited disorder testing 
(http://www.hopkinsmedicine.org/dnadiagnostic/tests/).  
 
The data were made available to registered CAGI participants, and all were required 
to deposit disease and variant assignments by a specified deadline. The anonymized 





(http://enigma.lbl.gov/chandonia-john-marc/) and Shamil R. Sunyaev 
(http://genetics.bwh.harvard.edu/wiki/sunyaevlab/), and results were later discussed at 
the CAGI4 conference. A paper on the assessment is part of this CAGI special issue 
of Human Mutation (Chandonia et al., 2017). 
 
The identification of causal variants requires a number of carefully controlled 
procedures for assessing the quality of the data, accurate variant annotation, handling 
of unphased genotypes, and an appropriate probability model that can prioritize 
primary and secondary disease findings. With these considerations in mind, we 
developed a new variant prioritization pipeline (implemented in Python) called VarP 
(https://github.com/kunduk/VarP) using a combination of open-source and in-house 
software tools for analyzing gene panel sequencing data. This pipeline was the most 
successful of those used in CAGI, in the sense that it resulted in the correct matching 
of the highest number of panel exomes to disease class. 
[https://genomeinterpretation.org/sites/default/files/protected_files/4-
Hopkins_clinical_panel_assessor1_AAdhikari_remixable.pptx]. Nevertheless, the 
results are far from perfect. In this chapter , we describe the design and 






2.3 Materials and Methods 
2.3.1 Capture bed files, gene panel sequencing data, and the disease class 
The Johns Hopkins DNA Diagnostic Laboratory panel sequencing procedure 
generates sequence for all exons plus a boundary of 50 bases up and down stream and 
some introns for 83 genes (1350 exonic and 39 intronic regions), covering 14 
monogenic disease classes. 73 of these genes are known to harbor mutations for one 
of the 14 monogenic disease classes. The remaining ten genes are known to harbor 
mutations for two or more disease classes. Sequences had been captured using one of 
the two custom probe sets (Agilent SureSelectXT Target Enrichment Kit) and 
sequenced using Illumina MiSeq to generate paired-end reads (2X100 nt reads). Two 
capture bed files (v01, v02) describing the two probe sets were provided as part of the 
challenge. The Hopkins group called sequence variants and produced two VCF files 
for each patient, one a gVCF for single nucleotide variants (SNVs; using GATK 
UnifiedGenotyper, v2.7-4) and the other a VCF for insertion-deletion variants (Indels, 
GATK HaplotypeCaller, v2.7-4). For the challenge, all VCF files from 106 patients 
had been combined into two files, one each for SNVs and Indels.  
 
2.3.2 Building the gene list for disease classes 
All the genes annotated in the two capture bed files (v01 and v02) were extracted to 
compile a list of genes to examine. The description of 14 disease classes was 
provided on the challenge webpage 
(https://genomeinterpretation.org/sites/default/files/protected_files/4-





Diagnostic Laboratory website to map genes to disease class 
(http://www.hopkinsmedicine.org/dnadiagnostic/). The website lists a number of gene 
panel tests and also gives a detailed description of the genes associated with each 
disease as well as their inheritance pattern. Using this resource we were able to group 
53 of the 83 genes to 12 disease classes and obtain the inheritance pattern. We used 
literature and the Genetic Home Reference Database (http://ghr.nlm.nih.gov/) to 
group another 24 genes to some of the disease classes and obtain the inheritance 
pattern. In total 77 out of 83 genes were grouped among the 14 disease classes as 
shown in Table 2-1. The remaining 6 genes (DHODH, TRIM37, EFTUD2, AMACR, 
AGXT and CAT) are associated with diseases that are not related to any of the 14 






Table 2-1. The 14 disease classes and genes identified as relevant to each class. 
Genes associated with more than one disease class are indicated by an asterisk.  
2.3.3 Gene Panel Sequencing data analysis pipeline 
The method developed for this challenge (VarP - Variant Prioritization) uses open-
source and in-house software tools to analyze gene panel sequencing data with 
respect to rare genetic disorders in an automated manner. The method has four 
modules – Variant annotation, QC (quality control) analysis, Variant Prioritization, 
and estimation of the probability of each variant being causative for the disease. The 
four modules were executed in a sequential manner (Fig. 2-1). The inputs were the 





each disease class and their inheritance pattern (autosomal dominant/recessive, 




Figure 2-1. The Variant Prioritization (VarP) Method. Circles represent the four 
modules. Modules are executed sequentially starting from Variant Annotation and 
ending with Probability Scoring. The ‘Varant’ tool in step 1 annotates variants with 
genomic region of occurrence, mutation type, minor allele frequency and prediction 
of pathogenicity for variants. Ts/Tv=Transition/Transversion, 
Het/Hom=Heterozygous/Homozygous AD=Autosomal Dominant, AR=Autosomal 
Recessive, CH=Compound Heterozygous, XD=X-linked dominant, XR=X-linked 




Variant Annotation: The two VCF files (one for SNVs and another for Indels) were 
annotated using Varant (http://compbio.berkeley.edu/proj/varant, 
doi:10.5060/D2F47M2C). Details on Varant are provided in the Appendix. Varant 
annotated each variant in the VCF files with region of occurrence (intron, exon, splice 





2016) and 1000 Genomes Phase-3 (Auton et al., 2015), mutation type (missense, 
nonsense, silent, frameshift and non-frameshift indels), predicted impact on protein 
function, and previously associated phenotypes reported in ClinVar (Landrum et al., 
2016). Varant used dbNSFP (v2.9) (Jian et al., 2014) database to fetch the mutation 
impact predictions from PolyPhen-2 (v2.2.2) (Adzhubei et al., 2013), SIFT (release 
Jan, 2015) (Kumar et al., 2009) and CADD (v1.2) (Kircher et al., 2014). The 
RefGene (Pruitt et al., 2014) gene definition file was used for gene and transcript 
annotations. The principal isoforms of each gene were taken from the APPRIS 
database (Rodriguez et al., 2013). In addition, the VCF files were annotated with 
SNPs3D (May, 2015) (Yue et al., 2006) mutation impact predictions, HGMD 
(version June 2014) (Stenson et al., 2003) disease-related variants and with dbscSNV 
(Jian et al., 2014) variants that potentially alter splicing.  
 
Quality control Analysis: Three types of QC analyses were run on the Hopkins’ 
dataset. The first QC analysis is a comparison of Transition vs. Transversion ratio 
(Ts/Tv), Heterozygous vs. Homozygous variants (Het/Hom), no call sites vs. low 
quality sites and common vs. rare vs. novel variant counts across all 106 samples and 
with those in a control variant set from 2,504 samples in 1000 Genomes Phase-3 
(Auton et al., 2015). No call sites (sites where neither reference nor alternate allele 
was called) and low-quality sites (sites not marked PASS and/or genotype quality less 
than or equal to 30) per sample were computed from the challenge gVCF file. A 
variant is considered novel if it was not present in the 1000 Genomes and ExAC (Lek 





both of these datasets. Other 1000 Genomes or ExAC variants were considered 
common. Only SNVs flagged as PASS in the VCF file and with a genotype quality 
(GQ) greater than 30 were included in the analysis. Scatter plots were generated to 
represent the results. The QC module also estimated which samples are of African 
ethnicity, to aid in interpretation of variant count differences. The ethnicity analysis 
used the population-specific allele frequency (AF) from the 1000 Genomes Phases-3 
dataset to identify population enriched variants (i.e. variants that are common (AF > 
0.05) in a population but rare (AF <= 0.05) in other populations). Samples whose 
African population enriched variant count was highest in number compared to other 
populations in 1000 Genomes (Admix American, South Asian, East Asian and 
European) were assigned African ethnicity. The second QC analysis is a comparison 
of the average read depth for 83 genes across 106 samples, using the read depth 
provided in the gVCF file. The module produced a heat-map of these data, allowing 
convenient visual inspection for anomalies. The third QC analysis identifies capture 
regions (exon or intron) with anomalous read depth with respect to other captured 
regions in the same gene, where the anomaly is found in at least 85% of the samples. 
Anomalous coverage was identified by first computing the average read depth across 
the gene (µ) and its standard deviation (σ), and then checking each region for 
significantly low (< µ - 2σ) or high (> µ + 2σ) coverage. The anomalous coverage 
regions were then visually inspected using gene coverage plots. 
 
Identification of potentially causative variants: Only rare or novel variants rated high 





search for causal variants. At this stage, a rare variant was defined as one reported in 
ExAC (Lek et al., 2016) with a minor allele frequency (MAF) less than or equal to 
0.01 and a novel variant was defined as one not found in ExAC. Indels in low 
complexity regions (LCR) were excluded from the analysis, based on the LCR dataset 
computed for the human genome by Heng Li (Heng Li, 2014). For each sample, each 
QC qualified variant in each of the 83 genes was assigned to one of four categories, 
ranked by the likelihood that the variant is causative.  
Category 1: Variants reported in HGMD with either DM (disease-causing mutation) 
or DP (disease-associated polymorphism) status, and/or reported in ClinVar with 
pathogenic or likely pathogenic clinical significance.  
Category 2: Variants annotated as nonsense mutations, direct splicing mutations 
disrupting either a splice donor or acceptor site, frameshift or non-frameshift causing 
Indels, splice altering variants predicted in the dbscSNV database, and missense 
mutations predicted as damaging by one or more of SNPs3D, SIFT, PolyPhen-2 and 
CADD. 
Category 3: Variants annotated as missense but not predicted to be damaging by any 
of the above methods, and UTR and intronic variants. 
Category 4: All other variants (including synonymous and all with MAF > 0.1). 
These were not considered as potentially causative.  
Each variant was also grouped by frequency based on its ExAC MAF: group 1 - 






For each sample, the variant assigned to the lowest category was taken as the 
potentially causative variant. If there were two or more variants with the same 
category, the one in the lowest frequency group was selected. When there were two or 
more variants with the same category and frequency group, all were selected. Once a 
selection had been made, no other variants in that sample were considered. Category 
1 variants were assumed to be of highest confidence, followed by category 2 and 3 
variants and so selection was made in that order: If a suitable variant or variants were 
found in Category 1, no category 2 ones were considered, and similarly, if suitable 
variants were found in Category 2, no Category 3 ones were considered. No phase 
information was available for these data, so for non-homozygous variants where the 
inheritance model of the gene containing the selected variant required a second allele 
as part of a compound heterozygous pair, the next ranked variant in that gene was 
selected. 
 
Thus, for each of the 106 samples, the output from the module was usually one (for 
dominant or homozygous recessive situations) or two (for compound heterozygous 
situations) potentially causative variants in a particular gene. Since each gene is 
associated with one or more of the 14 disease classes (shown in Table 2-1), 
identification of a gene implied one or in some cases two possible disease classes. For 
some samples, no potentially causative variants were found, or for compound 







Estimating probability for the disease: Table 2-2 lists the probability of pathogenicity 
assigned for each category of potentially causative variant. Category 1 variants (based 
on HGMD or ClinVar entries) were assigned a probability of 1.0, except for some 
missense variants where prediction methods suggested low impact.  Category 2 
missense variants were assigned a probability based on the extent of consensus 
among the four missense impact analysis methods used (SNPs3D, SIFT, PolyPhen-2, 
and CADD), utilizing a calibration from HGMD data and a control set of inter-
species variants. That calibration shows a strong and approximately linear 
dependence of pathogenic probability on agreement between methods (Supp. Figure 
S1). Other variant types were subjectively assigned probabilities as shown in Table 2-
2. For autosomal recessive situations, the combined probability of pathogenicity was 
taken as the product of probabilities for the two contributing variants. Those values 
were incremented by 0.2 for homozygous cases, as an ad hoc correction for increased 
confidence, and by 0.1 in compound heterozygous situations. Based on this scoring 
scheme, a probability of pathogenicity for a disease class was generated for all the 
samples in which one or more potentially causative variants were identified. For the 
cases in which a gene was associated with more than one disease class, equal 






Table 2-2. Pathogenicity probability estimates for each variant type. 
 
 
2.3.4 Post-challenge analysis 
We performed many post-challenge analyses on the results in order to gain insight 
into the performance, strengths, and weaknesses of the method, and in doing so, made 
a number of observations. We assessed performance based on the official answer key 
provided by the Johns Hopkins DNA Diagnostic Laboratory group. For each patient, 
the key specified the disease class, the possibly causative variants (if any) found in 
the subset of the 83 genes examined, and a classification of each of these variants 
(pathogenic, likely pathogenic, VUS (variant of uncertain significance), likely benign 
and benign). The Hopkins classifications were based on the ACMG evidence rules 







2.4.1 QC analysis summary 
Supp. Figures S2 and S3 and Supp. Table S1 (in Appendix) together with 
accompanying text provide details of the QC analysis. Overall, transition/transversion 
ratios and heterozygosity/ homozygosity ratios are consistent with those found in 
1000genome data, with the exception of one sample (P8) with excess homozygosity. 
There are a maximum of 2000 low quality and 940 no-call calls per sample in the v01 
capture data and lower numbers in v02. We expect that any causative variants at these 
positions would be missed. Common, rare, and novel variant (SNV and Indel) counts 
for all the samples are consistent with 1000 genome data, except for two outlier 
samples identified as of African ethnicity which have larger rare Indel counts. The 
average read depth per gene per sample is high (greater than 100X) with the 
exception of two capture regions (Exon-53 and Exon-60 of HYDIN gene in Supp. 
Figure S4) where anomalous coverage could potentially result in causative variants 
being missed or in false positives. 
 
2.4.2 Missense mutations are amplified in the potentially causative variant set 
The VCF files provided for the challenge have a total 2311 unique variants across the 
106 patients. This variant set consists of 40% intronic variants, 26% missense 
variants, 20% synonymous variants, and 14% of variants that are assigned as LoF 
(frameshift Indels, non-frameshift Indels, and nonsense), UTR, or splicing (Fig. 2-





frequency filters (MAF <= 1% in ExAC), the total number of variants was reduced by 
almost 50% to 1291, with 233 variants filtered because of low quality and 787 further 
variants filtered because of high MAF. Figure 2-2B shows that the frameshift and 
non-frameshift indels decreased the most (by 40% and 27%) on applying the PASS 
filter and NonSyn, Syn, UTR, CodingIntronic and ‘Close to splice site’ variants 
decreased the most (by 37 to 42%) on applying the frequency filter. After all filtering, 
138 out of the 1291 variants were assigned as potentially causative by the 
prioritization procedure. In this set, the fraction of LoF variant is 16% and the fraction 
of missense variants is doubled to more than half (56%), while intronic variants drop 
to 8% and synonymous to 1%. The high fraction of potentially causative missense 
variants emphasizes the importance of correctly interpreting this class of mutation. 
 
Figure 2-2. Distribution of variant types for the gene panel sequencing data for 83 
genes from 106 patients. Figure 2-2A: Distribution of variant types. The outer circle 





challenge. The middle circle shows the distribution of high-quality rare variants after 
applying PASS, GQ and frequency filters using data in the VCF file. The inner circle 
shows the distribution of potentially causative high quality rare and novel variants in 
104 patients after applying the variant selection algorithm. Missense and loss of 
function variants are substantially enhanced in the latter set. Figure 2-2B: Changes in 
the variant type distribution during the filtering process, from total VCF variants, to 
those annotated as PASS, to those with low frequency, and finally those selected as 
potentially causative. The heat map indicates the percent decrease in variants on 
applying each filter (in the direction indicated by the arrows): the larger the decrease, 
the more orange; the smaller the decrease, the more green. The frameshift and non-
frameshift Indel count decreased the most (by 40% and 27%) on applying the PASS 
filter and NonSyn, Syn, UTR, CodingIntronic, Close to splice site variants decreased 
the most (by 37 to 42%) on applying the frequency filter. 
 
 
2.4.3 Matching individuals to disease class 
Application of the categorization procedure described in Methods resulted in a non-
zero probability for a specific disease class being assigned to 87 of the 106 patients. A 
further 17 patients were assigned a non-zero probability for two disease classes, as a 
consequence of a single gene being associated with two of the 14 disease classes. 
Two patients (P59 and P86) were not assigned to any disease class. P59 had the 
lowest average read depth for 50 genes out of 83 and next to lowest for the other 33 







2.4.4 Correct disease assignments also made by Hopkins 
Overall, the assessors determined that we made correct disease assignments for 36 of 
106 cases (Fig. 2-3A), in the sense that the highest probability was assigned to the 
disease class specified in the Hopkins answer key. The Hopkins group reported 
“pathogenic”, “likely pathogenic, or “variant of uncertain significance” (VUS), based 
on ACMG variant classification, for 43 cases (Fig. 2-3B).  The VarP pipeline 
assigned the maximum probability to the same disease class for 26 of these 43 cases, 
with the same variants assigned as causative. There are two primary reasons for our 
non-identification of the other 17 cases (row 6 and row 10 in Fig. 2-3A). First, for 10 
of these patients, the Hopkins group found only one heterozygous variant in genes 
known to be associated with disease in a recessive inheritance pattern. Our method 
considered this insufficient evidence. Second, for the remaining seven patients we 
found an alternative disease that ranked higher in the variant categorization scheme. 
As noted in Methods, the selection scheme only considered the disease identified by 
the highest-ranked variants, and rejected all others. Had we considered diseases 
identified by lower confidence categorizations, five of these seven cases the Hopkins 
reported disease would have received 2nd ranking; one 3rd ranking; and one 4th 







Figure 2-3. Disease assignment statistics for the 36 patients with correctly identified 
disease class. Figure 2-3A: Distribution of the number of patients across prediction 
performance. The highlighted numbers represent the patients with correct disease 
class assignment. The reasons for incorrect disease assignment are described in the 
text. Figure 2-3B: Distribution of Positive cases (orange) are those found by Hopkins 
to be carrying pathogenic or likely pathogenic variants, the VUS cases based on 
ACMG guidelines (yellow) are those carrying variants of uncertain significance and 
Negative cases (grey) are those in which no causative variant was found by Hopkins. 
* indicates the number of cases with correct disease class assignment. The VarP 
pipeline assigned the correct disease class for 26 of the Positive and VUS cases and 
also correctly assigned disease class (with potentially causative variants) in 10 of the 







2.4.5 Additional correct disease assignments 
Out of the 63 patients for which the Hopkins analysis found no causative variants in 
the genes ordered as part of the clinical test, our method made 10 correct assignments 
of disease class and assigned potentially causative variants (row 5 in Fig. 2-3A). 
Seven of these patients were found to carry autosomal dominant or homozygous 
recessive variants and remaining three patients carried compound heterozygous 
variants. For nine of these 10 cases, the gene hosting the potentially causative variant 
was not analyzed by the Hopkins group, presumably because coverage was not 
selected by the requesting physician. For the remaining case, the Hopkins group did 
not report the potentially causative variant even though they analyzed the relevant 
gene. For the other 53 patients (row 6 and row 9 in Fig. 2-3A), neither our method nor 
the Hopkins group found any causative variants for the expected disease class. 
However, we found potentially causative variants for a different disease in four of 
these patients, suggesting alternative diagnoses (see the Alternative Diagnosis 
section).  
 
2.4.6 Assignment of probability 
In order to estimate the accuracy of our probability model, we checked how well the 
probability of pathogenicity scores correlated with incorrect disease class assignment. 
The dependence of incorrect disease assignment on assigned probability follows the 
correct trend, with a high fraction at low probability and a lower fraction at high 
probability (Fig. 2-4). However, there are 25 patients with incorrect disease class 





this: 1. High confidence given to DM status HGMD variants – 11 of the 25 anomalies 
are of this type. These are discussed below in the Selection section and listed in Table 
2-4. 2. In five cases, there were pairs of Indels (frameshift or non-frameshift) close 
together (less than 10 bp apart, Supp. Table S2) in the CCDC40 gene and classified 
by us as causative compound heterozygous variants. Very likely,  these are false 
Indels arising from alignment errors or errors near perfect repeat regions (Fang et al., 
2014). 3. In two cases there are two heterozygous variants predicted damaging by 
three methods in genes associated with recessive disease. It is possible that these are 
the same copy of the gene (no phasing information was available). 4. In the remaining 
seven cases, we found possible alternative diagnoses. These are discussed in detail 
below.  
 
Figure 2-4. Distribution of patients with incorrectly assigned disease class versus 





each bin (e.g. in the 0.8 to 1.0 bin, 10% of disease assignments are expected to be 
incorrect). Bars show the % of patients in each bin that actually have incorrect 
assignments. Bar colors show the number of patients with assignments made in each 
category (Category 1, most confidence). The error bar for each bin is the standard 
deviation of the number of patients in that bin. As should be the case for a good 
probability algorithm, patients with a high probability of a correct disease assignment 
do have a lower rate of incorrect disease classes. However, the plot also shows that 
there are 25 patients with high probability scores (> 0.8) but incorrect disease class. 
15 of these patients carry variant(s) reported as pathogenic (tagged as DM) in the 
HGMD database. Reasons for this are discussed in the text. 
 
 
2.4.7 Variant assignment accuracy for each Selection Category 
As described in Methods, we used a work flow to assign variants to one of three 
categories, ranked by likelihood of pathogenicity. Table 2-3 shows the percent of 
correct disease assignments for variants in each category. The highest fraction of 
cases (42%, 11 out of 26) agreeing with the Hopkins disease class were based on 
Category 1 variants. The corresponding fractions for Category 2 and Category 3 
variants are 38% and 23% respectively.  This trend is expected, since assignment 






Table 2-3. Percentage of correct disease assignments in each of the three variant 
selection categories. As expected, accuracy is highest in Category-1, then Category-2, 
then Category-3. Novel variant assignments are more accurate than for rare variants. 
 
 
As noted earlier, Category 1 variants are those annotated in HGMD and/or ClinVar as 
disease-causing. Further inspection showed that 11 of the 15 discordant assignments 
cases had conflicting database annotations and sometimes weak or no supporting 
evidence (Table 2-4). In seven cases, the corresponding variant is annotated ’DM’ 
(disease mutation) in HGMD but is annotated ‘benign’ or ‘likely benign’ in ClinVar. 
Consistent with the ClinVar annotation, a check of the supporting literature for these 
showed either no experimental support or no evidence favoring pathogenicity. For the 
other four cases, ClinVar had no relevant entry and there was no literature support. 
Seven of these 11 cases involved missense variants, and none of those were rated 
 
Category Variant Considered 
Minor Allele Frequency % Correct 
Assignment Novel <= 0.005 <=0.01 
Category-1 
In HGMD with DM, DP status 
and/or in ClinVar with 
Pathogenic or Likely pathogenic 
tag 
4/4 7/19 0/3 11/26: 42% 
      
Category-2 
Missense (Predicted damaging 
either by SNPs3D, SIFT, 
PolyPhen2 or CADD) 




Any variant predicted damaging 
by dbscSNVs 
9/14 7/28 2/5 18/47: 38% 
      
Category-3 
All other missense, UTR, and 
Intronic 













high confidence pathogenic by our consensus method. With the wisdom of hindsight, 
we should have factored these considerations into the categorization and probability 
procedures, and placed less faith in HGMD. The remaining four discordant 
assignments have either functional validation of the variant as damaging or are 
annotated as pathogenic in ClinVar as well. As discussed later, these four patients 
may really have a different disease. 
 
Category 2 variants are those selected because of being a LoF variant, the 
computational method assigning pathogenicity for missense variants, a direct hit on a 
splice site, or a prediction of an impact on splicing (Jian et al., 2014). The 18 correct 
assignment cases include seven compound heterozygous and 11 autosomal dominant 
or recessive cases. Seven out of these 11 cases carry a LoF (nonsense, frameshift or 
non-frameshift Indel) or direct splicing variant, and the remaining four carry missense 
variants (two predicted damaging by two methods and two predicted damaging by 
one method). The 29 cases with discordant disease class with respect to the Hopkins 
information in this category include 11 compound heterozygous cases and 18 
autosomal dominant or recessive cases. For the 11 discordant compound 
heterozygous cases, the assumption that the two variants are appropriately phased is a 
likely cause of misassignment. The 18 other cases include one frameshift Indel and 17 
missense variants. Of the 17 missense, only one was high confidence, predicted 
damaging by all four methods. Four were damaging by three methods (expected 
accuracy 0.8), 10 were damaging by two methods (expected accuracy 0.5), and two 






Category 3 variants are missense mutations predicted benign by all four 
computational methods and those which are intronic or in a UTR. All were assigned 
low causative probability, ranging from 0.05 to 0.29. There are only seven out of 30 
with correct disease class assignments that were assigned based on Category 3 
potentially causative variants. Six of these seven cases carried intronic insertions or 
deletions close to a splice site (within 5 to 30 bases), suggesting proper treatment of 
this mechanism is important. The remaining case carries a missense mutation 
predicted benign by the four mutation impact prediction methods.  
 
There is a marked dependence of level of agreement with the Hopkins disease class 
and the frequency of the potentially causative variants (Table 2-3): 49% of disease 
assignments made for novel variants agree with the Hopkins answer key, compared to 
27-30% for the other, non-novel variants with less than 1% MAF. 
 
 
Table 2-4. List of variants reported in HGMD with DM or DP status but not 
supported by other data and leading to an incorrect diagnosis. MAF: Minor Allele 
Frequency. These variants were present in 11 patients. Green: benign missense 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.8 Alternative Diagnoses 
There is an important difference between the Hopkins lab procedures and the CAGI 
challenge. In the lab, in accordance with clinical guidelines, for each patient, variant 
analysis was performed only on the subset of genes identified by the physician 
requesting the test, usually those for a single disease, and sometimes only a subset of 
genes for a single disease. On the other hand, the challenge required analysis of all 
genes for each patient. That led to a number of findings suggesting that in some cases, 
causative variants are overlooked in the clinic. Of the 70 cases where our disease 
assignments and the disease tested by the Hopkins pipeline differ, seven have strong 
evidence supporting assignment to a different disease (Table 2-5). In four of these 
cases, no variants supportive of the tested disease were found by ourselves or by 
Hopkins. In two further cases, the Hopkins pipeline reported only one variant in a 
recessive gene and for the remaining case (patient P8 in Table 2-5), there is evidence 
that the patient may have two diseases. These seven cases fall into three groups:  
 
1. Three cases where the patient carried variants likely causative of a disease 
phenotype that has overlapping symptoms with the disease tested at Hopkins. One of 
these is a patient (P36) carrying a very rare (AF=0.0047 in ExAC) autosomal 
dominant missense mutation (rs5738:G>A, NM_001039.3:c.589G>A, p.(E197K)) in 
exon-3 of the SCNN1G gene. This mutation is reported in HGMD and ClinVar to be 
causative for Bronchiectasis with pathogenic clinical significance (Fajac et al., 2008). 
The patient was tested for Diffuse Lung disease and no variants with the required 





previously shown to be associated with Idiopathic Pulmonary Fibrosis, one of the 
diseases in the Diffuse Lung disease class. ( International Consensus Statement of the 
American Thoracic Society and the European Respiratory Society. 2000; Bourke 
2006).  
 
2. One case where a patient (P8) carried a variant reported in HGMD and ClinVar to 
have pathogenic clinical significance for a disease other than that tested for, and 
where the tested and apparent diseases cannot be easily confused. P8 carries a very 
rare (AF=0.0051 in ExAC) homozygous recessive mutation (rs1800098:G>C, 
NM_000492.3:c.1727G>C, p.(G576A)) in the CFTR gene, consistent with the disease 
class ‘Cystic Fibrosis and CF-related disorders’. A functional study found the 
mutation causes an increased amount of skipping of exon-12 during splicing (Pagani 
et al., 2003). This patient was originally tested for Peroxisomal Beta-Oxidation 
Defects and a homozygous recessive frameshift mutation was found in the relevant 
gene. We did not report that variant because of finding the CFTR variant which we 
categorize as higher confidence of pathogenicity. The data are consistent with the 
patient having both diseases.   
 
3. Three cases where the patient carried variant(s) predicted damaging by all 
reporting computational methods or a LoF variant. For example, one of these is a 
patient (P46) to whom we assigned ‘Treacher Collins and Related Syndromes’ based 
on a very rare (MAF = 0.0002 in ExAC) missense mutation (rs538401137:C>T, 





damaging by all four computational methods. This patient was tested for the Diffuse 
Lung disease class in the Hopkins pipeline, and no variants consistent with that 
phenotype were found by them or us.  
 
 
Table 2-5. Patients carrying putative causative variants for an alternative disease. 
AD=Autosomal Dominant, AR=Autosomal Recessive, CH=Compound Heterozygous 
(for AR cases, the listed variant is homozygous). The table is divided into three case 











2.4.9 Protein structure coverage for potentially causative variants 
In principle, information from three-dimensional structure and on the detailed 
functional roles of residues, motifs, and domains should be of considerable value in 
evaluating the impact of missense variants. In practice, it is often ignored, and indeed 
we did not use it in this challenge. What difference might it have made? To 
investigate this, we considered only potentially causative missense variants that are 
not included in HGMD or ClinVar. Current ACMG guidelines (Richards et al., 
2015a) would place a low weight on computational analysis of these, and thus they 
would likely be reported as VUSs. There are 47 such missense variants distributed 
over 41 patients. ~50% (23/47) of these are either included in an experimental 
structure or can be included in a homology model based on 22% or higher sequence 
identity to an experimental structure (Fig. 2-5A). Three of these mutations are in 
proteins with experimental structure (X-ray structure). We use these three cases to 
illustrate how protein structure could be used to: (a) supplement the sequence analysis 
methods to increase confidence in a pathogenic or benign assignment and (b) 
understand the pathogenicity mechanism at the protein level. Two of these mutations 
have correctly assigned disease classes and causative variants in our submission. One 
of those is of a novel mutation (NM_000901.4:c.1807T>A, p.(C603S)) at a highly 
conserved position in the Mineralocorticoid receptor. This protein is associated with 
Pseudohypoaldosteronism Type 1. Although we correctly identified this mutation 
from sequence information, only two of the four (SNPs3D, SIFT, PolyPhen2, CADD) 
methods assigned it as pathogenic, and the other two did not. Thus additional 





structure (PDBID: 4TNT) showed that the wild-type amino acid (CYS-603) is a zinc 
ligand in a zinc finger domain (Fig. 2-5B). Many other zinc ligand mutations in these 
domains cause loss of function of the corresponding proteins (Kambouris et al., 2014; 
Vincent et al., 2014), providing additional evidence of pathogenicity. The second case 
with correct disease assignment is of another novel mutation 
(NM_000492.3:c.3849G>C, p.(R1283S)) at a highly conserved position in the second 
nucleotide binding domain of the CFTR protein. Mutations in CFTR cause Cystic 
Fibrosis, one of the disease classes in the Hopkins dataset. This mutation is predicted 
damaging by three out of four (SNPs3D, SIFT, PolyPhen2, CADD) sequence 
methods. Inspection of the protein structure (PDBID: 3GD7) hosting this mutation 
shows the wild type side chain (R1283) makes two charge-dipole interactions with 
main chain carbonyl groups of L1258 and R1259, providing a helix cap (Hol et al., 
1981), consistent with significant destabilization of the structure  (Fig. 2-5C). Loss of 
protein stability has been shown to be the most common cause of monogenic disease 
(Wang and Moult 2001; Yue et al. 2005).  A different mutation at this position 
(rs77902683, NM_000492.3:c.3848G>T, p.(R1283M)) has previously been found in 
CF patients (Cheadle et al., 1992) and has been reported as pathogenic in ClinVar and 
HGMD. 
 
The third mutation with experimental structure coverage is one where we made an 
incorrect disease assignment on the basis of just one of the four missense analysis 
methods predicting deleterious. Although that was already a low confidence 





ExAC) variant (rs147398624:G>A, NM_000901.4: c.2578G>A, p.(V860I)) in the 
Mineralocorticoid receptor, with an autosomal dominant pattern disease inheritance 
pattern. The mutation is located on the protein surface (PDBID: 2AA5) and is not part 
of any known interface, providing further evidence the mutation is benign. 
 
 
Figure 2-5. Structural coverage of prioritized missense mutations. Figure 2-5A: 
Missense variant distribution: 1) Known (variant reported in HGMD or ClinVar) 
versus VUS variants, 2) Structural coverage for VUS variants, 3) Number of 
mutations in different sequence identity ranges between the protein hosting the 
mutation and the closest available homologous protein in the PDB. Figure 2-5B and 
2-5C show two examples of structure assisting mutation interpretation. Figure 2-5B: 





including the mutation C603S found in a Hopkins patient, showing that C603 is one 
of the Zn ligands. Analogy to other zinc coordinating mutations in zinc fingers 
provides strong evidence structure and hence function will be disrupted. Figure 2-5C: 
Mutation R1283S, found in one of the Hopkins patients, is predicted deleterious by 
the three out of four computational methods. Inspection of the structure shows 
disruption of two charge-dipole interactions forming a helix cap, expected to 
significantly destabilize the structure. 
 
2.5 Discussion 
The CAGI4 challenge based on panel sequencing data provided by the Johns Hopkins 
DNA diagnostic laboratory has allowed a blind test of current methods for identifying 
causative variants in clinical rare disease sequence data. Participants were asked to 
match each of 106 patients to one of 14 classes of disease. To address this challenge, 
we developed an analysis pipeline, VarP, designed to identify potentially causative 
variants. Using this pipeline, we were able to correctly match 36 patients to the 
reported disease class. The analysis provided a number of insights into issues related 
to gene panel testing, including the relationship between data quality and success in 
finding causative variants, variant prioritization procedure limitations, inconsistencies 
in databases, and cases of possible alternate diagnosis.  
 
2.5.1 Undiagnosed cases 
Even with full knowledge of the reported disease class, the Hopkins pipeline could 





variants. As discussed below, we were able to find variants correctly matching a 
further 10, but that still leaves half (53) of the cases where neither we nor Hopkins 
could find variants. There are three major factors that may contribute to the high 
fraction of undiagnosed cases. First, a limitation in all studies of this type is data 
quality. Our QC analysis suggests the Hopkins data are generally of high quality. 
Read depth per gene per sample is high (between 107X to 983X) and each sample has 
only about 2000 positions with no call or a low-quality variant call. But there are 
some particular sample level properties in the data that may affect analysis. For 
example, sample P8 (tested for an autosomal recessive disease, Peroxisomal Beta-
Oxidation defect) has an abnormally high fraction of homozygous variant calls 
compared with heterozygous ones, increasing the chances of finding an apparently 
causative homozygous variant. Our pipeline identified a potentially causative 
homozygous missense variant in CFTR, consistent with cystic fibrosis, and annotated 
as pathogenic in both HGMD and ClinVar, whereas the Hopkins pipeline found a 
homozygous frameshift variant in HSD17B4, consistent with the tested disease. There 
are also some areas of low coverage, for instance 78 samples have zero coverage of 
Exon-60 in HYDIN. Variants in this gene may cause Primary ciliary dyskinesia. 
Overall though, sequencing data quality does not appear to make a large contribution 
to missing diagnostic variants. 
 
A second factor contributing to non-identification of causative variants is that there 
may be other, unknown, genes where variants cause the disease phenotype. Many 





year period, Beaulieu et al. 2014). Thirdly, the causative variants may have been not 
covered in the panel, which consists of mostly exon sequence. Missing variants may 
include those affecting the expression of a relevant gene, CNVs, and larger scale 
structural genomic changes. In some rare disease analyses using whole genome 
sequence (WGS), such as in the SickKids Genome Clinic 
(http://www.sickkids.ca/CGM/genome-clinic/index.html), the latter type of variant 
has been found to make a significant contribution (Stavropoulos et al., 2016). 
However, those patients mostly exhibit major developmental disease phenotypes, and 
may not be typical of rare disease patients in general.  
 
2.5.2 Correct diagnosis for cases where Hopkins pipeline did not find causative variants 
For 10 cases we were able to identify the reported disease class even though Hopkins 
reported no potentially causative variants. In nine out of these ten cases, the Hopkins 
pipeline did not include analysis of the gene carrying the diagnostic variant(s). 
Apparently this is because the requested test did not include the gene, a choice made 
by the referring physician. As noted earlier, Hopkins is only permitted to analyze the 
requested gene set.  For the 10th (a compound heterozygous case where one of the 
variants is missense predicted damaging by four methods and other is an intronic 
variant close to a splice acceptor), Hopkins did not report the potentially causative 






2.5.3 Missed diagnoses 
There are 17 cases where we did not identify the correct disease class, but the 
Hopkins analysis did find potentially causative variants. For 10 of these, the Hopkins 
variants are in genes expected to have a recessive inheritance pattern, and only one 
heterozygous variant was present – not sufficient for our evidence rule. Had we used 
such a weak criterion for inheritance model filtering many more false positives would 
have been generated. Thus these should not be regarded as failure of the VarP 
approach but rather an appropriate filtering strategy used in VarP.  In the other seven 
cases where Hopkins found variants, VarP found stronger evidence for a different 
disease class. For two of these, as discussed below, we consider the evidence that the 
patients have the VarP identified disease very strong, and if so, these also are not 
errors.  For the other five, we made two sorts of errors. One was placing too much 
trust in HGMD that affected three cases – in each of these cases the HGMD 
annotations were incorrect and contradicted or not supported by ClinVar or 
experimental data. The other source of error was for two compound heterozygous 
cases where one of the partner variants was a low impact missense (predicted benign 
by 1/4 methods) or an intronic variant and so provided very weak evidence. In 
retrospect, the procedure of taking just the most likely causative variant(s) and 
ignoring all other variants in a patient was sub-optimal. A better procedure would 
probably be to use all variants in each gene to assign a probability of pathogenicity 






2.5.4 Incorrect diagnoses 
For 25 patients VarP made high confidence (probability score > 0.8) incorrect disease 
class assignments. A primary factor was again over-reliance on HGMD annotation, 
accounting of 11 of the 25 cases. A further five cases involved pairs of Indels very 
close to each other (less than 10 base pairs apart), and consistent with a compound 
heterozygous cause for a recessive disease. In fact, these Indel pairs are probably 
coupled alignment errors. There are two cases where the assumption that a pair of 
recessive variants are on different copies of the gene may be incorrect (there was no 
phasing data available). In seven of the remaining cases, we found high confidence 
pathogenic variants in genes associated with a different disease from that in the 
Hopkins answer key. As discussed later, the evidence for some of these is sufficiently 
strong that they may not be errors.   
 
2.5.5 Distinct potentially causative variants that led to disease classification 
VarP identified 105 potentially causative variants each of which occurs once in a total 
of 78 patients. A further 14 potentially causative variants were seen in two or more of 
the other 28 patients (Supp. Table S3). We also considered accuracy in terms of the 
fraction of these 119 distinct variants which led to correct and incorrect disease 
assignments. By this measure, correct disease identification increases from 34% 
(36/106) to 36% (33/91). The improvement occurs because the majority of repeat 
variants are present in cases where an incorrect disease was assigned, and we 






2.5.6 Reliability of probability for disease assignments 
In the clinic, perhaps more important than having an accurate method of determining 
pathogenicity is having an accurate method for assigning a probability of correctness 
to a pathogenic assignment. The CAGI challenge required participants to also provide 
these probabilities, and so it was possible to evaluate how effective our approach was. 
We used a largely ad hoc probability scale in this analysis. Although there is a 
reasonable overall correlation between these quantities (Fig. 2-4), there were a 
substantial number of variants assigned a high probability that were not in fact 
pathogenic. There were two primary reasons for that – first, as noted earlier, we 
misjudged the reliability of HGMD assignments of disease mutations. Had we used a 
model that included disagreements between HGMD and ClinVar, these cases would 
have had more appropriate probabilities. Second, as discussed below, in a number of 
cases we consider the evidence strong that these patients had a different disease.  
 
2.5.7 Reliability of missense probability estimates 
As described in the Results, overall, the estimated probabilities of pathogenicity 
shows qualitative though not quantitatively correct properties. The majority of 
potentially causative variants are missense, so improved confidence in assigning a 
probability of pathogenicity to these are of particular importance. As described 
earlier, we assigned a probability based on the fraction of four different missense 
analysis methods reporting deleterious. The method was calibrated (Yin et al., 2017b) 
using a set of HGMD mutations (all assumed pathogenic) and a set of interspecies 





we were interested to see to what extent the estimated probabilities were useful. 
Interpretation of the results is complicated by the alternative diagnosis cases and by 
compound heterozygous cases, involving two different variants. Supp. Figure S5 
shows the relationship between estimated probabilities and correct disease class 
assignment, omitting those cases. Counts here are too small to draw firm conclusions. 
A high proportion of mutations assigned with a probability of less than or equal to 0.5 
are incorrect, consistent with expectations. However, more than half of the mutations 
with probabilities higher than 0.7 are also incorrect, not as expected. Further analysis 
Yin et al. (ref to Yin et al. CAGI issue paper when available) suggests that a 
probability method based on more than four missense impact prediction methods 
would have yielded better results. But clearly a more extensive blind test is needed to 
evaluate this approach.  
 
2.5.8 Apparent cases of alternative diagnoses 
Using quite stringent criteria we identified seven cases where the data are consistent 
with patients having a different disease class than that provided in the Hopkins 
answer key. Four of these patients carry variants for the alternative disease class that 
are reported in HGMD and ClinVar as pathogenic. The remaining cases carry 
missense variants predicted damaging by all reporting methods, frameshift or non-
frameshift indels, or variants directly affecting splicing. In three cases, symptoms of 
the answer key disease and the alternative overlap, so it is possible that there was a 
misdiagnosis in the referring clinic. The other cases are more puzzling. Since we have 





Hopkins group may not either), it is difficult to comment further. But it is concerning 
that in a number of cases there could be confusion of some sort as to what disease 
patients have. In these seven cases, the Hopkins pipeline did not report any variant for 
four cases, reported only one variant in a recessive gene for two cases and reported a 
homozygous frameshift mutation in the remaining case. The pipeline was prevented 
from discovering the possible alternatives by the current guidelines, which require 
that only requested genes for a specific disease test be examined. On the basis of 
these limited data, it is not clear whether on balance this practice is in the patients’ 
best interest. 
 
2.5.9 VarP performance improves when the patients’ clinical indications are known 
Clinical laboratories typically have information on each patient’s disease phenotype, 
and variants are evaluated with that knowledge. In that aspect, the CAGI Hopkins 
challenge creates an artificially harder problem, since disease class is not known to 
participants. If the disease classes were known, would VarP identify the variant(s) 
reported by Hopkins pipeline? We tested this scenario by searching for potentially 
causative variant(s) only in genes associated with each patient’s diagnosed disease 
class, using the VarP pipeline. On this basis, VarP identifies potentially causative 
variants for 61 patients, 18 more cases than the Hopkins pipeline. However, there are 
still nine cases where Hopkins identified potentially causative variants and VarP does 
not. As discussed earlier, these patients each carry only one heterozygous variant in a 






2.5.10 Better results have been obtained not using HGMD 
As noted earlier, 11 of the 25 incorrect disease class assignment cases with a 
probability of pathogenicity higher than 0.8 are a result of accepting HGMD 
annotations of pathogenicity. Such a high error rate from a single cause suggests that 
it might be better to ignore HGMD altogether and just use ClinVar for pathogenicity 
information. We tested this by running the VarP pipeline again, omitting HGMD. The 
success rate (correct match to disease class) increases from 36 to 40 (Supp. Table S4). 
 
2.5.11 Lessons learned 
Going forward, how would we now improve performance of the VarP analysis 
pipeline? As noted earlier, a suboptimal feature of the procedure was terminating the 
variant search once a suitable candidate had been found, rather than finding all 
possible causative variants and assigning each a probability. As also noted earlier, 
over-reliance on HGMD was a cause of errors and this can be corrected by 
considering ClinVar and HGMD annotations together, and, where appropriate, 
include missense impact analysis in assigning a probability to these Category 1 
variants. Structure also has the potential for contributing to the discovery of causative 
variants and providing mechanistic insight. However, full automation of that analysis 
will require the development of new methods. In general, much more work must be 
done to provide a reliable probability of pathogenicity, not only for missense but for 
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Chapter 3: MecCog: A knowledge representation framework for 
genetic disease mechanism 
3.1 Abstract 
Experimental findings on genetic disease mechanisms are scattered throughout the 
literature and represented in many ways, including unstructured text, cartoons, 
pathway diagrams, and network graphs. Integration and structuring of such 
mechanistic information will greatly enhance its utility. MecCog is a graphical 
framework for building integrated representations (mechanism schemas) of 
mechanisms by which a genetic variant causes a disease phenotype. A MecCog 
mechanism schema displays the propagation of system perturbations across stages of 
biological organization, using graphical notations to symbolize perturbed entities and 
activities, hyperlinked evidence tagging, a mechanism ontology, and depiction of 
knowledge gaps, ambiguities, and uncertainties. The web platform enables a user to 
construct, store, publish, browse, query, and comment on schemas. MecCog 
facilitates the identification of potential biomarkers, therapeutic intervention sites, 
and critical future experiments. 
 
3.2 Introduction 
Findings from experimental studies of disease mechanism are reported across 
multiple publications in varying combinations of structured and unstructured data and 
many different diagrammatic representations. A number of projects have addressed 





building disease-specific knowledge management resources (for example 
alzforum.org (Kinoshita & Clark, 2007)) and ontologies (ADO (Malhotra et al., 
2014), PDON (Younesi et al., 2015), CVDO 
https://bioportal.bioontology.org/ontologies/CVDO); compiling disease etiology 
databases (HGMD (Stenson et al., 2017), ClinVar (Landrum et al., 2018), CIVIC 
(Griffith et al., 2017), PanelApp (Martin et al., 2019)); development of biomedical 
text mining methods (DARPA’s Big Mechanism program (Cohen, 2015)); 
development of statistical methods for evidence integration and assessment (Konopka 
& Smedley, 2020); and community-driven expert systems medicine disease maps 
projects (Mazein et al., 2018). Each of these contributes elements of a solution, but a 
major omission is an integrated representation of mechanism knowledge in a clear, 
precise, and comprehensive manner. 
 
There have also been major technological advances in the development of tools to 
support mechanism descriptions, such as graphical notations (SGBN (Systems 
Biology Graphical Notation) (Novère et al., 2009b)) and languages (SBML (Systems 
Biology Markup Language) (Hucka et al., 2018), KGML (KEGG Markup language - 
https://www.genome.jp/kegg/xml/), BCML (Biological Connection Markup 
Language) (Beltrame et al., 2011), BioPAX (http://www.biopax.org/), BEL 
(Biological Expression Language - https://bel.bio/)) to encode representations; 
software to draw and visualize models (GO-CAM (Thomas et al., 2019), PathWhiz 
(Pon et al., 2015), Cytoscape (Paul Shannon et al., 2003)); linked data formats such as 





scientific assertions; and databases to store and query graph-based representations 
(Neo4j - https://neo4j.com/, (Daniel Scott Himmelstein et al., 2017)).  
 
With the help of these tools; pathway, network, and disease map representation types 
have been created to describe aspects of biological system mechanism and in some 
cases disease mechanisms as well. For instance, KEGG (Minoru Kanehisa et al., 
2016), and Reactome (Fabregat et al., 2017) pathways represent normal and perturbed 
molecular interactions that are part of cellular or metabolic processes. STRING 
(Szklarczyk et al., 2018) and GeneMANIA (Franz et al., 2018) networks represent 
integrated information on protein-protein interactions and associations that are part of 
normally functioning biological systems. Gene ontology (GO) causal activity models 
(Thomas et al., 2019) integrate GO annotations to generate larger models of normal 
biological function (such as ‘pathways’) in a semantically structured manner. The 
Disease Maps Project (Mazein et al., 2018) provides an encyclopedic description of 
disease-related signaling, metabolic, and gene regulatory processes. Although 
together these representations aptly describe the normal working of biological 
systems, representation of the disease-related perturbations is limited.  In the existing 
representations (such as KEGG or Reactome disease pathways), disease state 
perturbations and consequences are added locally to the depiction of the normal state 
of the biological system. Adding disease perturbation information to already complex 
pathway diagrams can be useful, but limits clarity. Also, uncertainties, ambiguities, 
and ignorance in mechanistic knowledge are not presented in most representations 





types only). Such knowledge gaps exist in almost all disease mechanisms (Greenberg 
& Amato, 2004; Kametani & Hasegawa, 2018).    
 
These considerations led us to propose a graphical framework with an integrated 
representation of genetic disease mechanisms from gene to phenotype. Our design 
goals were that the representation framework depict mechanism components across 
stages of biological organization; display perturbation propagation; make use of 
standard biomedical ontology terms wherever possible to name the components; 
provide an intuitive way to visualize ignorance, uncertainties, and ambiguities; and 
allow tight linkage to evidence in the literature and databases. The MecCog 
mechanism representation framework (Darden et al., 2018) incorporates all these 
features. The representation formalism is based on the analysis of biological 
mechanisms developed in the philosophy of biology (Craver & Darden, 2013): 
Mechanisms are characterized as entities and activities organized such that they are 
productive of regular changes from start or set-up to finish or termination conditions. 
In MecCog, a mechanism by which a genetic variant causes a disease phenotype is 
represented as a mechanism schema that displays the propagation of entity and 
activity perturbations across biological organizational stages 
(DNA→RNA→Protein→Complex→Organelle→Cell→Tissue→Organ→Phenotype) 
in the form of a graph (nodes are biological entities; directed edges are causal and 
labeled with productive activities) constructed from information in the biomedical 
literature in addition to established biological concepts. The schema structure uses 






In this article, we describe the implementation of the MecCog framework as a web 
platform with a collaborative environment to manually construct, store, publish, 
browse, query, and comment on mechanism schemas for genetic diseases. The 
schema building tool in MecCog is supported by specially designed graphical 
notations, curated ontology-informed terminology for the annotation of mechanism 
components (entities and activities), an interactive graphical user interface (GUI) to 
construct the schema drawings, application programming interfaces (APIs) to fetch 
reference information and scientific figures, tight integration and hyperlinking of 
evidence to the graphics, and a secure server to save schemas as JSON (JavaScript 
Object Notation) objects. The platform supports edit, version, and share operations on 
each schema to facilitate collaborative work. Mature schemas can be published on the 
platform, thereby adding to the collection of disease mechanisms available for 
browsing by MecCog web-site visitors. Sketchier schemas with gaps, ambiguities, 
and uncertainties can also be published to indicate where additional work needs to be 
directed. 
 
3.3 Methods and Results 
3.3.1 Mechanism schema representation structure 
In MecCog, a mechanism by which a genetic variant causes a disease phenotype is 
represented by multiple steps. Each step consists of a triplet with an input substate 
perturbation, a mechanism module, and an output substate perturbation (SSP-MM-





base change, altered stability of a protein, altered abundance of a molecular complex, 
altered state of a cell). A mechanism module represents the productive activity (e.g. 
transcription, translation, or protein-protein interaction) by which the input sub-state 
perturbation produces the output sub-state perturbation. The succession of 
overlapping SSP-MM-SSP triplets represents perturbation propagation across stages 
of biological organization (DNA, RNA, Protein, Complex, Organelle, Cell, Tissue, 
Organ, and Phenotype), and together form a mechanism schema. In MecCog, a 
schema is represented as a graph where the nodes are SSPs and edge labels are MMs, 
as illustrated in Figure 3-1.  
 
 
Figure 3-1. Principles of a mechanism schema. SSP: Substate Perturbation; MM: 
Mechanism Module. Each SSP represents a perturbed biological entity and each MM 
represents a productive activity (or a group of entities and activities) that produce an 
output SSP.  
 
Evidence about SSPs and MMs is curated from the literature. Ambiguities in a 
mechanism and possible alternative mechanisms are represented in a schema by 
branching. Branch points may be labeled with the logical operators AND, OR, or 
AND/OR. The degree of confidence as to whether each SSP and MM is part of a 
schema is indicated by an evidence strength color code (red least confidence to green 





other types of mechanism components are defined in MecCog: 1. Unknown 
mechanism module to represent ignorance about a mechanism component; 2. 
Biomarker to represent entities correlated with a disease phenotype; 3. Environmental 
factor to represent relevant external factors; 4. Hypothetical therapeutic intervention 
site; 5. Known therapeutic intervention site. 
 
3.3.2 MecCog platform web-architecture 
Figure 3-2 shows the web-architecture of MecCog. On the server-side, Node.js (an 
open-source JavaScript runtime environment) is used as the web-server, Sails.js is 
used to build the model-view-controller compliant web-application, and a MySQL 
relational database is used to store data on users and mechanism schemas. The 
MySQL database is connected to the web-application by the Object-relational mapper 
(ORM), Waterline, in Sails and all the database transactions use REST APIs secured 
by CSRF (Cross-site request forgery). The front-end GUI of MecCog is implemented 
using HTML, CSS, and Javascript, and is made responsive by Bootstrap.js javascript 
library. The schema building and visualizing GUI is powered by the Rappid 
Diagramming Javascript library (https://www.jointjs.com/). Rappid also provides a 
feature for converting diagrams to JSON format and for communicating with the 
database via AJAX requests. An open-source version of the IntenseDebate 







Figure 3-2. MecCog Web-Application Architecture. HTTP=Hypertext Transfer 
Protocol, REST API = Representational State Transfer Application Programming 
Interface, JSON=JavaScript Object Notation, SQL = Structured Query Language, 
ORM= Object-relational mapping.  
 
3.3.3 Graphical notation of mechanism components in MecCog 
Graphical notations symbolize components of a mechanism schema (Figure 3-3). An 
SSP (substate perturbation) is represented by a rectangle containing three types of 
information – the biological stage where the SSP occurs, the perturbation class name 
(curated from standard biomedical ontologies wherever possible), and the instance of 
that perturbation class. For example, a truncated NOD2 protein can be represented by 
an SSP with Protein as the stage name, Truncated Protein as the SSP perturbation 
class name (from BioAssay Ontology (Visser et al., 2011)), and NOD2:1007fs as the 
instance of the SSP class. A biomarker is a special case of an SSP and is represented 
by the same shape but with a different color. An environmental factor is represented 
by a cloud icon. Known and hypothetical therapeutic intervention sites are 
represented by pink and blue octagons respectively. A known mechanism module is 









Figure 3-3. Graphical notations for components in a mechanism schema. 
 
3.3.4 Mechanism schema meta-information and schema component annotations in MecCog 
Table 3-1 summarizes the mechanism schema data model. Table 3-1A shows the 
meta-information of a schema. Each schema in MecCog is identified by a unique 
accession number automatically generated by the platform. Schema authors provide a 
schema name, a schema caption, genes that are part of the schema, keywords relevant 
to the mechanism, names of authors who constructed the schema, and the name of the 
curator who publishes the schema, monitors comments, and approves changes. 
Authors also provide a schema description with scientific background information.  
 
Table 3-1B shows the mechanism component annotations. All mechanism 
components in a schema are annotated with a unique component identifier. Nine stage 





Complex, Organelle, Cell, Tissue, Organ, and Phenotype. For the molecular stages 
(DNA, RNA Protein, and Complex), a set of stage-specific SSP perturbation class 
names, such as SNV, mRNA abundance, or protein stability, have been compiled. 
Molecular stage MM classes, such as transcription, translation, and protein folding, 
are also defined (Table 3-2). Whenever possible the SSP and MM class names are 
curated from existing biomedical ontologies. Currently used ontologies are listed in 
Table 3-2. Where required, ontology terms may be prefixed with a modifier – 
increased, decreased, or altered. A MecCog schema builder may choose from the 
curated set of classes for a step, or may add new class names if needed. SSP and MM 
instance names are in free text. We are in the process of developing a disease 
mechanism ontology, based on the class names. Such an ontology is potentially useful 
for automatic text mining of SSP, MM, and triplet information from the literature, so 
speeding schema building by identifying relevant papers and sections of papers. 
Environmental factor names are in free text. Therapeutic intervention site components 
may be annotated with a potential therapy name or known drug name. 
 
For all mechanism components, five types of evidence annotation are defined (Table 
3-1C): 1. For Evidence PubMed IDs of papers that contain data supporting a 
component’s role in a mechanism; 2. Against Evidence PubMed IDs for papers that 
provide data suggesting a mechanism component is incorrect; 3. Links to figures in 
PMC that illustrate aspects of a schema by summarizing experimental results and 
evidence for spatial and structural features; 4. User assigned Confidence scores with 





on the strength of the available evidence; 5. Evidence Comments - brief free text 
comments that summarize the evidence. 
 
Table 3-1. Data Model of mechanism schema and component annotations. Text in 
parentheses indicates the data type.  
Table 3-1A. Mechanism schema meta-information 
Accession number (Automatically generated, versioned, alphanumeric) 
Schema Name (Free text – 300 character limit) 
Schema Caption (Free text – 500 character limit) 
Schema Description (Free text) 
Genes (Free text) 
Keywords (Free text) 
Curators (Free text) 
Authors (Free text) 
 
Table 3-1B. Mechanism component annotations 
Mechanism 
Component 
Component Specific Annotation 
SSP (Substate 
Perturbation) 
Component ID (Format: SSP#) 
Stage Name (Predefined list) 
SSP Class Name (Predefined list with the facility 
to add new names) 
SSP Instance Name (Free text) 
MM (Mechanism 
Module) 
Component ID (Format: MM#) 
MM Class Name (Predefined list with the facility 
to add new names) 
MM Instance Name (Free text; Optional) 
Biomarker 
Component ID (Format: BM#) 
Stage Name (Predefined list) 
Biomarker Class Name (Predefined list with the 
facility to add new names) 
Biomarker Instance Name (Free text) 
Unknown Mechanism 
Module 
Component ID (Format: MM#) 
Environmental factor 
Component ID (Format: EF#) 
Factor name (Free text) 











Component ID (Format: TT#) 
Potential therapy name (Free text) 
‘#’ represents an integer number denoting the order of the schema component (for 
example SSP1, MM3, BM1, TT2)  
 
Table 3-1C. Evidence annotations for the mechanism components 
For Evidence PubMed IDs (PMID number) 
Against Evidence PubMed IDs (PMID number) 
Figure links from PubMed Central (PMC figure number) 
Confidence score (Predefined integer score range 1 to 5) 





Table 3-2. Curated class names for Substate Perturbations (SSP) and Mechanism 
Modules (MM) at the molecular stages. The class names are curated from biomedical 















Number Variation, DNA Repeats, 
NCIT:DNA Structure, 
NCIT:Holliday Junction, DNA 
Supercoiling, DNA Curvature 
RNA 12 
SO:SNV, NCIT:IN/DEL, 
VARIO:Edited RNA, Fused 
mRNAs, RNA Repeats, mRNA 





Abundance, Edited RNA 









Fused Proteins, Protein Sequence 
Repeats, PLOSTHES:Protein 
Abundance, Splicing Isoform 
Abundance, Post-Translational 










Abundance, DNA-RNA Complex 
Abundance, BIPON:RNA-RNA 
Complex Abundance, GO:Protein-
DNA Complex Abundance, 
Transcription Complex Abundance, 
GO:Transcription Factor Complex 
Abundance, DNA-Scaffold 
Complex Abundance, DNA 
Replication Complex Abundance, 
DNA-Histone Complex Abundance, 
EDAM:Protein-Ligand Complex 
Abundance, ADMO:Protein-Protein 
Complex Abundance.  
MM - 24 
IXNO:Cleavage Rate, 
NCIT:Synthesis Rate, 
GO:Transport Rate, CRISP:Protein 
Degradation, NCIT:RNA 






Mediated Decay Rate, NCIT: 
Transcription Rate, GO:Translation 
Rate, DNA Internal Interactions, 
RNA Internal Interactions, Protein 
Internal Interactions, DNA-RNA 
Interaction, RNA-Ligand 
Interaction, IOBC:RNA-RNA 
Interaction, GRO:DNA Protein 
Interaction, GO:Scaffold Protein 
Binding, GO:Basal Transcriptional  
Machinery Binding, GO:Histone 
Binding, NCIT:RNA-Protein 
Interaction, NCIT:Protein-Protein 
Interaction, NCIT:Ligand Binding, 
Le Chatelier, GO:Signaling. 
SO: Sequence Ontology (Eilbeck et al., 2005); NCIT: National Cancer Institute 
Thesaurus (Sioutos et al., 2007); VARIO: Variation Ontology (Vihinen, 2014); 
EDAM: EMBRACE Data and Methods (Ison et al., 2013), MESH: Medical Subject 
Headings (https://meshb.nlm.nih.gov/), MI: Molecular Interactions 
(https://www.ebi.ac.uk/ols/ontologies/mi), CRISP: Computer Retrieval of 
Information on Scientific Projects Thesaurus 
(https://bioportal.bioontology.org/ontologies/CRISP), GRO: Gene Regulation 
Ontology (https://bioportal.bioontology.org/ontologies/GRO), BIPON: Bacterial 
interlocked Process Ontology (Henry et al., 2017), GO: Gene Ontology (The Gene 
Ontology Consortium, 2019), ADMO: Alzheimer Disease Map Ontology (Malhotra 
et al., 2014), PLOSTHES: PLOS Thesaurus 
(https://bioportal.bioontology.org/ontologies/PLOSTHES), BAO: BioAssay Ontology 





(https://bioportal.bioontology.org/ontologies/IXNO), IOBC: Interlinking Ontology 
for Biological Concepts (https://bioportal.bioontology.org/ontologies/IOBC). 
 
3.3.5 Rules for constructing mechanism schemas in MecCog 
1. Each schema begins with a genome perturbation and ends in perturbation of a 
disease-related phenotype such as greater risk of a disease.  
2. Overall, the sequence of SSPs in a schema progresses through successive stages of 
biological organization, from DNA, through RNA, proteins, macromolecular 
complexes, organelles, cells, tissues, organs, and finally to a phenotype. There may be 
one or more or no SSP at any particular stage of organization and the order of the 
stages need not follow a prescribed order. For instance, the schema for Lynch 
syndrome 
(http://www.meccog.org/mchain/showpubchain?accession=MS020700047.3), where 
a causative mutation results in decreased DNA mismatch repair, reverts to the DNA 
stage after stages involving macromolecular complexes.  
3. Each pair of SSPs is linked by an MM. The granularity of an MM may be a single 
activity (such as splicing, protein-protein interaction, ligand binding, or protein 
folding) or may represent telescoped combinations of entities and activities (such as 
protein synthesis, or cell-cell signaling). If an activity is unknown, the black oval 
unknown mechanism module notation is used.  
4. Class names for the SSPs and MMs at the molecular stages (DNA, RNA, Protein, 
and Complex) can be selected from the pre-compiled list shown in Table 3-2. If 





stages, class names are user-provided. Wherever possible these should be part of 
existing biomedical ontologies. The NCBO BioPortal site 
(https://bioportal.bioontology.org/) is a source for ontology terms. Since most 
ontologies describe the normal state of a system, a user may select one of the in-built 
modifiers (increased, decreased, altered) to prefix a class name so as to represent a 
perturbed state.  
5. An evidence-based confidence score (on the scale of 1 to 5, where one indicates 
low confidence and five indicates high confidence) should be assigned to each SSP 
and MM. Evidence on which a confidence score is based should be recorded in the 
form of supporting/contradicting PMIDs and PMC figure URLs, together with 
appropriate free text commentary.   
6. Two or more possible sub-paths can exist in a schema either because of ambiguity 
due to conflicting evidence, or alternative sub-mechanisms.  Branch points should be 
labeled with OR, AND or AND/OR.  
7. Schemas should explicitly include steps only where there is a perturbation from the 
normal system. Where the function of a portion of a schema is unperturbed, for 
example, representing the standard activity of transcription operating on a perturbed 
input DNA sequence or a standard cell signaling process operates with more or less 







3.3.6 Steps in constructing, managing, and publishing mechanism schemas 
Before beginning schema building a new user must register on the MecCog platform. 
A registered user may select the “Build Schema” tab to initiate building a new 
schema or the “My Schemas” tab to access the workspace for managing and editing 
their existing schemas. Figures 3-4A and 3-4B show the two interfaces used in 
schema construction: A. The Initiate Mechanism Schema form used to enter meta-
information about a schema, and B. The Schema Builder GUI used to draw a schema. 
In the schema builder, mechanism components can be dragged and dropped from the 
mechanism component catalog panel to the drawing board panel. Clicking on a 
component displays five associated control icons: i) Icon to connect to other 
components; ii) Icon to adjust the component size; iii) Icon to clone the component; 
iv) Icon to show the pop-up box; and v) Icon to delete the component. Clicking on a 
component also renders a component-specific annotation form on the rightmost panel 
of the interface (labeled in Figure 3-4B). This form is used to enter the stage, class, 
and instance name of the components, prefix class names with a  perturbation type if 
needed (increased, decreased, or altered), and record the evidence annotations (listed 
in the Evidence Annotations Table 3-1C). This is a dynamic form that automatically 
provides predefined possible perturbation class names for the selected stage (listed in 
Table 3-2) and creates fields for adding new PubMed IDs and PMC image URLs. The 
NCBI E-utilities application programming interface (API) is used on the server-side 
to fetch publication details for the PubMed IDs. All the evidence annotations are 
transferred to the current component pop-up box together with hyperlinked PMIDs 





control icon of the component.  Confidence score values selected in the annotation 
form are used to automatically apply the appropriate color to the current schema 
component (red: score 1, orange: scores 2, 3, 4 and, green: score 5). The color of the 
edge connecting two components is inherited from the target component, so 
indicating causal confidence. Schemas are saved to the database using the Click to 
save button. For each schema, a unique accession number is automatically generated 
in the database. The accession number format has a section indicating the version 
(default is .1) of the schema. The schema builder GUI also has a panel of interactive 
buttons to undo, redo, clear page, zoom, auto-layout, export (in SVG and PNG 
formats), and print schema diagrams. 
 
Figure 3-4C shows the view of a registered user’s workspace. Each schema can be 
versioned, edited, shared with other MecCog users, published, or deleted, using 
operation-specific buttons. The workspace has three sections: i) The Unpublished 
Mechanism Schemas section catalogs work-in-progress schemas.  ii) The Published 
Mechanism Schemas section catalogs published schemas. A button to remove each of 
these from the public collection is provided. iii) The Shared Mechanism Schemas 
section catalogs schemas that have been shared with the current user. For schemas 
with edit access privilege, the Copy to My Space operation is enabled, allowing the 
creation of a copy for the user to work on independently. All the schema accession 
numbers in the workspace page are hyperlinked to the schema specific landing page 






Published schemas are available for browsing via the main webpage of the MecCog 
site (as shown in Figure 3-4D) without the need for logging in. There is a search bar 
that allows schemas to be searched by gene name, keyword, or any component 
class/instance name. MYSQL’s FULLTEXT indexing 
(https://dev.mysql.com/doc/refman/5.6/en/innodb-fulltext-index.html) feature is used 





Figure 3-4. Graphical User Interface (GUI) to construct, manage, and browse 
mechanism schemas. Figure 3-4A shows the form for entering meta-information on a 
schema. Figure 3-4B shows the schema builder interface, including the mechanism 
component catalog panel (left), the drawing board panel, and the annotation form 
panel (right). Figure 3-4C shows the user workspace interface. Figure 3-4D shows a 
portion of the MecCog main webpage, designed to facilitate browsing publicly 
available mechanism schemas. 
 
 
The structured organization of mechanistic knowledge in MecCog allows this search 
to be used to find common entities or activities and common classes used in different 
schemas. On the main page, schemas are presented in a masonry layout view. Each 
tile in the view displays the schema name, schema caption, hyperlinked accession 
number of the schema linking to the corresponding schema landing page (described in 
the next section), and a hyperlinked schema image linked to an interactive web-based 
visualization of the schema (also described in the next section). 
 
3.3.7 Schema landing page, schema visualizer, and schema report 
A schema landing page displays schema meta-information in a tabular layout (Figure 
3-5A). A novel feature of this page is the display of references and hyper-linked 
PubMed IDs providing evidence for each aspect of the schema as well as PMC 
images selected to illustrate aspects of the mechanism. The Schema Visualizer button 
on the landing page directs a user to the GUI for interactively navigating the 





interactive features of the schema builder GUI (described previously). A unique 
feature of the visualizer is the tight integration of the graphical notations for the 
mechanism components and the associated evidence information (presented in the 
pop-up box). The pop-up box (yellow-colored box in Figure 3-5B) displays 
hyperlinked ontology sources for the SSP/MM class name (if the term is from an 
ontology), a brief builder-provided commentary on the evidence, and hyperlinked 
PMIDs and PMC figure IDs. There is a help icon (‘?’) in the visualizer to display the 
mechanism schema key. Clicking on the Comment button in the visualizer opens a 
modal box to view or enter comments about the schema. The Schema Report button 
on the landing page generates a narrative report in which the meta-information, 
mechanism components, and evidence annotations about the schema are presented in 
a structured format. The schema content can be downloaded as a JSON file from the 







   
 
Figure 3-5. NOD2 mechanism schema entry in MecCog. This schema describes the 
known mechanisms by which a frameshift mutation (rs2066847) in the NOD2 gene 







page of the NOD2 schema, displaying the meta-information in tabular format. This 
page includes the collection of thumbnails of PMC figures selected to illustrate 
aspects of the mechanism and the list of references with PubMed IDs from which 
evidence was derived (the list is truncated here - there are 26 references). Figure 3-5B 
shows the schema visualizer GUI used for interactive navigation of the schema. For 
this schema, four possible submechanisms with varying levels of evidence (indicated 
by the confidence colors – red=low, orange=medium, and green=high) are included. 
The example yellow pop-up box in Figure 3-5B displays hyperlinked evidence for the 
associated MM. The comment button on the top can be used to open a modal box, 




3.3.8 An example MecCog Schema: Known mechanisms by which a frameshift mutation in 
the NOD2 gene causes an increased risk of Crohn’s disease 
Figure 3-5 shows two pages of a MecCog mechanism schema 
(http://www.meccog.org/mchain/showpubchain?accession=MS031100031.9) 
describing the mechanism by which a frameshift mutation (rs2066847; 
NM_022162.3:c.3019dup (p.Leu1007fs)) in the NOD2 gene causes an increased risk 
of Crohn’s disease (CD). NOD2 is the first gene for which variants were found to be 
associated with altered CD risk (Hugot et al., 2001b; Ogura et al., 2001; Yamamoto & 
Ma, 2009) and the 1007fs mutation is most consistently associated with CD across 
multiple studies and population groups (Economou et al., 2004) with a very high 





controls (Ogura et al., 2001). Figure 3-5A shows the landing page displaying the 
meta-information of the schema and the list of references used as evidence in the 
schema, together with figures used to illustrate aspects of the mechanism. 
 
Figure 3-5B shows the view of the NOD2 1007fs schema in the interactive visualizer. 
This schema was constructed using information about mechanism reported in 26 
research articles. The left-most SSP (SSP1) represents the DNA stage perturbation 
(i.e. the single base insertion of cytosine - rs2066847 in the NOD2 gene). The paths in 
the schema show how the effect of this perturbation propagates through the RNA, 
protein, complex, and cell stages (represented by the stage-specific SSPs and MMs) 
so causing the increased Crohn’s disease risk phenotype (SSP12). At the RNA stage 
(SSP2), the rs2066847 variant causes the insertion of a cytosine after the first 
nucleotide of codon 1007, so introducing a premature downstream stop codon. This 
leads to the protein stage perturbation, a truncated NOD2 protein (SSP3) missing the 
last 33 amino acids of the wild-type sequence (Lécine et al., 2007). Following this, 
the schema branches represent the multiple submechanisms by which the truncated 
NOD2 protein may lead to the increased Crohn’s disease risk phenotype by altering 
the activation of the immune response (MM10) (Negroni et al., 2018; Park et al., 
2007; W. Strober & Watanabe, 2011). All the branches are labeled ‘AND/OR’ since 
none has fully compelling supporting evidence. The submechanism of each branch is 






A) The top branch (SSP3→MM3 → SSP4) shows a potential alteration to NOD2-
dependent regulation of Toll-like receptor (TLR) mediated NF-κB signaling that 
produces pro-inflammatory cytokines in response to the pathogen-associated 
molecular patterns (PAMPs) such as lipopolysaccharide (LPS), or muramyl dipeptide 
(MDP). This path is sparse and labeled medium confidence (orange) because the 
mechanism of interaction between NOD2 and TLRs is not known, nor is it clear how 
that interaction normally results in increased production of pro-inflammatory 
cytokines (Underhill, 2007). Different models have been proposed to describe the 
mechanism: synergistic production of TNF-α by NOD2 and TLR4 (Wolfert et al., 
2002); activation of the inflammasome by NOD2 via RICK to produce IL-1β from 
pro-IL-1β generated as the result of TLR signaling (A. Sarkar et al., 2006); and MDP 
(the primary agonist for NOD2 (Grimes et al., 2012)) dose-dependent TNF-α 
production by NOD2 and TLR2 (Borm et al., 2008). Further, for none of these 
possibilities has the effect of the NOD2 100fs variant been investigated. These details 
are provided in the pop-up box for MM3.   
 
B) The middle branch shows that truncated NOD2 protein has lost its ability to 
localize to the plasma membrane (MM4 → SSP5) (Barnich et al., 2005; Morosky et 
al., 2011) where binding to incoming  MDP normally produces an activated state of 
the protein (Al Nabhani et al., 2017). In turn, activated NOD2 forms complexes with 
RICK and with ATG16L1 (Barnich et al., 2005; Travassos et al., 2010). The schema 
shows these effects as lower abundance of the NOD2-RICK complex (MM5 → 





(Travassos et al., 2010). There is no experimental evidence of the NOD2 1007fs 
protein’s impact on complex formation. Therefore the MM5 → SSP6 step in the 
schema is labeled medium confidence (orange). Following this step, the lower 
abundance of the NOD2-RICK complex alters downstream NF-κB signaling 
(SSP6→MM6→SSP7) (Barnich et al., 2005; Caruso et al., 2014; Girardin et al., 
2003; Lécine et al., 2007), resulting in lower pro-inflammatory cytokine production, 
so contributing to an altered activation of the immune response (MM10) (Negroni et 
al., 2018; Park et al., 2007; W. Strober & Watanabe, 2011; Vilela et al., 2012). The 
perturbation of the NOD2-ATG16L1 complex affects the xenophagy process 
(autophagy against bacteria) (MM7) (Travassos et al., 2010) so leading to an increase 
in the abundance of bacteria in the lamina propria (SSP9) (Sidiq et al., 2016) and 
thereby likely contributing to a more aggressive response from other components of 
the immune system, as indicated by the altered activation of immune response 
(MM10). This sub-path is labeled high confidence (green) as its mechanism 
components are well understood based on the available evidence in the literature. The 
yellow pop-up box for MM4 shows an example of an evidence commentary with an 
associated hyperlinked PMC figure and PMIDs. 
 
C) The lower branch of the schema provides examples of the representation of a gap 
in knowledge and of overall low confidence. Commensal bacteria are largely 
prevented from penetrating the gut wall by an outer mucosal barrier and the epithelial 
cell layer. Paneth cells situated in the gut epithelial layer produce a range of antibiotic 





mucosal layer. Some data suggest that this process is partly dependent on MDP 
binding to NOD2 in these cells, likely signaling that significant numbers of bacteria 
are getting through to the epithelial cell layer, and so triggering an increased 
response. Data supporting that view come from an experiment showing stimulation of 
NOD2 by MDP binding induces production of defensin HNP-1 (human neutrophil 
peptide 1) in Caco-2 cells (Yamamoto-Furusho et al., 2010). It has also been shown 
that the NOD2 1007fs protein fails to induce the production of defensin hBD2 
(human β-defensin-2) in several epithelial cell lines (Voss et al., 2006). Hence the 
link between the presence of the 1007fs variant (SSP3) and increased defensin 
production (currently SSP10). But the mechanism by which MDP binding to NOD2 
normally causes defensin production is unknown, hence the black oval (MM11) 
linking those two SSPs. There is also evidence from other studies that do not support 
the mechanism represented by this schema path: In two out of four CD cohort studies 
(Hayashi et al., 2016; Simms et al., 2008; Jan Wehkamp et al., 2005), and in NOD2 
deficient mouse organoids (Wilson et al., 2015), the association between NOD2 and 
defensin was not reproduced. Hence this branch is labeled low confidence (red). 
Further along this schema branch, the decrease in defensin production (SSP10) leads 
to an increased abundance of bacteria in the mucosal layer (SSP11) due to decreased 
bactericidal activity (MM8). In turn, this contributes to increased bacterial abundance 
in the lamina propria due to increased bacterial influx from the mucosal layer (MM9) 






3.3.9 Representation of biomarker and therapeutic intervention sites in MecCog 
Figure 3-6A shows an example of the use of the biomarker symbol, in part of the 
Lynch syndrome schema 
(http://www.meccog.org/mchain/showpubchain?accession=MS020700047.3).  In this 
schema, microsatellite instability is a diagnostic biomarker (Vilar et al., 2014) for 
Lynch syndrome, resulting from defective base mismatch repair machinery, in turn a 
consequence of a mutation (rs63750245: C>T) in the MSH2 gene. Figure 3-6B shows 
an example of a putative therapeutic intervention site in a Crohn’s disease schema 
(http://www.meccog.org/mchain/showpubchain?accession=MS020500019.2) 
describing the mechanism by which a missense variant (rs3197999: G>A; R703C) in 
the MST1 gene (coding for Macrophage Stimulating Protein, MSP) increases disease 
risk. The missense variant causes a lower abundance of the MSP-RON protein 
complex by one or both of two mechanisms:  a weakened protein-protein interaction 
(Chao et al., 2014; Gorlatova et al., 2011) and reduced MSP abundance. Lower 
abundance of the complex is expected to result in reduced intracellular signaling 
affecting macrophage activation (Häuser et al., 2012; L. Kretschmann et al., 2010; M. 
H. Wang et al., 2002) and/or epithelial cell survival and growth (Danilkovitch et al., 
2000; Neurath, 2014). An appropriate compound that bridges the structural interface 
between MSP and RON could restore wild-type abundance of the complex and hence 
signaling strength and so eliminate the downstream consequences. (Of course, many 









Figure 3-6. Biomarker and Therapeutic intervention site representation in MecCog. 
Figure 3-6A shows part of a Lynch syndrome schema 
(http://www.meccog.org/mchain/showpubchain?accession=MS020700047.3) where 
the presence of a nonsense mutation (rs63750245: C>T) in the MSH2 gene causes 
Microsatellite instability (MSI), a known biomarker (symbolized by the red location 
icon on the SSP) for the Lynch syndrome.  Figure 3-6B shows part of a Crohn’s 
disease schema 
(http://www.meccog.org/mchain/showpubchain?accession=MS020500019.2) where 
the decreased abundance of the MSP-RON protein complex (SSP3) is a hypothetical 







appropriate small molecule binding across the protein-protein interface might restore 
the wild-type abundance.  
 
 
3.3.10 Validation of the MecCog representation framework 
Eleven MecCog mechanism schemas (nine for Crohn’s disease, one for cystic 
fibrosis, and one for Lynch syndrome) have so far been published, with additional 
schemas in progress on breast cancer and Alzheimer’s disease. Validation and 
improvement of MecCog content is obtained by soliciting feedback from specialists 
in the disease described in each schema. Feedback on the representation technique 
and platform can be provided using MecCog’s contact us form, encouraging users to 
provide suggestions and report problems. MecCog has also been used as an 
educational tool for senior undergraduate students in a Human Genetics class at the 
University of Maryland, providing valuable feedback, for example, linking PMC 
figures to aspects of schemas.  
 
3.4 Discussion 
We have developed MecCog, a graphical knowledge representation framework, to 
describe genetic disease mechanisms in a structured mechanism schema format. 
MecCog facilitates the assembly of mechanistic information in terms of perturbation 
propagation across stages of biological organization, evaluation of the evidence 
related to that information, and identification of uncertainties, ambiguities, and 
ignorance. The MecCog web platform provides functionalities to create, store, 





informed class terms so as to consistently and intuitively represent types of 
mechanism components found in schemas. The schema interactive visualizer in 
MecCog tightly integrates the graphics, text, and hyperlinks to evidence sources.  
  
Each schema in MecCog describes mechanisms by which a single genetic variant 
contributes to the increased risk for the disease phenotype. For complex trait genetic 
disease and cancer, multiple genetic variants contribute to disease phenotypes 
(Lilyquist et al., 2018; Peter et al., 2011). Further, contributions from variants may 
not be independent, as reflected by evidence of epistatic effects between pairs of 
variants for complex trait disease (Y. Li et al., 2020; Lin et al., 2017). The MecCog 
formalism also supports mechanism schemas with multiple input genetic 
perturbations. Interactions between these inputs results in a mechanism graph. An 
example for Crohn’s disease is a barrier integrity mechanism graph constructed by 
combining schemas on loci relevant to bacterial penetration of the gut-lining mucosal 
layer (Figure 3-7). This graph incorporates a number of non-additive interactions 
between mucin gene variants affecting mucosal-layer integrity (MUC1, MUC2), 
variants affecting the unfolded protein response (XBP1, ORMDL3), and variants 









Figure 3-7: Part of the barrier integrity mechanism graph for Crohn’s disease, 
showing the role of risk variants that affect bacterial penetration through the mucosal 
layer. SSP=Substate Perturbation and MM=Mechanism Module. An SNP (SSP1) in 
FUT2 affects glycosylation (MM1) of MUC1 (Kelly et al., 1995; Mcgovern et al., 
2010). The hypoglycosylated state of the MUC1 (SSP2) affects its interaction 
strength with other mucins (MM2) resulting in a less dense mucosal layer (SSP3) 
(Hall et al., 2017a). Weaker mucin interactions result in more rapid diffusion of 
bacteria through the mucosal layer (MM3) and faster mucin loss at the gut surface 
(MM6), one of the three factors contributing to an overall lower abundance of mucin 
(SSP8). A second factor is a missense SNP in MUC2 (SSP5), the main constituent of 





et al., 2006). The third factor is the state of the unfolded protein response (UPR) in 
the mucin-producing Goblet cells (MM9). The UPR system reduces protein 
production in response to the accumulation of excessive misfolded or unfolded 
protein in the ER (X. Ma et al., 2017). Because of the normal rapid loss of mucins at 
the gut interface, Goblet cells are among the most hard-working protein-producing 
cell types (Gersemann et al., 2009), and so are particularly susceptible to changes in 
the UPR (X. Ma et al., 2017). The UPR threshold is influenced by variants in two 
genes, XBP1 (Kaser et al., 2008) and ORMLD3 (Barrett et al., 2008; Moffatt et al., 
2007). The extent of misfolded protein is also influenced by the efficiency of 
autophagy (MM16), involving variants affecting four genes – NOD2 (Warren Strober 
et al., 2014), IRGM (Chauhan et al., 2016), LRRK2 (Hui et al., 2018) and 
ATG16L1(Salem et al., 2015). As the overall disease mechanism described in the 
mechanism graph has not been tested experimentally, all the branches are labeled 
medium confidence (orange color).  
 
 
Currently, MecCog schemas are manually constructed, relying on human 
understanding to extract and infer causal connections between mechanism 
components from literature. Given the scattered and incomplete nature of mechanistic 
information in literature, this process is complex and requires a combination of prior 
biological knowledge together with searching for and assimilating new facts and 
evidence from the literature. These activities are labor-intensive and work best when 
the schema builder is an expert on the schema subject. To achieve scale for the 





appropriate domain experts. The resource is structured so that experts can build 
schemas based on their knowledge and can also edit and comment on existing 
schemas. The current version of the MecCog platform supports these activities in the 
following ways: i) acknowledging contributors to a schema as authors and curators, 
ii) providing a schema specific commenting interface to solicit input, and iii) allowing 
versioning of schemas to update content. To implement the crowdsourcing model, we 
will work closely work with disease-specific research communities (such as IBD 
Genetics, Crohn’s & Colitis Foundation, and Alzforum). 
 
An obvious question is whether mechanism schemas can be constructed automatically 
given the structured and unstructured data available in the biomedical domain. The 
structure of a mechanism schema shares features with that of knowledge graphs 
(KG), a knowledge representation system initiated by Google in 2012 
(https://googleblog.blogspot.com/2012/05/introducing-knowledge-graph-things-
not.html). There nodes (aka subjects) represent entities such as real-world objects, 
events or concepts, and edges (aka predicates) link the nodes with relationships. 
Because of a KG’s ability to integrate and represent multi-relational databases, many 
biological KGs (Sosa et al., 2019; Celebi et al., 2019; Chen et al., 2019; Himmelstein 
et al., 2017; PDBe-KB consortium, 2020; 
https://digitalinsights.qiagen.com/coronavirus-network-explorer/) are being 
generated, using a combination of manual and automated mining of subject-predicate-
object (SPO) triplets from biomedical literature and from bioinformatics relational 





SPO triplets and so it is in principle possible to construct a schema by extracting 
appropriate triplets from a comprehensive knowledge graph. However, preliminary 
tests of this process suggest that current knowledge graphs do not capture a large 
fraction of the triplets incorporated in the corresponding mechanism schemas. There 
are multiple reasons for this, including the absence of biological knowledge in 
knowledge graphs and the absence of causal reasoning components. We envisage that 
in the future comprehensive and well-structured KGs will be combined with a 
repository of biological knowledge and reasoning machines to generate a wide variety 
of biological mechanisms, as well as providing evaluation of evidence strength and 
identifying current gaps in mechanism knowledge.  
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Chapter 4: A framework to quantitatively represent and analyze 
mechanisms relating genetic variants to complex trait disease 
4.1 Introduction 
Genome-wide association studies (GWAS) have identified thousands of associations 
between genetic variants and complex trait diseases (Dehghan, 2018). A major focus 
has been to further identify the mechanisms underlying these associations in order to 
develop full disease models. The construction of disease models is non-trivial for two 
primary reasons. First, mechanistic information is scattered throughout the literature, 
is established with varying degrees of confidence, and the results are often ambiguous 
or contradictory to other findings. Second, biological knowledge of disease 
mechanisms is qualitative and descriptive, and so not immediately amenable to most 
quantitative modeling. To address the first obstacle, we have previously developed 
MecCog (Darden et al., 2018) a framework for integrating and representing disease 
mechanism knowledge in a structured format. The resulting schemas are able to 
comprehensively represent mechanisms by which genetic variants cause disease 
phenotypes. However, they are still purely qualitative. Here, we describe two 
developments aimed at overcoming the second obstacle. The first is a framework to 
quantitatively encode MecCog schemas, providing a method for building quantitative 
models using biological knowledge of disease mechanism. Using simulated data, we 
show that these Disease Mechanism Circuit (DCM) models are useful for exploring 
properties of complex trait diseases that are not experimentally accessible. While 





mechanism limits their application. To address this, we have developed a hybrid 
neural network model of the relationship between genetic variants and disease-related 
phenotypes. We show that these models are able to learn key quantitative aspects of 
disease mechanism from GWAS data, so opening the way for large scale quantitative 
modeling of complex trait disease.  
 
We have applied both the disease mechanisms circuit model and the neural network 
to the analysis of the role of reduced gut wall barrier integrity in Crohn’s, a complex 
trait inflammatory bowel disease (Gorlatova et al., 2011; Pal, Chao, et al., 2017; Pal, 
Kundu, et al., 2017). More than 200 GWAS loci related to Crohn’s disease risk (De 
Lange et al., 2017) are known. Follow-up experimental work has revealed many of 
the mechanisms underlying those associations and has led to an overall model of the 
disease (Ahluwalia et al., 2018; Atreya & Siegmund, 2018; Fischer & Neurath, 2017) 
involving 11 subprocesses (Jostins et al., 2012). Briefly, the overall mechanism is as 
follows: The human gut contains a large load of commensal bacteria. Even in a 
healthy individual, a small number of these will continually pass through the gut wall 
and enter the underlying tissue (Schroeder, 2019). A concentration of immune system 
cells immediately below the gut wall normally ensures that penetrating bacteria are 
quickly removed. Some of the Crohn’s risk variants affect the integrity and thickness 
of the outer mucosal layer of the gut wall, the tightness of the epithelial cell junctions, 
and the effectiveness of outer antibacterial defenses, resulting in a higher flux of 
bacteria into the tissues. Risk variants in other genes affect the efficiency with which 





bacteria. Other risk variants affect the appropriateness of the inflammatory response. 
Finally, further risk variants affect the extent of gut wall tissue damage occurring as a 
result of inflammation and the efficiency of repair. In any particular individual, a 
subset of risk variants will be present - on average approximately half the maximum 
possible load. Each individual with the disease will likely have a different subset of 
risk variants from other individuals, and in this sense, the disease mechanism is 
different in each case.  
 
We demonstrate the utility of the circuit model by investigating two phenomena 
related to nonlinearity in the relationship between genetic variants and disease 
phenotypes. GWAS does not capture inter-gene dependencies of phenotypes, and 
these missing epistatic effects have been proposed as an explanation of why GWAS 
results only reflect a fraction of disease heritability (Maher, 2008). First, we use the 
model together with simulated GWAS data to investigate the extent to which 
differences in the effect size of single risk variants is observed in different 
individuals. Unavoidably GWAS provides average properties over a study 
population’s diverse genetic backgrounds and cannot show whether a variant has a 
large or small effect in a particular individual (Stringer et al., 2011). If disease 
phenotypes were a linear function of an individual’s relevant variants, this would not 
be an issue. But inter-gene interactions will result in varying effect sizes. Knowledge 
of an individual’s variant effect sizes may be key in judging what available treatments 
will be most effective.  Many model organism studies have demonstrated that the 





2016; Galardini et al., 2019; Vu et al., 2015). We show that the non-linear 
components of the barrier integrity circuit model do result in a dramatic variation of 
variant effect sizes across individuals in a GWAS population. Second, we directly 
address the extent to which interactions between relevant genetic variants are non-
linear, which is epistatic, using the circuit model. The extent of epistasis is a much-
debated question in studies of complex trait disease (Manolio et al., 2009; Wei et al., 
2014). Pair-wise knockout and RNA silencing experiments in a range of model 
organisms have shown that these effects are very wide-spread (Byrne et al., 2007; 
Cardinale & Cambray, 2017; Costanzo et al., 2016). Despite this evidence, pair-wise 
statistical tests using human GWAS data seldom detect epistatic effects (J. Li et al., 
2011). As with the variation in effect size for single variants, one reason for this may 
be that population epistatic effects are masked by averaging over all genetic 
backgrounds in a sampled population. Consistent with the model organism studies, 
we find a very large range of non-additive effects between risk variant pairs in a 
GWAS population. 
 
The circuit model provides an effective means of investigating the effect of genetic 
variants in each individual in a population, so overcoming major limitations in the 
GWAS data.  But it requires knowledge of not only the disease mechanism 
(represented by the mechanism graph) but also the functional form of each node’s 
response and the parameter values for those functions. Although functional forms 
may be estimated, as we do in the circuit model study, obtaining true parameter 





biological circuit, maybe almost impossible to obtain with sufficient accuracy (Chou 
& Voit, 2009). Machine learning methods, including neural networks, have been used 
to predict disease phenotypes from genotype inputs for complex trait diseases  
(Laksshman et al., 2017; Pal, Kundu, et al., 2017; Zeigler et al., 1990). Model 
parameters are learned from the data and at least for neural networks, there should be 
good robustness with respect to data noise (Borodinov et al., 2019). But although 
these methods perform as well as additive models (Pal, Kundu, et al., 2017), they 
provide no insight into the underlying mechanism. An attractive solution to this issue 
is the incorporation of prior knowledge of network architecture so that only nodes 
representing known functional units in the system are included. The approach was 
first suggested in 1992 for modeling bioreactor function (Psichogios & Ungar, 1992), 
but has been little explored. Recently, it has been successfully used for building an 
integrated model for yeast cells (Dcell (J. Ma et al., 2018a)). We have developed a 
sparse neural network representation of genetic disease mechanisms, a Mechanism 
Architecture Neural Network (MANN) model. We show that MANN input/output 
relationships can be learned from GWAS data, that individual nodes reproduce the 
model’s functional form and behavior, and that it is possible to distinguish between 








4.2.1 Mechanism of barrier integrity disruption in Crohn’s disease 
MecCog mechanism schemas (Darden et al., 2018) are composed of input substate 
perturbation – mechanism module – output substrate perturbation (SSP-MM-SSP) 
triplets, where each SSP represents a perturbed entity at some stage of biological 
organization (e.g. a DNA variant, altered protein abundance, altered cell state) and 
each MM (e.g. transcription, protein-protein interaction, cell signaling) represents the 
productive activity by which the input SSP produces the output SSP. Simple schemas 
follow the progression of substate perturbations from a single genetic variant across 
stages of biological organization (RNA, protein, macromolecular complexes, 
organelles, cells, organs) to the disease phenotype, and are suitable for representing 
the mechanisms underlying monogenic disease and individual cancer-relevant 
mutations (see www.meccog.org for examples). For complex trait diseases like 
Crohn’s, where multiple genetic variants affect the disease phenotype, contributing 
individual variant schemas are combined to produce a mechanism graph, including 
interactions between the variants. Figure 4-1 shows the graph for part of the barrier 
integrity mechanism, where eight Crohn’s risk variants affect the concentration of 
bacteria at the epithelial wall of the gut, 𝐵𝑒. A higher bacterial concentration at the 
epithelial wall causes higher bacterial flux into the underlying tissues where they 
interact with the gut immune cells that lead to inflammation and increased risk for the 
disease (Okumura & Takeda, 2018). Here, a SNP in MUC1 (Franke et al., 2010) 
affects the strength of the corresponding protein’s interactions with other mucins 





weaker mucin interactions result in more rapid diffusion of bacteria through the 
mucosal layer (M3) and faster mucin loss at the gut surface (S2), one of three factors 
contributing to an overall lower abundance of mucin (S3). A second factor is a 
missense SNP in MUC2, the main constituent of gut mucin, resulting in a less stable 
protein (M5) (Heazlewood et al., 2008; Moehle et al., 2006). The third factor is the 
state of the unfolded protein response (UPR) in the mucin-producing Goblet cells 
(M8). The UPR system reduces protein production in response to the accumulation of 
excessive misfolded or unfolded protein (X. Ma et al., 2017). Because of the normal 
rapid loss of mucins at the gut interface, Goblet cells are among the most hard-
working protein-producing cell types (Gersemann et al., 2009), and so are particularly 
susceptible to changes in the UPR (X. Ma et al., 2017). The UPR threshold is 
influenced by variants in two genes, XBP1 (Adolph et al., 2012) and ORMDL3 (M. 
Li et al., 2017). The extent of overall misfolded protein is also influenced by the 
efficiency of autophagy (M10), involving variants affecting four genes (NOD2 
(Warren Strober et al., 2014), IRGM (Chauhan et al., 2016), LRRK2 (Hui et al., 
2018), and ATG16L1 (Salem et al., 2015)). This barrier integrity graph is not 
complete: Additional components include a SNP in FUT2 affecting mucin-mucin 
interaction strength via alterations to glycosylation (Hall et al., 2017b). IL10 (Hasnain 
et al., 2013) also influences the UPR response, and in turn the influence of IL10 
variants is modulated by variants in two members of the intracellular signaling 
pathway, STAT1 and STAT3 (Hasnain et al., 2013). Other significant contributions 
to barrier integrity are the efficiency of xenophagy (Knodler & Celli, 2011) and 





tightness of the epithelial cell-cell junctions, influenced by a variant affecting 
C1orf106 (Mohanan et al., 2018). Nevertheless, the graph captures sufficient disease 
biology to provide a test system for the Disease Mechanism Circuit (DCM) and 











Figure 4-1. Part of the barrier integrity mechanism graph for Crohn’s disease, 
showing the role of variants in eight genes that affect bacterial penetration through 
the gut mucosal layer. Genetic variant inputs to the network are shown as yellow 
rectangles, substate perturbations as blue rectangles, and mechanism modules as clear 
ovals. Edge labels show variables output from the preceding node and provide input 
to subsequent nodes. For each mechanism component, the corresponding approximate 
node function is shown (for details see Methods). Parameters determining 
quantitative behavior are in green.  
 
4.2.2 Building a disease mechanism circuit (DMC) from a disease mechanism graph 
Each substate perturbation (SSP) and mechanism module (MM) in the barrier 
integrity mechanism graph represents an altered value of a physical quantity: 
abundance of a protein, strength of a protein-protein interaction, thickness of the 
epithelial layer, and so on. The magnitude of these quantities can be computed given 
one or more input values to the SSP or MM nodes. For example, in Figure 4-1 there 
are two inputs into the node S6 ‘Higher bacterial concentration at the epithelial wall’ 
– a thinner mucosal layer, T, output from S4; and a faster bacterial diffusion rate D 
through the layer, output from M3. Quantitatively this node (S6) represents the 
perturbation of the bacterial concentration at the epithelial cell wall arising from a 
thinner and less dense mucosal layer. The simplest model of this process is the 
diffusion of bacteria across a planar mucosal layer, with a rate proportional to the 





flux of bacteria arriving at the epithelial wall increases with faster diffusion (larger D) 
and with a thinner layer, T. We assume that at steady state, the bacterial concentration 
at the epithelial cell wall (Be) can be expressed as proportional to the incoming flux.   




where a23 is constant.  
Approximate analytical functions are assigned to each node. Table 4-1 (Methods) 
shows the node functions and the estimated parameters values. Any particular 
combination of risk genotypes for variants in the eight genes (the input risk genotype 
vector, where for each variant, 0 represents no risk alleles, 1 a single, heterozygous 
risk allele, and 2, homozygous risk alleles) will propagate through the circuit to 
determine 𝐵𝑒. A higher Be, indicating a higher bacterial concentration at the epithelial 
wall, will cause higher bacterial flux into the underlying tissues and so higher disease 
risk (Okumura & Takeda, 2018). Thus, Be is an intermediate Crohn’s disease risk 
phenotype.  
 
4.2.3 Sources of non-linearity in the DMC of barrier integrity 
As noted earlier, nonlinear interactions between variants will result in a nonlinear 
relationship between input risk genotypes and disease phenotypes. There are two 
explicit sources of inter-gene non-linearity in the circuit: First, the division function 
(F12 in Table 4-1) at node S6, representing the relationship between bacterial 
diffusion rate (D), the thickness of the mucosal layer (T), and the bacterial 





representing the unfolded protein response (UPR). In practice, the sigmoid function 
dominates the non-linear behavior of the circuit.  
 
4.2.4 Functional form of the Unfolded Protein Response (UPR) 
The UPR is a cellular response to the accumulation of unfolded protein. There are 
two main components, both resulting from unfolded proteins binding to and so 
activating kinases, IRE1, and PERK (Mendez et al., 2015). Activated IRE1 acts as an 
RNAase that results in abnormal splicing of XBP1, leading to increased chaperone 
production and so an increase in the amount of successfully folded proteins. 
Activated PERK phosphorylates the α-subunit of eukaryotic translation initiation 
factor 2 (eIF2α) (Harding et al., 1999) and traps it in the GDP-bound inactive state, so 
blocking eIF2α recycling. That results in the attenuation of global protein synthesis 
(Harding et al., 2000; Wek et al., 2006). Three experimental studies (Korennykh et 
al., 2009; Han Li et al., 2010; Mendez et al., 2015) have shown that IRE1 RNase 
activity (representing UPR activation) has a sigmoidal response to the concentration 
IRE1 enzyme. The Hill coefficient found in these studies is between 3.3 and 8 (The 
Hill coefficient is a dimensionless parameter characterizing the steepness of a 
sigmoid-like response (Frank, 2013).  No data are available for the response of PERK 
to increase in unfolded protein abundance, relevant to the barrier integrity model. We 
expect that the Hill coefficient of that response will not be less than for IRE1, and 
will likely be greater: whereas a relatively gradual increase in chaperone 
concentration (mediated by IRE1) is expected, protein production shut-down is a 






Sigmoid functions, in which at a low concentration of some molecule in the system 
there is no response, but at some threshold, there is a co-operative transition to a large 
system response, which then saturates, are very often found in biological system 
input/output relationships (Andersen et al., 2002; Frank, 2013). The Hill coefficients 
are often large, for example in MAPK signaling pathways up to 8 (Blüthgen & 
Herzel, 2003), in the response of the bacterial flagellar motor to the concentration of 
the chemotaxis response regulator CheY-P, 20 (Yuan & Berg, 2013), and in oocyte 
maturation in response to progesterone concentration in Xenopus Oocytes, a Hill 
coefficient of 35 (Ferrell & Machleder, 1998). 
  
In the barrier integrity model, the sigmoid function at node M8 describes a cell’s total 
protein production rate (P) in response to the total abundance of unfolded or 
misfolded protein (U) in the cell:  
𝑃 = 𝑎11 + (
𝑎12
1 + 𝑒−𝑢(𝑈−𝑈0) 
) 
where 𝑎11, 𝑎12 𝑎𝑛𝑑 𝑢 are constants. 
The model assumes that below some threshold of unfolded protein abundance, U0, 
cells produce new protein with a rate independent of that quantity. Above the 
threshold, there is a progressive shut-down of protein production, with a rate 
determined by the parameter ‘u’. We have investigated the behavior of the circuit 







Figure 4-2 illustrates how the sigmoid function results in a variation in the effect size 
of single variants as a function of genetic background and in variable epistatic 
interactions between risk alleles affecting gene pairs. At low unfolded protein 
abundance, represented by the plateau on the left of the plot, cell protein production is 
unaffected. Then, at some unfolded protein threshold (around 0.75 in the figure) there 
is a rapid decline in production to the low plateau (0.1 of the maximum in this model) 
at the right side of the plot. Panel A shows the positions of the three risk genotypes of 
NOD2 for a particular genetic background from the other seven genes affecting this 
node. All three NOD2 genotypes fall on the initial plateau, so that production and 
hence Be are unaffected by the which genotype is present. That is, the effect size is 
zero. In panel B, a different genetic background from the other genes results in a 
higher level of unfolded protein and so shifts the NOD2 genotypes to the right. The 
no-risk genotype is still on the plateau, but the single risk variant is at the start of the 
slope, and the homozygous risk variant genotype is near the bottom. The homozygous 
risk genotype now has a very large effect size. The NOD2 genotypes in each 
individual in a population will fall at different positions depending on the individual’s 
genetic background, and so a range of effect sizes is produced.  
 
To see one way in which non-linear, epistatic, interactions are created between pairs 
of genes, consider two genes with a genetic background such that each gene’s 
genotypes all fall on the initial plateau, as for NOD2 in panel A. The linear 
expectation is that the phenotype effect of the combined risk variants for the two 





see that the combined impact on the unfolded protein level may actually result in a 
large loss of protein production by producing a point on the slope. As with the single 
variant case, different genetic backgrounds will produce different degrees of 




Figure 4-2. Model of the unfolded protein response (UPR). The X-axis is the relative 
abundance of unfolded protein and the Y-axis is the fraction of full protein production 
in the cell. At low unfolded protein abundance, protein production is unaltered, but at 
a threshold of around 0.75 in this model, production begins to be reduced and then 
falls fairly rapidly to a lower threshold (0.1 of full production). Risk variants in eight 
genes affect the unfolded protein abundance. The three points on each panel represent 
the unfolded protein abundance for each NOD2 genotype (no risk variant,  green; 
heterozygous risk variant, orange; and homozygous risk variant, red) for a particular 
genetic background of the other seven genes. In panel A, all the genotypes fall on the 
leading full protein production plateau, so that production is unaffected by the 
genotype status of NOD2. In panel B, a higher risk variant background in the other 





NOD2 genotype is still on the plateau, the single risk allele is on the start of the 
downslope, resulting in a small decrease in production, and the homozygous risk 
allele genotype falls near the bottom of the slope, resulting in a large change. 
Examples here are for the more strongly non-linear model.  
 
4.2.5 Characteristics of the barrier integrity model 
The quantitative behavior of the barrier integrity circuit was simulated by calculating 
the output relative epithelial layer bacterial concentration (Be) for each possible vector 
of input risk genotypes. Genotypes were encoded as 0 for the homozygous non-risk 
alleles, 1 for heterozygous, and 2 for homozygous risk alleles. There are 6561 (38) 
possible input genotype vectors. Parameters values of the circuit are listed in Table 4-
1. Each genotype vector was feedforward to generate the corresponding output Be 
value. Two sets of simulation data were generated corresponding to moderately non-
linear behavior of the UPR (u =-1 in F7, Hill coefficient approximately 3) and a 
higher value (u = -6, Hill coefficient approximately 15). In order to generate a 
reference linear approximation, a linear regression fit of Be to the eight genotype 
input values was performed, using the python scikit-learn package’s linear regression 
module (https://scikit-
learn.org/stable/modules/generated/sklearn.linear_model.LinearRegression.html) with 
default parameters.   
 
Figure 4-3A shows the distribution of relative bacterial abundance, Be, for the set of 





distribution is skewed towards low Be, with ~79% of genotype vectors generating Be 
values less than 10, and only ~4.5% above 20. In contrast, Figure 4-3C shows that Be 
values generated by the more strongly non-linear model (u=-6) are skewed more 
towards large Be values, with ~24% above 20. Figure 4-3B shows that for the 
moderately non-linear model there is an approximately parabolic curve relating model 
Be values to those generated by linear regression, with the predicted values for low-
risk situations negative. That is, a best fit linear model substantially underestimates 
the high risk Be values and will be inaccurate for low risk. For the more strongly non-
linear model (Figure 4-3D), the regression fit is not monotonic and has little 







 Figure 4-3. Distributions of bacterial concentration (Be) across the 6561 input 
genotype vectors. Figure 4-3A shows the distribution of Be values and Figure 4-3B 
shows the scatter plot between the true Be values (Y-axis) and a linear regression 
approximation (X-axis) in the moderately (u=-1) non-linear UPR model. Figures 4-
3C and D show the corresponding results for a more non-linear model (u=-6). The Be 
distribution plot is skewed towards low Be (<10) in the moderately non-linear case but 
skewed towards larger Be (>20) in the more strongly non-linear case.  The linear 




4.2.6 Single variant effect varies across genetic backgrounds 
The Barrier Integrity DMC provides a human disease model for investigating the 
degree to which the population average obtained from a GWAS experiment masks 
variation across individuals with different genetic backgrounds. To this end, we have 
examined the variation in effect size for each of the eight risk variants as a function of 
genetic background.  
 
For every risk variant in the barrier integrity graph, there were 2187 (37) genetic 
backgrounds to be considered. For a specific background, the effect size of the risk 
variant was calculated as:   
𝑉𝑎𝑟𝑖𝑎𝑛𝑡 𝐸𝑓𝑓𝑒𝑐𝑡 𝑆𝑖𝑧𝑒 (𝑉𝑠) =  𝐵𝑒𝑔𝑖





where 𝐵𝑒𝑔0 is the Be value when the genotype of the risk variant is 0 (non-risk allele 
homozygous) in the background g, and 𝐵𝑒𝑔𝑖 is the Be value when the genotype of the 
risk variant is i=1 (heterozygous) or 2 (risk allele homozygous) in the background g. 
To simplify the analysis, only i=2 was considered. In addition to considering all 
possible backgrounds, we also considered just those backgrounds found in a human 
population, using the WTCCC genotype dataset of 2000 Crohn’s patients and 3000 
controls (Burton et al., 2007). 
 
Figure 4-4 shows the variation in the effect size of the ATG16L1 risk variant. In the 
moderately non-linear model (Figure 4-4A), the effect size in the WTCCC population 
varies from near zero to ~14. The maximum value for any genotype vector is 42 
(Figure 4-3), so that the effect size for this one variant spans 1/3 of the full range. The 
average is only 2.6. That is, the GWAS result suggests that this risk variant will only 
make a small contribution to increasing bacterial concentration, but in fact, for 
particular individuals, fully 1/3 the maximum possible bacterial load is caused by this 
single variant. The variation is even larger in the more strongly non-linear model 
(Figure 4-4B), varying between ~zero and ~60, spanning the total spread found across 
all genotype vectors (Figure 4-3). The average is 10.5, for some individuals only 
about 1/6 of the actual effect size. Although individual variant effect size tends to 
increase with the number of other risk variants present, there is a very large scatter. 
For instance, in the moderately non-linear ATG16L1 model, at a typical level of 





effect size varies from about 1 to 9. The other seven genes show similar patterns 
(Figure S6).  
 
Thus, to the extent that the model represents the properties of real biology, average 
effect sizes derived from GWAS data mask a wide range of variation across 
individuals - in one individual an ATG16L1 risk allele may contribute almost no 
increase in bacteria penetrating the gut mucosal layer. In another individual, the 
increase may be very substantial, so contributing greatly to increased disease risk. As 
described earlier (Figure 4-2), in this model, the variation in effect size primarily 
arises from the nature of the sigmoid response to the level of unfolded protein. 
  
  
Figure 4-4. Variation in the ATG16L1 risk variant effect size as a function of the 
genetic background for the barrier integrity model. Each point represents the effect 
size for homozygous risk variants in ATG16L for one specific genetic background. 
Figure 4-4A shows the effect size distribution for the moderately non-linear 
simulation model and Figure 4-4B for the more strongly non-linear model. The X-





from 0 where no other risk alleles are present to 14 where the seven other genes have 
homozygous risk alleles). Red points are for the 252 genetic backgrounds found in the 
WTCCC study population dataset and blue points cover all possible backgrounds 
(2187). The average effect sizes expected in GWAS are given above each plot. The 
effect size increases with the background risk variant load, though very non-
monotonically. In the moderately non-linear model, effect sizes vary from zero to 14 
in the WTCCC study population, about 1/3 of the total variation across all genotype 
vectors (zero to 42, Figure 4-2). For the more strongly non-linear model, the variation 
is from zero to 60 in the WTCCC population. In each case, the population average 
masks the range.    
 
4.2.7 Epistatic effects are masked by population averaging 
The size of each of the possible 28 pair-wise epistatic interactions was evaluated as a 
function of the genetic background of the other six risk variants. For every variant 
pair in the barrier integrity graph, there are 729 (36) possible genetic backgrounds. 
For a specific background, the non-additive epistatic effect of a variant pair was 
calculated as:   
𝐸𝑝𝑖𝑠𝑡𝑎𝑡𝑖𝑐 𝐸𝑓𝑓𝑒𝑐𝑡 𝑆𝑖𝑧𝑒 (𝐸) =  (𝐵𝑒𝑔𝑖𝑗
 − 𝐵𝑒𝑔00) − { (𝐵𝑒𝑔0𝑗 − 𝐵𝑒𝑔00) + (𝐵𝑒𝑔𝑖0 − 𝐵𝑒𝑔00)} 
where 𝐵𝑒𝑔00 is the epithelial layer bacterial concentration when the genotype of both 
the variants is 0 (homozygous non-risk-alleles) in a specific background g; 𝐵𝑒𝑔𝑖𝑗
  is 
the value when the genotype of both of the variants is i=j=1(heterozygous) or i=j=2 





genotype of one variant (i) is 0 and the other is j=1 or j=2 in the specific background 
g; and 𝐵𝑒𝑔𝑖0 is the value when the genotype of variant (j) is 0 and the other is i=1 or 
i=2 in a specific background g. This formula captures the change in Be when both the 
variants carry risk alleles versus the change in Be assuming the contribution from each 
of the contributing variants is additive. A positive E value indicates a positive 
epistatic effect (i.e. the effect is higher than the additive effect), and a negative value 
indicates a negative epistatic effect (i.e. the effect is lower than the additive effect). 
To simplify the analysis, only i=2 and j=2 were considered. For each variant pair, the 
set of 729 possible backgrounds was considered as well as the set of backgrounds 
found in a human population, using the WTCCC genotype dataset of 2000 Crohn’s 
patients and 3000 controls (Burton et al., 2007).  
 
 
Figure 4-5A shows the variation in the epistatic effect for an example risk variant 
pair, ATG16L1 – NOD2, using the moderately non-linear UPR model. For the 
WTCCC population, the ATG16L1 – NOD2 epistatic effect size varies from 0 to ~13, 
but the average is only 4.1. Other gene pairs (Figures S7) show a similar pattern of 
highly variable positive epistatic effects, with population averages much lower than 
the effect in many individuals. As is the case in the single variant analysis (Figure 4-
4), the very largest effects are seen in the highest risk genetic backgrounds, not often 
found in the WTCCC population. But within the population, epistatic effects are still 
substantial, with up to a 10-fold higher bacterial concentration at the epithelial layer 







Figure S8 shows that the size of the epistatic effects is substantially larger in the more 
strongly non-linear model (up to a 50-fold change in bacterial concentration over the 
that expected from the linear model) and for many gene pairs may be positive or 
negative depending on the genetic background. The presence of both positive and 
negative effects leads to a greater damping of population average values. For 
example, for ORMDL3 – XBP1 (Figure 4-5B) the size of the epistatic effect in the 
WTCCC population varies from approximately -10 to +10, resulting in an average of 
only 0.48. As outlined earlier, the variable nonlinear effects arise primarily from the 
sigmoid for the sigmoid response to the amount of unfolded protein (Figure 4-2).  
 
 
Figure 4-5. Variation in the epistatic effect as a function of the genetic background. 
Figure 4-5A shows the epistatic effect distribution of the ATG16L1 – NOD2 risk 
variant pair in the moderately non-linear UPR model. Figure 4-5B shows the 
distribution for the ORMDL3 – XBP1 risk variant pair in the more strongly non-linear 
model. The X-axis of each plot is sorted by the risk-allele load in the background 





have homozygous risk alleles, in total 729 combinations). Red points are for genetic 
backgrounds found in the WTCCC study population and blue points cover all 
possible backgrounds. The average epistatic effect sizes are shown above the plots. 
The size of the epistatic effect varies dramatically as a function of the genetic 
background in each individual, resulting in misleadingly low population averages.  
 
4.2.8 Constructing a Mechanism Architecture Neural Network 
As outlined earlier, representing a mechanism graph as a sparse neural network 
should allow node functions to be learned from GWAS data, avoiding a major 
limitation of the circuit model. We designed and implemented a version of this 
approach, a Mechanism Architecture Neural Network (MANN). In this 
representation, a MANN is a sparse neural network where each substate perturbation 
and mechanism module in a mechanism graph is represented by a node and the 
internode connectivity is that of the mechanism graph. Figure 4-6 shows the barrier 
integrity MANN. Each node is represented by one neuron. 
The output from each neuron is: 
𝑂𝑢𝑡𝑝𝑢𝑡 = 𝐵𝑎𝑡𝑐ℎ𝑁𝑜𝑟𝑚(𝑇𝑎𝑛ℎ (∑ 𝑥𝑖𝑤𝑖 + 𝑏)) 
where {𝑤𝑖} are the weights on the ‘i’ edges connecting inputs to the neuron, {𝑥𝑖} are 
the values output from the input nodes, and b is the bias parameter. Tanh is the 
nonlinear transforming hyperbolic tangent activation function. The Batch Norm (Ioffe 
& Szegedy, 2015) function normalizes input values for each hidden layer in a 
network leading to faster convergence, decreased importance of initial weights in the 





normalization-in-neural-networks-1ac91516821c). PyTorch (https://pytorch.org/), an 
open-source machine learning library, was used to implement and train the MANN. 
There are 71 parameters to be trained (the weights on each of 25 edges, a bias 
parameter and two Batch Norm parameters for each of the 15 internal nodes, and a 
bias parameter for the output node).  
 
 
Figure 4-6. Mechanism Architecture Neural Network (MANN) for the Crohn’s 
barrier integrity model. Each blue dot corresponds to one of the nodes in the 
mechanism graph (Figure 4-1) and is represented by a neuron. Red dots indicate the 








4.2.9 Training and testing the Barrier Integrity MANN 
The Disease Mechanism Circuit (DMC) generated Be values corresponding to each of 
the input 6561 genotype vectors were used to train and test the MANN. Using the 
moderately non-linear UPR model data the average MSE (Mean Square Error) of the 
MANN is 0.13. The two equivalent fully connected FCNN reference networks have a 
slightly large MSE of 0.22 for the two hidden layer network and 0.38 with the single 
hidden layer. This pattern is the same for the more strongly non-linear data, with an 
MSE for the MANN of 2.17, FCNN with two layers 3.20, and FCNN with single 
layer, 32.22. Based on these results, the MANN is able to learn the relationship 
between input genotype vectors and Be with high accuracy and its overall 
performance is slightly better than fully connected networks with an approximately 
equal number of parameters. Figure 4-7 shows a more detailed performance 
comparison. The moderately non-linear data plots show that the FCNNs fail to 
accurately predict the high Be values (>30) possibly due to the lack of sufficient 
training data in this range (as shown in Figure 4-3A). But the MANN is able to fit this 
portion of the data as well as the rest.  For the more strongly non-linear model, the 
plots show that a single hidden layer network is unable to properly represent the data, 
while the double layer network and the MANN are more successful. The fully 
connected double layer network likely does better here than with the moderately non-
linear data because there are more training points at high Be values. Overall, the 






We also trained and tested the networks using the experimental WTCCC dataset 
(Burton et al., 2007) and disease status (1 for disease, 0 for control) instead of 
simulated bacterial concentration as the output. The MANN delivers an average ROC 
(Receiver Operating Characteristics) - AUC (Area Under The Curve) of 0.63, slightly 
better than the FCNN with two layers (0.59). Thus, the MANN is able to learn the 
relationship between an individual’s genotype data and their disease status slightly 
better than a conventional network. Apparently, with the noisy experimental data, 
explicitly incorporating knowledge of the interactions between the genetic variants 
results in an improved fit between the genotype-phenotype data. Interestingly, 
including 86 risk variants with a fully connected neural network (one hidden layer 
with three neurons, 265 parameters) yields a ROC-AUC of only 0.72, and attempts by 
a number of groups to obtain better results with a range of machine learning methods 
and up to 160 risk variants did not succeed in obtaining a larger AUC (Daneshjou et 







Figure 4-7. Comparison of MANN performance in reproducing the output bacterial 
concentration Be with that of fully connected neural networks, for a sample cross-
validation set. Each point corresponds to a specific input genotype vector. A perfect 
model would have all points on the diagonal. For both the moderate and more 
strongly non-linear data, the MANN performs better than the fully connected 
networks. FCNN: Fully connected Neural Network, DMC: Disease mechanism 
circuit, MSE: Mean square error, MANN: Mechanism Architecture Neural Network.  
 
 
4.2.10 The Barrier Integrity MANN is able to learn node functions 
While it is useful that a MANN representation can capture the relationship between 
genotype inputs and the bacterial concentration, Be, and does so more robustly than a 
conventional neural network (Figure 4-7), the real advantage should be in also 
capturing aspects of a biological mechanism circuit that may not be known. To 
examine this, we next ask to what extent individual nodes in the trained Barrier 
Integrity MANN exhibit the same response to genotype inputs as the corresponding 
nodes in the DMC. That is, can the network effectively learn DMC node functions 
from the data? For this purpose, the output from each neuron representing a node is 
compared with the calculated output from the corresponding DMC node, for each 
input genotype vector. Figure 4-8 shows the results for the 10 nodes where the output 
is a physical quantity, for example, total protein production, P (F7), and the thickness 
of the mucosal layer, T (F11) (Table 4-1). For the five nodes in the top row of the 





genotypes of  MUC1 (nodes M1, M2, and M3) or MUC2 (M5 and S5), and so only 
three points of comparison. Nevertheless, the node functions of two of these, M2 and 
M3, are exponentials so that capturing their behavior is non-trivial. For the five nodes 
in the second row of the plots, the consequences of combinations of input genotype 
vectors from multiple genes must be captured, so reproduction by the neural network 
is generally demanding. For example, the output from node M8, the total protein 
production ‘P’, is determined by the sigmoid function representing the unfolded 
protein response (the UPR), and input genotype combinations from six genes. The 
output behavior of this node is well reproduced, with correlations coefficients of 0.99 
and 0.96. The relatively poor correlation coefficients for nodes S3 and S4 (down to 
0.92) are a consequence of the single output from S3 providing the single input to S4. 
Although these two nodes represent distinct physical quantities (total mucosal protein 
abundance ‘𝑀′’ for S3 and mucosal layer thickness ‘𝑇′’ for S4) the simple coupling 
between them allows multiple combinations of node performance to satisfy the final 
output requirement. With this exception, the output node functions do faithfully 









Figure 4-8. Relationship between output from nodes in the Barrier Integrity MANN 
and the model on which it was trained (model node functions are listed in Table 4-1). 
Each point represents a node output generated by a specific input genotype vector. ρ 
is the Pearson’s correlation coefficient. F numbers refer to the functions in Table 4-1 
and M and S to the nodes in the Disease Mechanism Circuit (figure 4-1) and the 
MANN (figure 4-6). The upper panel shows the results for the moderately non-linear 
model and the lower for the more strongly non-linear one. Results for a single 





captures a disease circuit’s node properties would result in all points on the diagonal 
and a correlation coefficient of 1.0. The worse correlation coefficient is 0.92. 
 
 
4.2.11 The Barrier Integrity MANN is able to distinguish between alternative mechanism 
graph topologies 
In practice, the connectivity of a disease mechanism graph is often uncertain - there 
may be alternative hypotheses for particular steps in a mechanism and some aspects 
of the mechanism may be speculative or missing. As a result, mechanism graphs may 
have incorrect connections and missing connections or components. To evaluate 
whether a MANN can be used to distinguish between possible alternative topologies 
of this type, 300 alternate versions of the barrier integrity MANN were constructed. 
Each alternate topology was set up such that the input genotype vector to the network 
had the genotypes arranged in a different order than the one used for the original 
barrier integrity MANN. Changing the order feeds the input to the wrong nodes in the 
network. This is equivalent to creating and dropping an equal number of edges in the 
network. 300 randomly ordered input vectors were created to represent the alternate 
topologies. Each of the randomly ordered vectors was used to train the MANN using 
the protocol described above, on both the moderately and more strongly non-linear 
models. The average mean square error (MSE) for the test sets was used as a metric 
for choosing between topologies: In principle, the network with the correct topology 
should have the lowest MSE between the model and MANN generated bacterial 





Figure 4-9A shows that the topologies trained on the moderately non-linear model 
have a very narrow range of MSE relative to the range of Be values (1 to 43, Figure 4-
2). The correct barrier integrity topology is ranked 20th among other topologies.  
Figure 4-9B shows a wider range of the MSE when the topologies are trained on the 
more strongly non-linear data. The correct barrier integrity topology model is ranked 
1st in this set with a MSE of 0.73. This result suggests that as non-linearity in the 
system increases, a MANN’s power to distinguish the correct topology improves.  
 
Figure 4-9. Ranking of alternative MANN topologies by performance. MSE: Mean 
Square Error. MANN: Mechanism Architecture Neural Network. Each point 
represents the MSE for a specific topology. The red bar shows the position of the 
correct barrier integrity mechanism graph topology. Figure 4-9A shows the 
performance of MANN topologies trained on the moderately non-linear model. 
Figure 4-9B shows the performance on the more strongly non-linear simulation data. 
Topologies are sorted by MSE. The figures show that the MANN is usually able to 







4.3.1 Summary of the results 
This chapter presented a framework to build a quantitative model of mechanism for 
complex trait disease. The model was generated from a MecCog mechanism graph 
that qualitatively represents the mechanisms by which genetic variants cause disease 
phenotypes as a result of perturbation propagation across stages of biological 
organization. For the model, an explicit analytical function and parameters were 
added to each node in the mechanism graph, representing its physical properties. The 
node functions, together with the mechanism graph connectivity generate a circuit 
where output quantitative phenotype values can be computed from a given set of 
input disease-associated genetic variants. We used this Disease Mechanism Circuit to 
investigate the role of gut barrier integrity in Crohn’s disease. The circuit allowed us 
to address key questions concerning the interpretation of Genome-Wide Association 
Study (GWAS) data, specifically, the extent to which the effect size of a variant 
contributing to disease risk varies as a function of the genetic background in an 
individual and the extent to which averaging over a GWAS population masks 
epistatic effects between pairs of variants. We also implemented a hybrid neural 
network approach, including prior knowledge in a neural network. For this, we 
constructed a mechanism architecture neural network (MANN) by integrating the 
topology of the mechanism graph into the architecture of the neural network. We 
showed that a MANN can reproduce the relationship between input genotype vectors 
and the output barrier integrity phenotype as effectively as a fully connected neural 





network using experimental genotype case-control data obtained from a large scale 
GWAS  for Crohn’s disease. We also showed that the MANN can learn individual 
complex node behavior from the data, and that it can also be used to address 
uncertainties in graph topologies. These results are for model systems but suggest a 
number of practical applications. Two of these are outlined below. 
 
4.3.2 Evaluating the effectiveness of drug targets 
Genetic background has been shown to play a role in the effectiveness of existing 
drugs (Madian et al., 2012; Mallah et al., 2020). A drug can be regarded as altering 
the function of a node in the mechanism graph for a disease, for example, by 
inhibiting the action of a protein. Our results suggest the MANN framework can be 
used to identify whether a drug will be effective for a particular individual, given 
their genetic variants. One possible case where this may be applied is for Mongersen 
(Sands et al., 2020), an antisense SMAD7 inhibitor. A clinical study found that only 
65% of Crohn’s patients respond to the drug (Monteleone et al., 2015), and given the 
large variation among risk variants in Crohn’s patients, at least some of that response 
variation is likely genetic. Mongersen acts to increase the anti-inflammatory TGB-
beta signaling by decreasing the abundance of SMAD7 protein, found to be elevated 
in Crohn’s patients (Monteleone et al., 2012). However, there are many other genes 
with Crohn’s risk variants (such as αvβ8 Integrin, STAT3, TLR4, SMAD2, SMAD3) 
that are part of the anti-inflammatory TGB-beta signaling pathway. A MANN 
representing the mechanism graph that links the risk variants of Mongersen relevant 





Then in each individual, the activity of the SMAD7 node is reduced, mimicking the 
action of the drug. The effect of this change on predicted disease risk should then 
provide an estimate of drug effectiveness. 
 
4.3.3 Coarse grain MANN 
Complex trait disease mechanism graphs can often be decomposed into semi-
autonomous subprocesses. For example, eleven subprocesses have been proposed for 
Crohn’s disease (Jostins et al., 2012). In each individual, the extent to which a 
subprocess is affected will vary. For example, the contribution of the barrier integrity 
subprocess circuit to overall disease risk is represented by the concentration of 
bacteria at the gut epithelial cell wall, Be . Our analysis shows this likely varies 
substantially from individual to individual, as a function of the eight associated risk 
variants. In choosing appropriate treatments it can be valuable to know which 
subprocesses are most involved in a patient. To this end, we propose the design of a 
coarse-grain MANN to investigate the contribution of subprocesses to complex trait 






Figure 4-10: Example of a coarse grain MANN architecture with three subprocesses. 
Each dot represents a neuron. Each subprocess is represented by a local neural 
network, with input genotype vectors. Outputs from these networks are feed into a 
neural network that produces a final phenotype value. 
 
 
The full network has two stages. The first stage has separate networks for each 
subprocess considered, three in this example. Each of these subnetworks has a 
conventional architecture, with one input node for each risk variant affecting that 
subprocess. An assumption here is that these subnetworks will be able to capture the 
non-linear interactions between variants within a subprocess. Outputs from the 
subnetworks are then fed into the second stage integrating network. This second stage 
network models the interactions between the subprocesses to output disease risk or 
another disease-related phenotype. Measuring the output from each subprocess 
network for an individual’s input genotype vector will provide an estimate of the 
contribution of each subprocess to the disease phenotype. 
 
4.4 Methods 
4.4.1 Node functions and parameter values 
Quantitative encoding of the barrier integrity mechanism graph was done by adding 
analytical functions for each substate perturbation and mechanism module in the 
graph. Functions are intended to capture the physics and chemistry represented by 
each node. Table 4-1 shows the node functions and parameter values of the barrier 





The node functions were defined as follows:  
M1: Decreased MUC1-MUC1 interactions 
The presence of MUC1 risk allele results in reduced glycosylation of the MUC1 
protein. In turn, that results in weaker interactions with other mucins and with the 
other MUC1 molecules (Hall et al., 2017b). The interaction strength is expressed in 
terms of the free energy change of binding, 𝛥𝐺, a negative number in units kcal/mol. 
The change in free energy resulting from the presence of risk variants is 𝛥𝛥𝐺, a 
positive quantity. With this assumption, 𝛥𝐺is computed as:   
𝛥𝐺 = 𝑎1 ∗ {1 − 𝑎2 ∗ 𝐺(𝑀𝑈𝐶1)} 
where G(MUC1) is the number of MUC1 risk variants (0, 1, or 2) and  𝑎1 and 𝑎2 are 
constants. The unperturbed value of  𝛥𝐺 is assumed to be 5 kcal/mol, so 𝑎1= 5. 𝑎2 is 
set to 0.10, so that each risk allele reduces the protein-protein interaction free energy 
by 10%.   
 
M3: Increased bacterial diffusion rate 
Weaker interactions between MUC1 protein molecules results in a higher fraction of 
the molecules dissociated from each other. 𝐾𝑑, the dissociation constant is related to 
the free energy of association between two MUC1 molecules by 𝐾𝑑 ∝ 𝑒
−∆𝐺/𝑅𝑇. 
Assuming the rate of bacterial diffusion coefficient, D, is proportional to the fraction 
of unassociated MUC1 molecules, normalized 𝐷′ can be expressed as: 
𝐷′ ∝ 𝐾𝑑 ∝ 𝑒
−∆𝐺/𝑅𝑇 







where R is gas constant (1.985 X 10-3 kcal K-1 mol-1), T is body temperature (310.50 
K), and 𝑎3 is constant. 𝑎3 is chosen so that 𝐷
′ = 1 when 𝛥𝐺 = 5.  
 
M2: Increased Loss of MUC1 protein at gut surface 
MUC1 protein molecules normally become detached from the mucosal layer as a 
result of peristaltic motion in the gut (Paone & Cani, 2020). Weaker interactions 
between the mucin molecules will result in a greater rate of detachment. 𝑘𝑜𝑓𝑓 
represents the rate at which mucin molecules become detached. We assume that 𝑘𝑜𝑓𝑓 
depends on the change in the free energy of association between two MUC1 
molecules carrying the risk variants: 
𝑘𝑜𝑓𝑓 ∝ 𝑒
−∆𝐺/𝑅𝑇 
Thus, at steady state, the normalized abundance of MUC1 can be expressed as – 
𝑀1
′ = 1 − 𝑎4 ∗ 𝑒
−𝛥𝐺
𝑅𝑇  
where 𝑎4 is constant. For a non-risk allele status of MUC1, 𝑀1
′ = 0.9 and 𝛥𝐺 = 5.  
 
M5: Altered MUC2 protein internal interactions and S5: Increased misfolded 
MUC2 
 The MUC2 risk alleles are associate with decreased stability of the MUC2 protein 
(Heazlewood et al., 2008; Moehle et al., 2006), assumed to result in lower protein 
abundance. The normalized abundance of misfolded MUC2, 𝑁2
′ is assumed to be 
proportional to the number of risk alleles (0, 1, or 2):  
𝑁2
′ = 𝑎5 ∗ 𝐺(𝑀𝑈𝐶2)     






′ = 1 − 𝑎5 ∗ 𝐺(𝑀𝑈𝐶2)                            
  
M10: Decreased autophagy 
As described earlier, risk alleles associated with four genes (ATG16L1, NOD2, 
IRGM, LRRK2) are expected to affect the efficiency of autophagy in removing 
unfolded/misfolded proteins. The functional dependency of autophagy and the 
interdependence between risk alleles for different genes is not known. A simple linear 
sum over the risk alleles is used, with separate weights for each gene. For ATG16L1 
the effect of risk variants is accentuated by a positive feedback loop - the presence of 
risk alleles increases the rate at which the protein is subject to proteolytic cleavage 
(Kaser & Blumberg, 2014). The rate of cleavage also depends on the extent of cell 
stress, and the lower the abundance of ATG16L1, the greater cell stress because of 
decreased autophagy. The impact of this loop is modeled by a parameter S that 
increases the co-efficient for ATG16L1.  
𝐴′ = 𝑎6 ∗ {𝑎7 ∗ 𝐺(𝑁𝑂𝐷2) + 𝑎8 ∗ 𝐺(𝐼𝑅𝐺𝑀) + 𝑎9 ∗ 𝐺(𝐿𝑅𝑅𝐾2) + 𝑎10
∗ 𝐺(𝐴𝑇𝐺16𝐿1) ∗ 𝑆)} 
 
where 𝐴′ is the relative abundance of unfolded protein due to impaired autophagy 
(zero for no risk allele in these genes), 𝑎7, 𝑎8, 𝑎9, 𝑎10 are the weight coefficients of the 
for each gene. 𝑎6 is such that when all risk alleles are present A= 0.9.  
 
M8: Increased unfolded protein response 
As described earlier, the unfolded protein response (UPR) is a mechanism by which a 
cell shuts down protein production if too much unfolded/misfolded protein 





unfolded/misfolded protein there is no UPR, above that threshold, complete shut-
down of protein synthesis is triggered until conditions improve. The total protein 
production rate of the cell is modeled using a sigmoid function: 
𝑃 = 𝑎11 +
𝑎12
1 + 𝑒−𝑢(𝑎13∗𝑈− 𝑎14∗𝑈0
′) 
 
 where 𝑈 is the accumulated unfolded/misfolded protein, 𝑈0
′  is an offset of the UPR 
so there is no reduction in protein production at low levels of 𝑈, 𝑢 determines the 
steepness of the transition, and 𝑎11, 𝑎12, 𝑎13, 𝑎14 are constants.  
The threshold  𝑈0
′  is affected by risk variants in two UPR related genes, XBP1 and 
ORMDL3. We assume that these reduce the threshold for the onset of the UPR as a 
linear function of the risk variant genotypes:  
𝑈0
′ = 1 − {𝑎18 ∗ 𝐺(𝑋𝐵𝑃1) + 𝑎19 ∗ 𝐺(𝑂𝑅𝑀𝐷𝐿3)} + 𝑎15  
where 𝑎15,𝑎18, 𝑎19 are constants.  
The value of U is calculated as the sum of the abundance of the MUC2 misfolded 
protein (𝑁2
′) and the abundance of the unfolded proteins arising from impaired 
autophagy (𝐴′). 
 
S3: Decreased mucin abundance and S4: Thinner mucosal layer 
The normalized total mucin abundance (𝑀′) is determined by the overall relative rate 
of protein production, P, and the abundance of the principal mucin proteins, MUC1 
(𝑀1
′) and MUC2 (𝑀2
′ ). The normalized thickness (𝑇′) of the mucosal layer is assumed 
to be directly proportional to the total mucin abundance: 
𝑀′ = 𝑃 ∗ (𝑎20 ∗ 𝑀1
′ + 𝑎21 ∗ 𝑀2
′ ) 





where 𝑎20, 𝑎21𝑎𝑛𝑑 𝑎22 are constants. As MUC2 is the secreted form of mucin and 
dominates the composition of the mucosal layer (Johansson et al., 2011), a higher 
weight (𝑎21 = 0.9) is assigned to it compared to MUC1 (𝑎20 = 0.1).  
 
S6: Higher bacterial concentration at the epithelial wall 
 
This node describes the perturbation of the concentration of bacteria at the epithelial 
cell wall arising from a thinner and less dense mucosal layer. The simplest model of 
this process is the diffusion of bacteria across a planer mucosal layer. According to 
this model, the influx of bacteria arriving at the epithelial cell wall is proportional to 
the diffusion constant 𝐷′ (output from node M3) and inversely proportional to the 
mucosal layer thickness 𝑇′ (output from node S4). Thus, we assume that at steady 






























= 𝑎1 ∗ {1 − 𝑎2
∗ 𝐺(𝑀𝑈𝐶1)} 






































































= 𝑎6 ∗ {𝑎7 ∗ 𝐺(𝑁𝑂𝐷2) 
+ 𝑎8 ∗ 𝐺(𝐼𝑅𝐺𝑀) + 𝑎9
∗ 𝐺(𝐿𝑅𝑅𝐾2) + 𝑎10
∗ 𝐺(𝐴𝑇𝐺16𝐿1) ∗ 𝑆)} 
a6 = 0.28 
a7 = 0.50 
a8 = 0.25 
a9 = 0.25 
a10 = 0.25 



















a11 = 0.10 
a12 = 0.90 
a13 = 3.00 
a14 = 3.00 







F8 𝑈 = 𝑎16 ∗ 𝑁2
′ + 𝑎17 ∗ 𝐴
′ 
a16 = 1.00 










= 1 − {𝑎18 ∗ 𝐺(𝑋𝐵𝑃1)
+ 𝑎19 ∗ 𝐺(𝑂𝑅𝑀𝐷𝐿3)}
+ 𝑎15  
a18 = 0.05 














a20 = 0.10 
























cell wall (Be) 
F12 𝐵𝑒  = 𝑎23 ∗
𝐷′
𝑇′
 a23 = 1.00 
 𝐺(𝑌) represents the genotype of the risk variant affecting gene ‘Y’.  For example, 
𝐺(𝑀𝑈𝐶1) represents the genotype of the risk variant associated with MUC1.  
 
4.4.2 Training and testing the Barrier Integrity MANN 
Two types of datasets were used to train and test the MANN: First, the Disease 
Mechanism Circuit (DMC) generated Be values corresponding to each of the input 
6561 genotype vectors. Second, the experimental WTCCC genotype dataset (Burton 
et al., 2007) of 2000 Crohn’s cases and 2000 controls. For each of these datasets, the 
train-test divisions were generated by randomly dividing the dataset into a 75%-25% 
ratio using python’s scikit-learn train_test_split module (https://scikit-
learn.org/stable/modules/generated/sklearn.model_selection.train_test_split.html). For 
cross-validation, 30 random train-test sets were generated. PyTorch modules were 
used to train the network using the Mean Square Error (MSE) loss function, the 
ADAM stochastic gradient descent algorithm as the optimizer, and a mini-batch size 
of 500. To evaluate the performance, the average of the mean square error (MSE) for 
the DMC dataset and ROC-AUC for the WTCCC dataset over the test portions of 30 





connected neural network (FCNN) were also trained. One is a single hidden layer (5 
neurons) network (61 parameters), and the other a two hidden layer network (4 
neurons in each layer) network (77 parameters). As a control for the WTCCC dataset, 
a two hidden layer network (4 neurons in each layer) network (77 parameters) was 
trained. The node configuration, training, and evaluation procedures for the fully 
connected networks were the same as used for the MANN. 
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Chapter 5: Conclusion  
In this dissertation, I developed computational methods to identify disease-causing 
variants from sequencing data, qualitatively represent the mechanism by which these 
variants cause the disease phenotype, and quantitatively encode the mechanism 
representations to analyze emergent properties in complex trait diseases. In the last 
chapter, I briefly summarize the conclusions of each project and discuss future 
directions in each area. 
5.1 Interpreting causative variants in DNA sequencing tests  
In the first part of my dissertation, I developed a variant prioritization pipeline VarP 
to address an incompletely solved problem on building accurate computational 
methods for variant interpretation that can be used in DNA sequencing tests to 
provide the clinical diagnosis. We objectively assessed VarP on data from the John 
Hopkins DNA Diagnostic Laboratory as part of a CAGI gene panel challenge. The 
challenge assessment revealed that VarP performed the best among 17 other 
submissions, and correctly matched 36 out of 106 patients to one of the 14 monogenic 
disease classes, using sequence data for the 83 panel genes. The correctly matched set 
included 10 cases where the Hopkins pipeline could not find causative variants, but 
VarP was able to. We then investigated the incorrectly matched cases and found 17 
where VarP did find a causative variant and 53 undiagnosed cases where neither 
VarP nor the Hopkins pipeline could find any causative variant relevant to the tested 
disease class. Investigating the missed diagnosed cases revealed several sub-optimal 





on variant pathogenicity annotations in the Human Gene Mutation Database 
(HGMD). In post-analysis, we showed that omitting the HGMD annotations increases 
the success rate of correctly matching disease class from 36 to 40. We then 
investigated sequencing artifacts in the data to check if these contributed to the high 
number of undiagnosed cases. We found that generally, the data was of high quality 
with rare artifacts such as zero coverage for exon-60 of the HYDIN gene for 78 
samples and an abnormally high homozygous/heterozygous ratio in one sample. 
These did not appear to make a large contribution to the missing diagnostic variants. 
Re-analyzing the incorrectly matched cases revealed seven patients where VarP 
found high confidence pathogenic variants in genes associated with a different 
disease class from the one referred for testing at the Hopkins laboratory. We speculate 
that these may be cases of incorrect clinical diagnosis. Lastly, we integrated protein 
structure data to the VarP pipeline to investigate if mechanistic insights could be 
derived for the putative causative variants. We found that ~50% of the missense 
variants with unknown clinical significance had structure coverage and analyzing the 
structures revealed potential molecular mechanisms of the variants. 
  
5.1.1 Improving genetic disease diagnosis 
The Hopkins laboratory dataset revealed that the clinical diagnosis for ~50% of the 
cases could not be confirmed because neither the Hopkins pipeline nor any of the 
CAGI methods found causative variants in the tested genes. Others (Clark et al., 





below 50%. There are several possible explanations for the low yield of diagnostic 
variants: 
A) The disease-causing gene list is incomplete as evidenced by the fact that many 
new genes are continually being discovered (Posey et al., 2019) and cataloged in 
crowdsourced resources such as the Genomic England PanelApp (Martin et al., 
2019). As a result, if causative variants are in genes that are not part of the panel 
sequencing gene list, they will be missed. For such undiagnosed cases, follow-up 
whole-exome sequencing can be performed to identify a larger set of genes hosting 
possible causative variants and investigating if any of these genes are related to the 
disease phenotype. Whole exome sequencing (WES) has helped to resolve cases of 
newborns with a severe combined immunodeficiency disease phenotype that were not 
solved using panel sequencing (Chan, Punwani, Kadlecek, Cowan, Olson, Mathes, 
Sunderam, Fu, et al., 2016; Mallott et al., 2013; Patel et al., 2015b). However, 
expanding the gene list for variant analysis can also be challenging in terms of time to 
analyze the data and chances of increasing false positives.   
B) The impact of coding variants might not be accurately estimated by the general in 
silico predictors (such as PolyPhen (Adzhubei et al., 2013), SIFT (Kumar et al., 
2009), or CADD (Smedley et al., 2016)). For example, in chapter 2 we showed a case 
of a missense variant (C603S in NR3C2 protein) where two out of four general 
predictors estimated it to be deleterious indicating a 50% chance of it being 
pathogenic. But analysis of protein structure revealed it to be a strong case of a 
protein destabilizing mutation. Similarly, variants disrupting existing splicing 





overlooked by the general predictors. To this end, building advanced gene-specific 
predictors or mechanism-specific predictors that make use of the specialized features 
can be beneficial. In the recent CAGI, a gene-specific ensemble variant interpretation 
method (Yin et al., 2017a) and a sequence feature based-splicing impact prediction 
method (Cheng et al., 2019) have shown promising results.        
C) Causative variants can be in the non-coding region of a patient’s genome. But 
these variants are often not screened and if they are, they are ignored in the analysis 
because accurately interpreting their impact on the disease phenotype is difficult. As 
GWAS data shows that most disease-associated variants are mapped to the non-
coding region of the genome, it suggests that regulator elements can have a prominent 
role in genetic diseases (Farh et al., 2015; Hindorff et al., 2009). Given the recent 
availability of the regulatory data in GTEx (Lonsdale et al., 2013) and ENCODE 
(Dunham et al., 2012), steps can be taken to compile accurate and comprehensive 
annotations for the regions of the genome relevant for disease phenotypes. These 
high-quality annotations can then be integrated into the variant interpretation 
pipelines as well being used to develop impact prediction in silico tools for non-
coding variants.    
D) It may be possible that the DNA sequencing approach is adequate for diagnosing 
specific types of genetic diseases such as inborn errors of metabolism (IEM), and that 
biomarker-based approaches can yield better diagnostic power. A recent study 
(Adhikari et al., 2020) showed that WES is less effective in newborn screening for 





approach. Therefore, a strategy where the two approaches are used in conjugation 
may help to reduce the false positive and negative rates in diagnostic tests.  
 
5.1.2 Standardizing evidence of pathogenicity for causative variants 
The American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) have proposed different types of 
evidence that can be used to assess the impact of the clinically relevant variants. 
These include variant segregation data, functional data, population data, and 
computational predictive data (Richards et al., 2015b). Despite this remarkable effort 
to standardize evidence assessment, several issues with its use have been recognized: 
A) Older clinically relevant databases like HGMD are not using these guidelines; 
instead it uses its evidence-based classification system that has resulted in erroneous 
labeling of disease-causing variants as shown in chapter 2 and by others (Cassa et al., 
2013); B) The ClinVar database uses the guidelines, but a recent study (Shah et al., 
2018) shows instability in the classification system, where a large fraction of variants 
previously labeled pathogenic become reclassified to uncertain significance and 
conflicting interpretation; C) Others (Nykamp et al., 2017) have been developing new 
guidelines based on the ACMG-AMP guidelines. This lack of convergence for 
evidence of pathogenicity is leading to an unclear definition of “known pathogenic” 
variants (van Rooij et al., 2020). We propose that a possible solution for evidence 
assessment can be implemented in two steps: 1) Developing an expert-sourced 
evidence of pathogenicity ontology that will contain a comprehensive collection of all 





be tagged with appropriate ontology terms based on the available evidence. Such an 
idea has been implemented in the Gene Ontology community, where the Evidence 
and Conclusion Ontology (ECO) (Chibucos et al., 2017) has been developed to 
describe the evidence supporting gene annotations. 2) Developing an expert-sourced 
variant impact classification scheme that makes use of the evidence types described in 
the above ontology. Software for this can be distributed as executable for easy 
integration into existing clinically relevant resources.  
 
5.2 Systems-level representation of mechanisms by which genetic variants cause 
disease phenotypes  
In the second part of my dissertation, I co-developed the theory of a graphical 
representation framework for genetic disease mechanisms called MecCog, based on 
concepts in the philosophy of biology and computational biology. Next, I 
implemented it as a web-based platform to manually build integrated systems-level 
representations (a.k.a., mechanism schemas) of mechanisms by which a genetic 
variant causes a disease phenotype. The MecCog platform facilitates the integration 
of mechanism information in terms of perturbation propagation across stages of 
biological organization, evaluation of the evidence related to that information, and 
identification of the uncertainties, ambiguities, and ignorance in that information. The 
platform provides functionalities to create, store, browse, and search schemas. I have 
designed graphical notations and curated ontology-informed class terms so as to 
consistently and intuitively represent the types of mechanism components found in 





the graphics, text, and hyperlinks to evidence sources. We have built MecCog 
schemas to describe mechanisms in monogenic disease (cystic fibrosis), cancer 
(Lynch syndrome), and complex trait disease (Crohn’s disease). We have also tested 
and shown that the MecCog formalism can be used to create mechanism graphs by 
combining multiple schemas to describe interactions between genetic variants. Lastly, 
I have equipped the MecCog platform with features to support expert-sourcing for 
schema construction. 
 
5.2.1 Scaling mechanism schemas in MecCog 
The manual construction of the MecCog schemas relies on human understanding to 
extract and infer causal connections between mechanism components from the 
literature. The scattered and incomplete nature of the mechanistic information in the 
literature makes this process complex and requires a combination of prior biological 
knowledge together with searching for, assimilating, and assessing new facts and 
evidence from the literature. This makes schema construction labor-intensive. To 
achieve scale, some degree of automation in the construction process is needed. A 
combination of the following strategies can help in this regard: 
A) A lot of biological information is already represented in a structured format such 
as pathways (KEGG (M Kanehisa & Goto, 2000), Reactome (Fabregat et al., 2017)), 
networks (STRING (Szklarczyk et al., 2018)), relational databases (UniProt (Bateman 
et al., 2017), PDB (Burley et al., 2017)), and knowledge graphs (Hetionet (Daniel 
Scott Himmelstein et al., 2017)). It is possible to extract the information from these 





SSP-MM-SSP units of a schema are a subset of SPO triplets, parts of the schema can 
be automatically generated this way. Nevertheless, an assessment needs to be done as 
to what extent these extracted triplets represent the disease mechanism space, and 
devise strategies to shortlist high confidence and relevant triplets for a schema. B) To 
mine biological information from literature, BioCreative (Critical Assessment of 
Information Extraction systems in Biology) has identified a series of Natural 
Language Processing (NLP)-based tools 
(http://biocreative.sourceforge.net/bionlp_tools_links.html) for the bio-entity 
recognition and relationship extraction tasks. Using these tools, databases of SPO 
triplets from PubMed such as SemMedDB (https://skr3.nlm.nih.gov/SemMedDB) 
(Kilicoglu et al., 2012) are being generated. Such NLP-based tools and databases can 
also be explored to retrieve connections between mechanism components in a 
schema. However, a potential caveat of these automatically generated triplets can be 
that they will miss out on the biological knowledge whose information is spread out 
across paragraphs in literature and so, would need a reasoning strategy to piece them 
together for creating the triplets. C) One of the critical activities while building a 
schema is to find and analyze all the evidence of a particular component to assess its 
relevance for the disease mechanism description. A first and important step for this is 
to find all the papers that discuss the component in the context of the disease 
phenotype. Unsupervised machine learning techniques like Topic modeling 
(http://machinelearningtext.pbworks.com/w/file/fetch/47924743/BleiLafferty2009.pd
f) can be helpful in this case, inferring the latent topical structure of a collection of 





document set. This technique can be used to automatically identify the set of PubMed 
articles that are characterized by the words relating directly or indirectly to the 
mechanism component. 
 
5.3 Quantitative representation of mechanisms relating genetic variants and complex 
trait disease  
In the third part of my dissertation, I developed a framework to quantitatively 
represent and analyze the mechanism described in the MecCog mechanism graph 
format. Using a subsystem on the role of gut barrier integrity in Crohn’s disease, we 
demonstrated that a mechanism graph can be transformed into a computable circuit 
by assigning appropriate node functions and parameters that represent the behavior of 
the graph components. We also showed that the degree of non-linearity in the circuit 
can be altered by the choice of parameter values. We then investigated the use of the 
circuit to get insights for interpreting GWAS data which otherwise would require a 
demanding experimental setup. The circuit showed: A) The effect size of a GWAS 
risk variant can change drastically as the function of the specific risk allele-load in the 
genetic background; B) The size of the epistatic effect between pairs of GWAS risk 
variants can get diluted by averaging the effects across genetic backgrounds. Next, we 
demonstrated that the node functions and parameters can be learned in a data-driven 
manner using a Mechanism Architecture Neural Network (MANN) – a sparse neural 
network wired based on the topology of the mechanism graph. We also showed 






5.3.1 Complex trait disease risk assessment using MANN  
MANN provides a novel way to quantitatively encode a systems-level representation 
of mechanism by which genetic variants cause disease phenotype. The inclusion of 
prior biological knowledge in the form of the neural network topology provides a 
number of practical advantages such as a decreased number of training parameters 
compared to a fully connected neural network, a need for fewer training data, more 
interpretable, and easy testing of multiple topologies. In addition, as these sparse 
neural networks can also facilitate analysis of how a genotypic profile can influence 
disease phenotype, they can be a useful system to study many diagnostic and 
therapeutic aspects of complex trait diseases. One of these areas is risk prediction. 
Most often, the genetic risk of an individual is assessed through the polygenic risk 
score (PRS), a weighted sum of the number of risk alleles an individual carries (C. M. 
Lewis & Vassos, 2020). This summing across variants strategy in PRS assumes an 
additive genetic architecture of complex trait diseases, with independence of risk 
variants. It does not consider possible nonlinear interactions between variants that can 
influence the disease phenotype. A few studies have compared PRS with machine 
learning (ML) algorithms that can model non-linearity (such as support vector 
machines, random forests, gradient boost) and interestingly found that PRS performs 
better than the ML algorithms (Gola et al., 2020; Vivian-Griffiths et al., 2019). Going 











Varant is an open-source genetic variant annotation tool (written in Python, 
http://compbio.berkeley.edu/proj/varant). Varant provides five categories of 
annotation based on 17 data sources: variant identity and frequency, experimentally-
defined genomic features, predicted genomic features, variant/gene phenotypes, and 
prediction of mutation impact. It has been used in a number of clinical research 
studies (Chan, Punwani, Kadlecek, Cowan, Olson, Mathes, Sunderam, Man Fu, et al., 
2016; Patel et al., 2015a; Punwani et al., 2016). 
 
QC Analysis Results 
Supp. Fig. S2A shows that the Ts/Tv ratios for all the samples are clustered between 
2.2 and 3.2. For the human genome based on 1000Genomes data, Wang et al. 2015 
have shown that the Ts/Tv ratio is ~3 for SNVs inside exons and ~ 2 elsewhere. Since 
the capture regions cover more than just exons (1350 exonic and 39 intronic regions 
for 83 genes), the Ts/Tv ratio for SNVs is expected to lie between 2 and 3, consistent 
with the plot and the pattern is very similar for the 1000 Genomes samples. The 
Het/Hom ratios for all samples except one (P8) are clustered between 1.1 and 2.6. P8 
is an outlier and carries more homozygous SNPs. It is established that on a genome-
scale, the Het/Hom ratio is close to 1.5 (McKernan et al., 2009; Schuster et al., 2010) 
but it also depends on whether a population incorporates recent admixture (skewing 





Het/Hom ratio range here is similar to that of the 1000Genomes sample. Thus, by 
these measures, the data, with the exception of P8, are of good quality.  
Supp. Fig. S2B shows that for the capture v01 samples have 1200 to 2000 low quality 
and 200 to 940 no call sites. The captures v02 samples have 230 to 330 low quality 
and 90 to 180 no call sites. We expect that if any causative variant falls on one of 
these no call or low-quality sites it will be completely missed.  
Supp. Fig. S2C shows that the number of common SNVs per sample cluster between 
232 and 312 for the 96 samples sequenced using Capture v01 and between 132 and 
175 for the 10 samples sequenced using Capture v02, consistent with Capture v02 
covering 19 fewer genes than Capture v01. Non-African samples have a lower rare 
variant load (ranging from 8 to 33) than the African samples (ranging from 19 to 80). 
This pattern is also seen in the samples from 1000Genomes samples and has been 
previously reported in the literature (Durbin et al., 2010; Zawistowski et al., 2014). 
The novel (i.e. not found in 1000 Genomes and ExAC) SNV count is in the range of 0 
to 8 with a median of 1 per sample and is similar to the count observed in the 1000 
Genomes dataset where the range is 0 to 12 with a median of 2 per sample. These 
novel variants be present in the patient’s family or be de novo in the patient but it is 
not possible to distinguish these two situations given only the patient’s variant data.  
Supp. Fig. S2D shows that for the 96 Capture v01 samples, the common Indel count 
is between 5 and 16 whereas for the 10 Capture v02 samples the count is 3 to 6 per 
sample. We observe that the distributions of the rare Indel is between 0 and 12 and 
novel Indel is between 0 and 4. Two African samples (P2 and P83) are identified as 





Genomes dataset. However, the Indel counts are similar to the 1000 Genomes dataset. 
By all these measures, the Hopkins data appears to be of high quality. 
Supp. Fig. S3 shows the distribution of average read depth for 83 genes across all 
samples. Average read depth varies more substantially across the 106 samples 
(horizontal variation) than across the 83 genes (vertical). Genes not included (blue 
boxes) in the 10 capture v02 samples are evident. Though there is variation in the 
gene coverage across samples, from 107X to 983X, even the lowest coverage should 
be adequate for diagnostic analysis and confirmatory testing as shown by Strom et al. 
2014.   
We identified nine capture regions (occurring in eight genes) with anomalous read 
depth in more than 90 of the 106 samples (Supp. Table S1). One of these has very 
high coverage and the others have low coverage. Two of these regions lie in the major 
isoform of one gene, HYDIN, one high (Exon 53) and one low (Exon 60). Exon 53 
has greater than 600X coverage in 70 samples (Supp. Fig. S4). Exon 60 has no 
coverage in 78 samples and less than 20X coverage in three more samples. The other 
anomalous regions are unlikely to affect downstream analysis because they are either 
deep intron, present in a minor isoform of the gene or the actual coverage of the 







Figure S1. Relationship between the fraction of methods that agree on a deleterious 
assignment for variants and the positive predictive value, PPV (fraction of predicted 
deleterious variants that are deleterious), for 10695 HGMD missense mutations and 
10240 interspecies variants with available predictions for at least two out of the four 
methods (SNPs3D Profile, SIFT, Polyphen2 and CADD). By this measure, 77% of 






Figure S2. Comparison of variant calling quality for 106 Hopkins samples versus 
2,504 1000Genomes samples across the 83 genes in the panel. Only high-quality calls 
are included. HS: Hopkins Samples, KGS: 1000 Genomes samples, KGS_AFR: 
African samples in 1000Genomes, KGS_NonAFR: Non-African samples in 1000 
Genomes. Circles represent HS sequenced using Capture v01 and triangles represent 
the HS sequenced using Capture v02. African samples are blue, Non-African are 
brown. Figure S2A shows the distribution of Transition vs. Transversion (Ts/Tv) and 
Heterozygous SNVs vs. Homozygous SNVs (HetALT/HomALT). By both measures, 





P8, an outlier with an excess of homozygous SNVs. Figure S2B shows the 
distribution of no call sites versus low-quality sites (not PASS in the gVCF file). 
Causative variants falling on any these sites will probably be missed. Figure S2C 
shows the distribution for common, rare and novel SNV types. For the common and 
rare SNV types, the HS and KGS distributions are similar. The lower counts of HS 
common SNVs for capture 2 reflects the fact that only 64 genes are included. There is 
a similar effect for rare variants, obscured by the crowding of points (medium 20 
counts for capture v01 and 15 for v02).  The rare variant distribution for both HS and 
KGS reflects the fact that Non-African samples have a lower rare variant load than 
the African samples. The novel variants load (between 0 and 8 variant with a median 
of 1 per sample) in HS is much lower than the rare variants. Figure S2D shows the 
distribution for common, rare and novel Indels. The distribution of common and rare 
Indels in HS is similar to the KGS distribution. Like SNVs, the lower counts of HS 
common indels for capture 2 is evident, in the plot. Two African samples (P2 and 
P83) are seen to carry more rare Indels and are outliers compared to the 
1000Genomes dataset. For six samples there is a slightly higher number of rare than 












Figure S3. Heat-map of average read depth for 83 genes across the 106 samples, 
color-coded red (low depth: ~100) to green (high: ~950). Blue indicates the 
corresponding gene was not captured. Each column is for a different sample, and 
there are 83 rows, one for each gene.  It is evident that coverage varies substantially 








Figure S4. Exon-wise read depth for the HYDIN gene. Each purple line represents 
one sample and each rectangle represents one exon. The red rectangle indicates exons 
with anomalous coverage. The plot shows that Exon 53 has very high coverage and 
Exon-60 has very low coverage or no coverage for many samples compared to other 
exons in the gene.  The inset shows a zoomed-in view of the read depth for Exon 59, 






Figure S5. Distribution of correct and incorrect assignments of pathogenicity for 




Table S1. The nine regions with anomalous average read depth observed in more 
than 90 of the 106 samples. The eight “LOW COVERAGE” capture regions have low 
average read depth compared to other regions in the same gene. The one “HIGH 
COVERAGE” capture region has high read depth compared to other regions in the 
same gene. The “# of Samples” column is subdivided into coverage bins from no 
coverage to high coverage for “LOW COVERAGE” regions and from high to very 
high for “HIGH COVERAGE” regions. The HYDIN gene has two anomalous capture 
regions – 1. Low coverage, no reads in 78 samples and 2. A very high coverage of  > 
600X in 70 samples. The other anomalous regions are either deep intron, or present 
only in a minor isoform or actual coverage of the region is at least greater than or 



















Table S2. Five cases where two pairs of Indels in the CCDC40 gene were selected to 
satisfy a compound heterozygous model and leading to incorrect disease assignments. 
Each pair of Indels is very close to each other suggesting possible false variants 
arising from realignment errors or errors near repeat regions in the genome.  
 
 
Table S3. Number of distinct variants that led to disease class prediction in 106 
patients. 105 distinct potentially causative variants occurred only once in 78 patients. 
14 potentially causative variants occurred twice or more in the remaining 28 patients. 








Table S4. Percentage of correct disease assignments in each of the three variant 
selection categories after removing HGMD from the method. Accuracy increases 
compared to the pipeline with HGMD. Overall trends remain the same - as expected, 
accuracy is highest in Category-1, then Category-2, then Category-3., and novel 








Figure S6. Variation in risk variant effect size as a function of the genetic 
background for the barrier integrity model for all genes. Each panel shows the effect 
size distribution of a specific risk variant against genetic backgrounds. Figure 4A 
shows the effect size distributions for the moderately non-linear simulation model and 
Figure 4B for the more strongly non-linear model. The X-axis of each plot is sorted 
by the risk-allele load in the genetic background (ranging from 0 where no other risk 
alleles are present to 14 where the seven other genes have homozygous risk alleles, 
Red points are for the genetic backgrounds found in the WTCCC study population 






Figure S7. Variation in the size of the epistatic effect size as a function of the genetic 





Each panel shows the epistatic effect size distribution for a variant pair against 
genetic backgrounds. The X-axis of each plot is sorted by the risk-allele load in the 
background (ranging from 0 where no other risk alleles are present to 12 where the 
six other genes have homozygous risk alleles, in a total of 729 combinations). The 
load was calculated as the linear sum of the genotype values in the background. Red 
points are for genetic backgrounds found in the WTCCC study population dataset and 
blue points cover all possible backgrounds. The average epistatic effect size over all 









Figure S8. Variation in the size of the epistatic effect size as a function of the genetic 





Each panel shows the epistatic effect size distribution for a variant pair against 
genetic backgrounds.  The X-axis of each plot is sorted by the risk-allele load in the 
background (ranging from 0 where no other risk alleles are present to 12 where the 
six other genes have homozygous risk alleles, in a total of 729 combinations). The 
load was calculated as the linear sum of the genotype values in the background. Red 
points are for genetic backgrounds found in the WTCCC study population dataset and 
blue points cover all possible backgrounds. The average epistatic effect size over all 
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